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As a consequence of the worldwide improvement of living conditions, 
the average life-span of elderly persons has significantly increased in the last 
100 years. This change is accompanied by a dramatic increase in diseases 
associated with aging, including neurodegenerative disorders, cancer, 
infections, as well as cardiovascular diseases (CVDs). Moreover, life style 
changes, such as sedentary life, diet, smoking as well as stress, are risk factors 
contributing to the development of the above mentioned diseases. 
Atherosclerosis, a chronic inflammatory disease of the arteries, is the 
underlying pathological process of most CVDs, which are nowadays the leading 
cause of mortality in the Western Society.(1) In the last decade(s) researchers 
tried to unravel, which immune cell subsets/ mechanisms are crucially 
contributing to atherosclerosis development. The subsequent introduction will 
give a short overview on the immune system, how different cell subsets 
influence immune responses – focusing on dendritic cells- and how the 
immune system is involved in atherosclerosis, which serves as a guideline on 
the following chapters. 
 
1. The immune system 
The immune system is the body's defense against infectious organisms, 
build up by a network of specialized cells -called white blood cells or 
leukocytes- tissues, and organs that work together. The immune system is 
divided into the innate (non-specific) and the adaptive (also known as 
acquired) immune system. The innate immune system is the first line of 
defense against pathogens. Activation of the innate immune system relies on a 
set of specific pattern recognition receptors (PRRs)(2) that recognize so-called 
pathogen-associated molecular patterns (PAMPs). These receptors function as 
a switch to trigger the innate immune system, and to regulate adaptive 
immune responses to microbial infections. In mammals, Toll-like receptors 
(TLRs) are the best characterized innate immune receptors.(3, 4) They are 
expressed throughout the body and are mainly found on professional innate 
immune cells, including macrophages, dendritic cells (DCs) and mast cells. The 
activation of the innate immune system induces a rapid inflammatory 
response to eliminate pathogens.(5) However if the innate immune system fails 
to remove dangerous invaders, the activation of the adaptive immune system 
becomes crucial. Specialized antigen-presenting cells (APCs), most importantly 
DCs, trigger adaptive immune responses through presentation of pathogenic 
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antigens to T and B cells, which subsequently leads to their activation. T and B 
cells have the unique ability to form receptors, which are not germline-
encoded, but are de novo generated from rearranged gene segments. This 
leads to a great variability and adaptive capacity in antigen receptors, 
important for eliciting specific immune responses.(6) Activated T cells induce 
cell-mediated immune responses, whereas B cells excite humoral immune 
responses. (7) 
 
2. Dendritic cells- orchestrators of innate and adaptive immune responses  
DCs constitute a heterogeneous family of cells with distinct phenotype 
and function. As specialized antigen-presenting cells they are central mediators 
of adaptive immune responses and, depending on the local environment, of 
the development of immunological memory and tolerance. DC development, 
as well as phenotype and function of the distinct subsets will be described in 
the following sections. 
 
2.1. Dendritic cell development 
Both innate and adaptive immunity are built on various leukocyte 
subsets, which are derived from hematopoietic stem cells (HSC) in the bone 
marrow. HSCs further differentiate into common lymphoid precursors (CLPs) 
and common myeloid precursors (CMPs).(8) The latter gives rise to monocytes/ 
macrophages, granulocytes, DCs, and megakaryocytes, which are all belonging 
to the innate immune system. CLPs give rise to T and B cells, but can also 
differentiate into DCs, emphasizing a key role for DCs as orchestrators of 
innate and adaptive immunity.(9) Monocytes and DCs share a common 
progenitor called the monocyte dendritic cell precursor (MDP; lin- ckithigh 
CD115+ CX3CR1
+ Flt3L+),(10, 11) whereas a common DC progenitor (CDP; lin- ckitlow 
CD115+ Flt3L+) is restricted to generate classical DCs and plasmacytoid DCs 
(pDCs).(12) MDPs and CDPs are confined to the bone marrow (Figure 1).(9) 
Macrophage colony-stimulating factor (M-CSF) and FMS-related tyrosine 
kinase 3 (Flt3L) are essential growth factors for the differentiation of the 
myeloid cell lineage, where M-CSF is critical for the development of 
monocytes, and Flt3L for DC lineage development.(13)  
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Figure 1. The developmental pathways of lymphoid and myeloid progenitors to lymphocytes (T 
and B cells), DC subsets and macrophages, and key transcription/ growth factors essentially 
required for DC development (indicated by vertical lines). MDP, CDP, and pre-DC development 
are confined to the bone marrow. Monocyte and DC development depends on the transcription 
factor PU.1, which regulates the expression of the cytokine receptors FLT3R, M-CSFR and GM-
CSFR. CD11b+ cDCs require a set of transcription factors for their development, including RELB, 
interferon-regulatory factor 2 (IRF2), IRF4 and Ikaros, as well as M-CSF and GM-CSF. CD8α+ and 
CD103+ cDCs are dependent on IRF8, inhibitor of DNA binding 2 (ID2), E4 promoter-binding 
protein 4 (E4BP4) and basic leucine zipper transcription factor, ATF-like 3 (BATF3), as well as on 
FLT3 signalling. pDCs require E2-2, Ikaros and IRF8 for their development. CDP: common DC 
progenitor; CLP: common lymphoid progenitor; CMP: common myeloid progenitor; LMPP: 
lymphoid-primed multipotent progenitor; MDP: monocyte and DC progenitor; FLT3: FMS-related 
tyrosine kinase 3 receptor; M-CSFR: macrophage colony-stimulating factor receptor; GM-CSF: 
granulocyte– macrophage colony-stimulating factor receptor. 
 
2.2. Conventional dendritic cells  
Conventional dendritic cell (cDC) precursors (pre-DCs) leave the bone 
marrow and migrate via the blood stream to secondary lymphoid organs 
(lymph nodes, spleen and thymus), and peripheral tissues such as skin, lung, 
the intestinal tract, kidney and liver, where they convert into lymphoid 
resident and migratory cDCs, respectively.(14) The phenotypic characterization 
of cDCs is quite complex. In human, three major CD11c+ circulating cDC 
subpopulations are described: (1) CD16+, (2) blood dendritic cell antigen 
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(BDCA)-1+ and (3) BDCA-3+ cDCs, which can be distinguished in their immune 
functions, including cytokine release and T cell stimulatory capacity.(15) In 
mouse, cDCs can be categorized into different subsets. The (1) CD11b+ DCs 
include the CD4+ and CD4- CD8- lymphoid-tissue resident cDCs, the dermal 
CD11b+ DCs and their counterparts in lung and other tissues, the Langerhans 
cells, and the CD103+ CD11b+ DCs of the gut. The (2) CD11b- cDC subset 
includes lymphoid-resident CD8α+ cDCs, as well as the CD103+ langerin+ DCs of 
skin, lungs and other tissues.(16) Newly generated cDCs have an immature 
phenotype, characterized by the low surface expression of major 
histocompatibility complex (MHC) molecules I and II, and T cell co-stimulatory 
molecules (CD40, CD80, CD86).(17) While monitoring the environment for the 
presence of bacterial and viral pathogens, cDCs maintain an immature state. 
Without an overt presence of stimuli, steady-state immature cDCs induce and 
foster peripheral tolerance.(18) Upon inflammation, cDCs capture pathogenic 
antigens, but also self-antigens from damaged or apoptotic cells through PRRs, 
such as TLRs, C-type lectin receptors (CLRs) and CD1 receptors, which in turn 
induces DC maturation.(19) This is accompanied by characteristic functional 
changes of DCs, such as loss of endocytic capacity, up-regulation of MHC 
molecules, T cell co-stimulatory molecules and the production of cytokines 
such as tumor necrosis factor α (TNF-α), interleukin 12 (IL-12), IL-23 and IL-
10.(19) Concomitant with their maturation process, migratory and lymphoid-
resident cDCs traffic to the T cell zones in the secondary lymphoid organs to 
prime and stimulate naïve, memory and effector T cells, and natural killer T 
(NKT) cells by antigen presentation.(20) CD11b- cDCs are dedicated to prime 
cytotoxic T cell immunity and responses to cell-associated antigens, whereas 
CD11b+ cDCs are principally involved in CD4+ T cell stimulation, as well as 
humoral immunity and responses to extracellular pathogens.(16) DC-T cell 
crosstalk predominantly occurs in secondary lymphoid organs, but it is well 
accepted that under certain pathological conditions the maturation of cDCs 
can also take place in the periphery, where DCs cluster with T lymphocytes at 
sites of infection.(17) 
 
2.3. Plasmacytoid dendritic cells 
pDCs are an apart DC subset, first described as plasmacytoid T cells or 
plasmacytoid monocytes in human.(21-23) They represent a rare leukocyte 
population, originating in the bone marrow from a common DC progenitor,(13, 
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14) and are specialized in the secretion of type I interferons (IFNs), i.e. IFN-α, 
IFN-β, IFN-ω, IFN-λ.(24, 25) Human pDCs have a unique cell surface phenotype, 
expressing blood dendritic cell antigen 2 (BDCA-2) and BDCA-4, CD123 (IL-3Rα), 
immunoglobulin-like transcript 7 (ILT7), CD4 and MHC class II, and being 
negative for lineage markers (CD3, CD19, CD14, CD16) and CD11c.(26-28) The 
mouse pDC counterpart is characterized by the expression of bone marrow 
stromal antigen 2 (BST-2), Siglec-H, B220 and Ly6C. They can also express 
variable amounts of CD8α.(29) Under healthy steady-state conditions, pDCs are 
present in low numbers, mainly in T cell areas of lymph nodes and spleen, 
mucosal-associated tissues, thymus and liver, while accumulating in lymphoid 
and non-lymphoid tissues under pathological conditions.(29) pDCs are 
characterized by their ability to release high amounts of type I IFN upon viral 
infection, thus inducing a strong antiviral state.(25, 30-32) Viruses and pathogens 
are sensed through TLR7 and TLR9.(24, 33) Besides the production of type I IFNs, 
pDCs also secrete IL-12, IL-6, TNF-α, as well as pro-inflammatory chemokines 
such as CXCL9, CXCL10, CCL3, CCL4 and CCL5. Thereby, pDCs can attract CD4+ 
and CD8+ T cells to sites of infection, inducing long-term T cell survival and 
memory,(34) T helper 1 (Th1) polarization, cytolytic T cell responses,(35) DC 
maturation(36) and differentiation of B lymphocytes into immunoglobulin-
secreting plasma cells.(37) Upon maturation, pDCs undergo important 
phenotypic changes, most notably being the acquisition of a dendritic 
morphology and concurrent up-regulation of MHC and T cell co-stimulatory 
molecules (CD40, CD80, CD86). This enables pDCs to present antigens to CD4+ 
T cells, although less efficiently than cDCs.(35, 38) Thus pDCs have the unique 
capacity to promote anti-viral innate as well as adaptive immune responses. 
General Introduction | 1 
15 
 
 
Figure 2. Simplified scheme representing the phenotypic characterization of immature and 
mature conventional and plasmacytoid dendritic cells. Uptake of epitopes, derived from 
invading pathogens or released from injured tissue, by certain receptors (mainly Toll-like 
receptors), leads to major phenotypic changes and maturation of different DC subsets. Activated 
pDCs are characterized by their ability to release huge amounts of type I IFNs, f.e. IFN-α, 
whereas cDCs mainly produce IL-12, TNF-α and IL-23. Both matured cDCs as well as pDCs can 
either act immunogenic (induction of Th1, Th2 or Th17 CD4+ T cells; activation of cytotoxic CD8+ 
T cells) or tolerogenic (induction of Treg’s) upon stimulation. DAMP: danger-associated 
molecular patterns; HLA-DR: human leukocyte antigen DR; IFN: interferon; IL: interleukin; 
PAMPs: pathogen-derived molecular patterns; Th: T helper; TNF: tumor necrosis factor. 
 
2.4. Monocyte-derived inflammatory dendritic cells 
 During pathogenic inflammation an additional DC subset appears in 
human, which is termed the ‘inflammatory DC’. Inflammatory DCs are the 
equivalents of murine Ly6Chigh monocyte-derived inflammatory DCs.(39) 
Monocytes are short-lived myeloid cells that originate from the bone marrow, 
and upon release they are circulating patrolling sentinels.(9) In mouse and 
human, several monocyte subsets have been described. Mouse Ly6Chigh CCR2+ 
CX3CR1low monocytes (equivalents of human CD14high CD16low) are referred to 
as (1) ‘inflammatory’ monocytes as they preferentially recruit to inflamed 
tissues, whereas (2) Ly6Clow CCR2- CXC3CR1high monocytes (equivalents of 
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human CD14low CD16high) patrol healthy tissues through crawling on the resting 
endothelium, which enables them to rapidly invade tissues at sites of 
infection.(40) Under homeostatic conditions monocytes might be involved in 
scavenging dead cells and toxic molecules.(41) During inflammation, circulating 
monocytes migrate to the inflamed tissue where they can differentiate into 
inflammatory macrophages or DCs.(42) Human and mouse inflammatory DCs 
share a similar phenotype, both expressing CD11b, CD206, CD172a, and 
FcεRI.(43-46) Inflammatory DCs migrate to secondary lymphoid organs, where 
they present antigens to both CD4+ and CD8+ T cells,(44, 45) or transfer them to 
resident DC subsets.(47) Moreover, peripheral memory T cells can get directly 
activated by inflammatory DCs.(48) 
 
2.5. T cells 
 As discussed above, immune responses are very much dependent on 
the interplay of different immune cell types, and the local context. Thus, DCs 
are being influenced by others, but also induce specific immune responses by 
interfering cell subsets, among which T cells are briefly described. 
T cells differentiate from CLPs and are an essential part of the adaptive 
immunity. After their complete maturation in the thymus, they consist of two 
principal groups, based on the expression of CD4 and CD8 on their surface. 
Upon stimulation via APCs, mainly DCs, naïve CD4+ T helper (Th) cells can 
differentiate into various Th cell subsets, based on their cytokine profile and 
the immune responses they elicit. Th1 cells are characterized by an interferon-
γ (IFN-γ) signature and mediate cellular immune responses, whereas Th2 cells 
are involved in allergic responses and asthma by secretion of IL-4, IL-5, IL-10 
and IL-13, and the activation of B cells to produce antibodies.(49, 50) Instead, 
Th17 cells are involved in host responses to fungi and extracellular bacteria, 
such as Candida albicans and Staphylococcus aureus,(51, 52) but also in the 
development of certain autoimmune diseases such as inflammatory bowel 
disease, rheumatoid arthritis and experimental autoimmune 
encephalomyelitis.(53) Interestingly, Il-6, IL-23 and low levels of TGF-β were 
found to be required for the differentiation of IL-17/ IL-10 producing Th17 
cells, whereas IL-1β is essential for the induction of IL-17/ IFN-γ double 
producing Th17 cells (cells with a hybrid Th17/ Th1 phenotype).(54) Th1, Th2 
and Th17 cells have been shown to counterbalance each other. Regulatory T 
cells (Treg’s) are of protective nature, specialized in maintaining central and 
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peripheral immune tolerance by suppressing auto-reactive and pathogenic T 
cell responses. Natural Treg cells develop in the thymus and are important for 
the recognition of self-antigens, whereas induced Treg cells develop from 
naïve peripheral CD4+ T cells at foci of sustained inflammation under the 
induction of either IL-10 (Tr1 cells) or tumor growth factor-β (TGF-β) (Th3 cells) 
during ongoing inflammatory processes.(55) CD8+ T cells have the ability to kill 
virus-infected and tumor-cells, due to their release of perforins and granzymes. 
Hence, they are also called cytotoxic T cells, and recognize their targets via 
MHC I molecules. CD4+ T cells recognize antigen-MHC II complexes presented 
by APC.(56) 
 
3. Atherosclerosis 
CVD is one of the leading causes of death and morbidity 
worldwide.(57,58) Several systemic risk factors, such as hypertension, type II 
diabetes mellitus, obesity, and hypercholesterolemia,(59, 60, 61, 62, 63) as well as 
physical inactivity and smoking(64, 60) can disturb the cardiovascular system. 
Coronary artery disease, peripheral arterial disease, and cerebrovascular 
disease are the most common forms of CVD. The main underlying pathological 
process is atherosclerosis, a slowly progressing disorder of large and medium-
sized arteries that becomes apparent when it causes thrombus formation and 
vessel occlusion.(65-67) Our understanding of the pathophysiology of 
atherogenesis has evolved fundamentally. Atherosclerosis was first identified 
as a lipid-storage disease, but is now additionally recognized as a chronic 
inflammatory disease of the vessel wall, characterized by the infiltration of 
immune cells, which interact with each other and with cells of the arterial 
wall.(68-70) The first signs of atherosclerosis are characterized by the formation 
of fatty streaks, which occur already early in life, with children showing lipid-
rich lesions in the aortic arch and the abdominal aorta.(71, 72) In the last years it 
has been evidenced that plaque formation occurs particularly at sites with 
disturbed laminar flow, such as arterial branch points.(73, 74) This phenomenon 
implies endothelial cell (EC) activation, leading to an increase in endothelial 
permeability, and to a pathological elevation of endothelial adhesion 
molecules, such as vascular cell adhesion molecule-1 (VCAM-1) and 
intracellular adhesion molecule-1 (ICAM-1). Finally, EC dysfunction supports 
low-density lipoprotein (LDL) influx, and the migration of inflammatory cells 
into the subendothelial space.(75, 76) LDL particles, enriched beneath the 
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endothelium in the intimal space, are sensitive to oxidative modifications by 
reactive oxygen species (ROS) or enzymes such as myeloperoxidase and 
lipoxygenase, released from resident vascular cells. Accumulated LDL and 
oxidized LDL (oxLDL) further increase the expression of chemokines and 
adhesion molecules on ECs, such as E- and P-selectin, thereby promoting 
immune cell invasion to the site of injury.(77, 78) Fatty streak lesions, enriched in 
lipid-loaden foam cell macrophages,(79, 80) progress into mature atherosclerotic 
plaques, due to the continued recruitment of leukocyte subsets and the 
accumulation of extracellular lipids.(81) Additionally, vascular smooth muscle 
cells (vSMC) start to proliferate and to migrate from the media into the intima 
in response to growth factors such as fibroblast growth factor (FGF), platelet-
derived growth factor (PDGF) and TGF-β.(82, 83) This leads to the formation of a 
core region that is surrounded by a cap consisting of vSMCs and a collagen-rich 
matrix. Advanced stable plaques are relatively quiescent in nature, although 
they can provoke blood vessel narrowing (stable angina). Over time, a more 
complex lesion develops, enriched in inflammatory cells as well as necrotic and 
apoptotic cells, cell debris and cholesterol crystals, leading to the formation of 
a necrotic core that is covered by a fibrous cap. The rupture-prone shoulder 
region is particularly enriched in activated macrophages, mast cells, DCs and T 
cells, which are sustaining ongoing inflammatory processes in the lesion due to 
the release of pro-inflammatory cyto- and chemokines.(84) The secretion of 
matrix-degrading proteases, such as matrix-metalloproteinases (MMPs) can 
cause fibrous cap thinning and plaque rupture, which exposes the 
thrombogenic material of the necrotic core to the blood. This leads to the 
formation of an atherothrombus, which can elicit myocardial infarction or 
ischemic stroke due to vessel occlusion.(70, 84)  
 
4. The contribution of the immune system to atherosclerosis 
The concept that the immune system plays an indispensable role in 
atherosclerosis has gained widespread acceptance. Both innate and adaptive 
immune responses influence disease onset and progression.(67, 85) In the next 
paragraphs the role of innate immune signals, the contribution of different 
innate immune cell subsets, as well as the adaptive immunity in 
atherosclerosis will be described. 
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4.1. Innate immune signals in atherosclerosis 
It has been shown that TLRs are expressed in the non-diseased human 
vessel wall,(86) and the expression of certain TLRs is increased in mouse and 
human atherosclerotic plaques, mainly recognized on macrophages, ECs and 
vSMCs.(87-90) Studies, using mouse models for atherosclerosis, in which specific 
TLRs and their downstream signaling intermediates were genetically deleted, 
demonstrated a significant pro-atherogenic contribution for TLR2 and TLR4.(91-
94) Apart from pathogenic agents, TLRs are able to recognize endogenous 
ligands, present at sites of inflammation. These ligands are products of tissue 
damage, so-called danger-associated molecular patterns, which alert the 
innate immune system of tissue injury in the absence of infections.(95) During 
the last years, considerable evidence has supported the involvement of 
endogenous ligands, such as heat shock proteins (HSP), high-mobility group 
box 1 (HMGB-1), and RNA/ DNA immune complexes, which are released from 
necrotic and dying cells, as well as degradation products of extracellular matrix 
macromolecules, such as fibronectin and hyaluronan, to be involved in innate 
immune activation in atherogenesis. Additionally, cholesterol crystals and 
(modified) LDL particles were shown to activate immune cells, thereby driving 
atherogenesis.(96-102)  
 
4.2. Cells of the innate immune system in atherosclerosis 
 Over the past two decades it has been evidenced that immune cells 
are critically involved in the pathogenesis of atherosclerosis. The continued 
recruitment and accumulation of various leukocyte subsets within the plaque 
is associated with lesion progression and plaque rupture. 
Monocytes and macrophages were the first inflammatory cells to be 
associated with atherosclerosis, and are the predominant cell type within the 
plaque.(80) Blood monocyte depletion in rabbits was shown to significantly 
reduce lesion size, thus emphasizing their importance in atherosclerosis.(103) 
During atherogenesis, Ly6Chigh monocytes are continuously recruited to the 
plaque, and monocyte accumulation was found to correlate with lesion 
size.(104) In hyperlipidemic mice, Ly6Chigh monocytes make use of the chemokine 
receptors CCR1, CCR2 and CCR8 to enter the plaque and to differentiate into 
macrophages, whereas Ly6Clow monocytes employ CCR5 and CX3CR1.
(105) 
Combined genetic deletion of CCR2, CCR5 or CX3CR1 almost abolished 
atherosclerosis in apolipoprotein E deficient (ApoE-/-) mice, stressing the 
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importance of chemokine receptors in monocyte recruitment to the 
atherosclerotic plaque.(106) Monocyte-derived macrophages play a pivotal role 
during all stages of atherosclerosis. Advanced plaques contain various 
macrophage subsets, including M1, M2, M4 and Mox macrophages. However 
the phenotype of lesional macrophage subtypes is incompletely 
understood.(107) Lipoprotein uptake by macrophages is mediated via certain 
scavenger receptors (CD36, CD68, SR-A, MARCO, SR-B and LOX-1) and leads to 
macrophage activation and the formation of lipid-laden foam cells.(108) 
Macrophages metabolize and eliminate lipoproteins through their ATP-binding 
cassette transporters (ABCs), such as ABCA1 and ABCG1. An imbalance in 
lipoprotein uptake and efflux capacity (defective efferocytosis) leads to 
macrophage apoptosis, a process that contributes to necrotic core formation 
and subsequently to plaque progression and destabilization. Additionally, 
release of pro-inflammatory cytokines and matrix-degrading enzymes by 
macrophages further provoke fibrous cap thinning.(109) 
 
In the recent years it has been shown that resident vascular DCs are 
present within the healthy aorta and may play a role in the maintenance of 
vascular homeostasis.(110) Local inflammatory processes in the vascular wall 
promote the recruitment of further DCs to the aorta. Mature DCs are 
described to be located in inflammatory spots in the plaque-shoulder area in 
close proximity with activated T cells.(111) However, there is still limited 
information about DC (subset) phenotype and functionality within the 
atherosclerotic plaque. The current knowledge of the various DC subsets, and 
their interplay with certain immune cell subsets will be described in-depth in 
the following chapters of my thesis. 
 
Next to DCs, neutrophils and their mediators have been identified in 
mouse and human early lesions as well as in rupture-prone atherosclerotic 
plaques within regions of high inflammatory activity.(112, 113) Neutrophils are 
classically described as short-lived phagocytes characterized by the release of 
vast amounts of soluble anti-microbials, including azurocidin, LL-37, 
myeloperoxidase (MPO), MMPs, and cathepsins, as well as neutrophil 
extracellular traps (NETs = fibers composed of chromatin and serine 
proteases), important during bacterial infections.(114) It has been shown that 
hyperlipidemia induces neutrophilia by stimulating the egress from the bone 
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marrow, and circulating neutrophil numbers correlate with plaque size and 
cardiovascular events.(112) A recent study demonstrated that disruption of the 
CXCR4-CXCL12 axis caused neutrophilia and aggravated atherosclerosis, 
whereas neutrophil depletion markedly diminished early lesion size,(115) thus 
pointing towards a functional role for neutrophils in murine atherosclerosis. 
Several recent studies suggested an important role for neutrophils in the onset 
of atherosclerosis by triggering monocyte and T cell recruitment to the 
lesion.(116) Besides, experimental data encourage a contributory role of 
neutrophils to plaque destabilization by release of MPOs, and MMP-2 and 
MMP-9.(117, 118)  
 
Another important cell type of the innate immune system is the mast 
cell. Mast cells are large granular cells, best known for their functions in allergy 
and anaphylaxis. Recent studies confirmed the presence of mast cells in 
coronary and carotid artery plaques at sites of plaque erosion, rupture or 
hemorrhage, and in mouse mast cell presence was associated with plaque 
progression and lipid accumulation, as they provoke high-density lipoprotein 
(HDL) degradation and impair cholesterol efflux.(119, 120) In addition, mast cells 
have been shown to promote murine plaque instability and rupture through 
release of pro-inflammatory cytokines (IL-6, IFN-γ) and serine proteases, such 
as chymase and tryptase.(121, 122)  
 
4.3. Adaptive immunity in atherosclerosis 
In the last years it has been evidenced that the adaptive immune 
system is deeply involved in chronic inflammatory processes that drive the 
development of atherosclerosis.(123) Initial studies have ascribed a pro-
atherogenic role for T cells in atherosclerosis.(124) Remarkable numbers of T 
cells, mainly CD4+ Th cells, were characterized in all lesion stages in mouse and 
human, and were correlated with disease severity.(124) CD4+ T cells are 
attracted to the atherosclerotic plaque through DC-derived chemokines via 
CCR7, such as CCL19 and CCL21, and they are co-localized with mature DCs 
within the plaque.(125) It is believed that T cell activation is elicited in the lesion 
in response to LDL/oxLDL and endogenous ligands in a MHC-dependent 
manner.(126, 127) The importance of antigen presentation through MHC 
molecules was underlined by results of a study demonstrating that deficiency 
in the MHC class II invariant chain (CD74) significantly attenuated T cell 
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activation and plaque development in low-density lipoprotein receptor 
deficient (Ldlr-/-) mice.(128) Besides, the interplay between APCs and T cells in 
the atherosclerotic plaque has been evidenced by several studies, in which co-
stimulatory receptor-ligand pairs, known to be indispensable for T cell 
activation, were interfered. For instance, inhibition of the CD40-CD40L 
signaling pathway, a co-stimulatory dyad that promotes inflammatory 
processes through T cell stimulation, led to reduced lesion development and a 
more stable plaque phenotype.(129-131) 
During early lesion formation Th1 cells predominate over other Th cell 
subsets and IFN-γ release by Th1 cells can exert potent pro-atherogenic actions 
by activating macrophages and DCs. It has been shown that deficiency in IFN- γ 
or its receptor significantly reduced lesion size in ApoE-/- mice, and led to a 
more stable plaque phenotype.(132) The contribution of Th1 cells to lesion 
development and plaque destabilization was further supported by studies in 
which the T-box transcription factor TBX21 (T-bet), a key transcription factor 
for Th1 differentiation, was genetically deleted in Ldlr-/- mice. TBX21-deficiency 
reduced the atherosclerotic plaque burden, and caused a switch towards Th2 
cells.(133) In summary, these data corroborate the pro-atherogenic nature of 
Th1 responses. 
 In the context of atherosclerosis, Th2 cells have been denoted to 
function anti-atherogenic, and they are regarded as counterplayers of Th1 
cells.(134) In the mouse plaque severe and persistent hyperlipidemic conditions 
seem to shift the balance from a Th1 towards a Th2 cell type, accompanied by 
a loss of IFN-γ producing Th1 cells and the formation of anti-oxLDL IgG1 
autoantibodies, further supporting the anti-atherogenic effect of Th2 cells. 
However, the role of Th2 cells in atherosclerosis remains controversial, and 
seems to depend on the stage of lesion, the site of disease, and the 
experimental animal model used. For instance, the development of 
atherosclerosis in IL-4 deficient Ldlr-/- mice was reduced, specifically in the 
aortic arch and the thoracic aorta, whereas results of another study did not 
show effects of IL-4 deficiency on lesion development.(135, 136) In contrast, IL-10 
deficiency in ApoE-/- mice resulted in more advanced plaques that were prone 
to rupture and enriched in T cells and IFN-γ.(137) Nevertheless, IL-10 deficiency 
can also compromise Treg as well as tolerogenic Th17 cells. 
  A functional role for Th17 cells in atherosclerosis remains subject for 
discussion, and results are divergent. Hematopoietic deficiency in the IL-17 
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receptor in Ldlr-/- mice resulted in derogated atherosclerotic plaques.(138) In 
line, blockade of the IL-17 signaling in ApoE-/- mice by administration of IL-17 
neutralizing antibodies was shown to decrease atherosclerosis 
development.(139) In addition, IL-17 mRNA expression in human carotid plaques 
was correlated with complicated, unstable, and lipid-rich lesions.(140) In 
contrast, elevated levels of IL-17 in Ldlr-/- mice were seen to decrease the 
expression of VCAM-1 on ECs, thereby reducing vascular inflammation, and 
attenuating atherosclerotic lesion size.(141) To summarize, defining a functional 
role for Th17 cells in chronic inflammatory diseases, such as atherosclerosis, 
needs further examinations. 
Several studies have shown anti-atherogenic activities of Treg cells, 
either by direct effects on T cells or through effects on APCs.(142) For instance, 
loss of natural Treg cells by use of CD25 neutralizing antibodies deteriorated 
atherosclerosis.(143, 144) A recent study identified DC-derived CCL17 as a central 
regulator of Treg homeostasis in atherosclerosis. Deficiency or antibody 
blockade of CCL17 in hyperlipidemic mice reduced athero-progression by 
expanding Treg cells, whereas CCL17 expression in DCs restricted Treg cell 
maintenance to promote atherosclerosis.(145) 
 
 B cells, the second cell type of the adaptive immune system, are 
implicated in atherosclerosis as well. Their main function is to produce 
antibodies of various isotypes. Besides, they can also function as APCs. In 
recent years, the contribution of B cells to atherosclerosis has been confirmed. 
Several studies suggested a protective role for B cells, mainly through 
production of IgG and IgM anti-oxLDL autoantibodies.(146, 147) B cells have been 
detected in mouse and human atherosclerotic plaques, preferentially localized 
in the adventitia.(148, 149) Chimeric Ldlr-/- mice, deficient in B cells, revealed 
aggravated atherosclerotic plaques,(150, 151) supporting a protective role for B 
cells in atherosclerosis. However, a more recent study argued B cell deficiency 
to be athero-protective.(152) B cell depletion by use of a monoclonal anti-CD20 
antibody in Ldlr-/- and ApoE-/- mice resulted in significantly reduced 
atherosclerosis, and was accompanied by reduced DC and CD4+ T cell 
activation. 
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Hypothesis and study aims of this thesis 
 
Noticeable progress has been made in the recent years to understand 
the contribution of innate and adaptive immune responses to the onset and 
progression of atherosclerosis, as can be appreciated from the above sections. 
Specialized immune cells are involved in the pathophysiology of 
hyperlipidemia-associated atherosclerosis. In recent years different DC subsets 
were shown to be present in the healthy vasculature and the heart. In this 
regard, a possible role for DCs as contributors to inflammatory processes in 
atherosclerosis is gaining more and more attention, as they are important 
players in bridging innate and adaptive immune responses. The functionality of 
certain DC subsets under hyperlipidemic conditions and in the atherosclerotic 
plaque remains poorly understood, and studies addressing these issues are 
rare.  
 
Here, we hypothesize that different DC subsets are crucially involved in the 
pathophysiology of atherosclerosis by triggering immune responses. 
Therefore, one of the processing goals of this thesis was to explore their 
participation, with special emphasis on pDCs, in inflammatory processes in 
hyperlipidemia-associated atherosclerosis.  
In particular I will address the following research questions:  
 
• Do pDCs influence plaque development and progression? 
• Does a cholesterol-rich environment influence homeostasis and activation 
status of different peripheral (p)DC subsets? 
• Do pDCs have a specific gene signature in the human atherosclerotic 
plaque? 
 
In Chapter 2, a potential role for various DC subsets in certain CVDs, 
with a focus on the current knowledge in atherosclerosis, and their prospective 
use as therapeutic target in CVDs is reviewed. In Chapter 3, we studied effects 
of pDC depletion on atherosclerosis onset and progression in Ldlr-/- mice by use 
of a specific depletion antibody (120G8). We were the first to identify an 
athero-protective role for pDCs by tuning peripheral T cell proliferation and 
activity. In Chapter 4, we made use of a second conditional pDC ablation 
model - the BDCA-2 diphtheria toxin receptor (DTR) model- to study pDC 
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influence on atherosclerosis. A subgroup of mice additionally received a CD4+ T 
cell depleting antibody to address the contribution of CD4+ T cells to pDC 
immunity in atherosclerosis. In Chapter 5 we hypothesized that a dyslipidemic 
microenvironment inhibits TLR9-induced activation of pDCs, skewing T 
cell-mediated immunity. Therefore, we investigated how lipoprotein exposure 
affects human pDC maturation, activation and T cell stimulating capability. In 
addition, we investigated in Chapter 6, whether a hyperlipidemic environment 
is influencing DC homeostasis, their maturation and T cell priming ability in 
peripheral organs. In Chapter 7 we examined the impact of human plaque 
pDCs on its local context. Besides comparing the gene expression patterns 
between pDC-enriched and pDC-deficient regions, we employed co-expression 
cluster analyses to pinpoint specific pDC-associated gene modules that 
correlate with the presence of T cells and macrophages in the pDC-enriched 
plaque regions. Chapter 8 affords a discussion of the most relevant results of 
this thesis and debates future perspectives.  
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 Cardiovascular diseases (CVD) are the number one cause of death in 
the Western World. It has been so for decades, notwithstanding a wide array 
of – mostly preventive - treatment modalities targeting known risk factors, 
such as hyperlipidemia, type 2 diabetes mellitus, hypertension or obesity. 
Recent technical and conceptual advances have unveiled important 
contributions of the immune system in the pathophysiology of CVD. The 
pronounced presence of several subsets of dendritic cells (DC), central 
orchestrators of both innate and adaptive immune responses, in vasculature, 
heart and brain during disease onset as well as progression already alludes to 
such a role. In support, recent studies point to their likely involvement in 
immune responses in atherogenesis, as well as after myocardial infarction and 
ischemic stroke. DCs might thus represent a real opportunity to treat CVD not 
by a preventive strategy, but by interfering with the pathophysiological 
processes themselves: they hold promising potential as therapeutic tools in 
cardiac transplantation or as part of a future atherosclerosis vaccination 
strategy. In recent years, several research groups have addressed different 
aspects of DC biology in CVDs. Nevertheless, the full scope of DC-driven effects 
in CVD is still unclear. Here, we present an overview of the current knowledge 
on DC’s impact on CVDs. We shall discuss pitfalls and shortcomings, and define 
questions required to enable a thorough appreciation of the validity and 
potential of DCs as therapeutic targets in CVDs. 
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1. Introduction 
 
Cardiovascular diseases (CVDs) are one of the leading causes of 
mortality worldwide.(1) A growing body of evidence points to a pivotal role of 
the immune system in the pathophysiology of a variety of CVDs such as 
atherosclerosis, ischemic stroke, chronic heart failure, and other myocardial 
conditions like myocardial ischemia and reperfusion, viral myocarditis and 
cardiac transplantation.(2-4) In many of these disorders so-called danger-
associated molecular patterns (DAMP), released from necrotic tissue and dying 
cells, can lead to the activation of certain immune cell populations such as 
monocytes/ macrophages, granulocytes and T cells, thus aggravating ongoing 
inflammatory processes at the lesion site. Dendritic cells (DCs) are key 
modulators of immunity, pivotal in directing innate and adaptive immune 
responses against microbial, but also modified self-antigens present at sites of 
injury.(5) Given the tissue trauma underlying various CVDs, it is not surprising 
that recent observations have allocated a regulatory role for DCs in CVD-
associated immune responses. Interestingly, non-diseased arteries of young 
individuals were seen to host a network of resident vascular DC(6), a finding 
that was confirmed for the atherosclerotic-prone lesser curvature and sinus of 
aorta in mouse models of atherosclerosis.(7) DCs, exhibiting an immature 
phenotype with low expression of co-stimulatory molecules, are present in the 
subendothelial space with occasional probing into the vascular lumen. DCs 
have also been observed in human heart and in cardiac valves of healthy 
C57BL/6 mice.(8) It is assumed that these immature, resident DCs contribute to 
the maintenance of vascular homeostasis and tolerance by scanning their 
microenvironment for self and non-self antigens. Indeed, Choi et al. were able 
to show that resident DCs, isolated from the aorta and the valves of wild-type 
mice, have the capacity to present antigens to CD8+ T cells in vitro and in vivo, 
indicating that they are fully functional in eliciting a T cell response.(9)  
In diseased vessels, heart and brain of human CVD patients, but also in the 
circulation, DC subset numbers were reported to be modified, associating DCs 
with CVD onset and progression.(10-12) This notion is substantiated by a wealth 
of experimental animal studies addressing the involvement of DCs in CVDs. 
However, it remains mainly unsettled whether actions of different DC subsets 
are either detrimental or beneficial for lesion formation. Then again, DCs might 
function both-way, dependent on the lesion stage. This review thus aims to 
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provide an in depth overview of the role of DC subsets in several 
cardiovascular conditions in human and experimental animal models to reveal 
underlying patterns, expose lacunae in our current understanding of DC’s 
function in CVDs, and explore possible therapeutic opportunities, exerted by 
modified DCs.  
 
2. Dendritic cells: conductors of innate and adaptive immune responses  
 
DC are professional antigen-presenting cells (APC) that originate from 
hematopoietic precursors in the bone marrow and are distributed throughout 
the whole body. DCs have the unique ability to induce T cell responses by 
capturing, processing and presenting antigens to naïve T cells. As such, they 
are central mediators of adaptive immune responses, and, depending on 
subset and activation status, of the development of immunological memory 
and tolerance.(5) Since the discovery by Steinmann and Cohn,(13) DCs were seen 
to represent a heterogeneous family of cells, differing in terms of 
development, migratory cues, compartmentalization, phenotype and 
immunological functions. DCs are categorized into conventional DCs(cDCs) and 
non-conventional DCs, the latter comprising plasmacytoid DCs (pDCs) and 
monocyte-derived inflammatory DCs,(5) characterized by the expression of a 
panel of specific surface markers. For further details we refer the reader to a 
variety of excellent reviews on DC development, phenotyping and/or DC 
functions.(14, 15) 
 
3. Circulating DC subsets in patients with coronary and peripheral arterial 
disease 
 
As an indirect measure of DC’s association with CVDs, DC (precursor) 
numbers and functionality have been evaluated in blood of patients with CVD, 
such as coronary and peripheral artery disease.(16, 17) In 2006, van Vre et al. 
were the first to describe a marked decrease in circulating DC precursors 
(circulating cDC and pDC) in patients with coronary artery disease (CAD), 
defined by angiography as > 50% stenosis in one or more coronary arteries.(18) 
Until now, several studies confirmed a significant decrease in blood DCs (cDC 
and pDC) in CAD patients, irrespective of CAD grade (stable vs unstable angina 
pectoris, AMI), number of diseased vessels, or subset markers used for DC 
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enumeration.(16, 19-25) In sharp contrast, Shi et al. reported increased circulating 
cDC and unaltered pDC numbers in patients with stable CAD.(26) By 
investigating the distribution of circulating DCs in patients with different stages 
of peripheral arterial disease, including patients with intermittent claudication 
and critical limb ischemia, Dopheide and coworkers showed that blood cDC 
numbers were increased, whereas pDC numbers were reduced in peripheral 
arterial disease patients compared to healthy controls.(17) Of note, both cDCs 
and pDCs from critical limb ischemia patients revealed an immature 
phenotype, suggesting that severe ischemia and/or prolonged inflammation in 
this ailment might lead to an attenuation in the pro-inflammatory membrane 
patterns of circulating DC subsets.(17)  
Generally, most patient studies show declined blood DC numbers in CAD 
patients. Inconsistent results may be explained by differences in the extent 
and localization of disease, the timing of blood sampling (before/ after a 
surgical intervention; lesion onset versus progression), the prevalence of risk 
factors across the patients included in these studies, and the cohort sizes 
consulted (Table 1).  
Nevertheless, the actual cause for reduced circulating DC numbers remains 
unaddressed. One possibility for the decrease in circulating DCs might be their 
enhanced recruitment to the disease site (hence plaque or the ischemic 
heart).(10) Alterations in circulating DCs have been described in other 
autoimmune diseases as well, such as systemic lupus erythematosus (SLE),(27) 
where markedly lowered blood DC numbers correlated with an accumulation 
of activated DC in the inflamed tissue. In analogy, DCs could well be recruited 
to secondary lymphoid organs to prime naïve T cells.(28) Circulating oxidized 
low-density lipoprotein (oxLDL) or circulating immunocomplexes,(29) but also 
ischemic tissue derived DAMPs were seen to induce DC activation,(30) thus 
promoting their extravasation to spleen or lymph nodes. Actually, several 
studies have shown in CAD patients a more mature phenotype on a minor 
subset of circulating CD11chigh (BDCA-1+) cDCs, BDCA-2+ pDCs, as well as on 
monocyte-derived DCs, represented by the up-regulation of CD83, CD80, CD86 
and/ or CCR7.(31, 32) Second, the apparent blood DC depletion could however 
also be explained by increased DC turnover, due to increased circulating 
cholesterol levels. Indeed, Alderman et al. have demonstrated in vitro that high 
concentrations of oxLDL provoke DC apoptosis.(33) Otherwise, declines in DC 
numbers could be a temporary response to acute ischemia. Third, reduced 
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blood DC numbers might also result from decreased release from bone 
marrow. Interestingly, van Brussel et al. have shown diminished plasma levels 
of FMS-like tyrosine kinase 3 ligand (Flt3L) in CAD patients, a growth factor that 
is responsible for DC differentiation and release from bone marrow.(22) Fourth, 
the altered blood DC abundance, phenotype and function could be owing to 
CAD patient’s medication, including aspirin, statins, beta-blockers and 
angiotensin-converting enzyme (ACE-) inhibitors. While supported by several in 
vitro studies,(34-37) the validity of this notion needs further investigation.  
Recapitulating, circulating DC decline cannot be exclusively linked to the 
compartmentalization of this subset, be it to atherosclerotic plaque or 
lymphoid organs, as other covariates may as well modify blood DC numbers 
and functionality. This needs to be further addressed in future studies. 
Moreover, these observational studies leave unaddressed whether DCs are 
active contributors or just casual bystanders.  
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Table 1. Circulating DC populations in human CVDs. Overview of the most important studies 
describing DC numbers in blood of patients suffering from various cardiovascular conditions. 
Publications are grouped per condition, and results on total DC, cDC and pDC numbers are 
summarized. In addition, information about the build-up of the cohort size is given as well as the 
article citation. CAD: coronary artery disease, PAD: peripheral artery disease, T2D: type 2 
diabetes, HF: heart failure, CTR: control, EXP: experimental group, SAP: stable angina pectoris, 
UAP: unstable angina pectoris, AMI: acute myocardial infarction, mDC: myeloid DCs, STEMI: ST-
segment elevation myocardial infarction, NSTEMI: non-STEMI, IC: intermittent claudication, CLI: 
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critical limb ischemia, ACI-S: asymptomatic cerebral infarction stenosis, TIA: transient ischemic 
attack, AIS: acute ischemic stroke, AHS: acute haemorrhagic stroke, NYHA: New York Heart 
Association (classification for heart failure). 
 
 
4. DC involvement in vascular inflammatory processes 
 
Beside their presence in atherosclerosis, DC attendance has been 
described in other chronic inflammatory vasculopathies, such as giant cell 
arteritis, Takayasu’s arteritis and Kawasaki disease.(38-40) It is hypothesized that 
they contribute to the first critical steps in disease pathogenesis through 
breakdown of vascular tolerance. In these vasculopathies resident DCs are 
located in the adventitia and adventitia-media border, and (c)DC numbers are 
seen to increase with disease progression.(40) Dense infiltrates of mature cDCs 
and T cells have been described at later stages as well, reflective of DC-
initiated, antigen-specific immune responses. Considering that DC networks 
are present in healthy arteries and that they function as professional APCs, 
they might well be involved in disease onset and progression through 
presentation of modified (self-) antigens to T cells. The actual triggers to 
activate vascular DCs are yet unknown, as is their relative contribution to 
immune priming in comparison to other vascular resident APCs such as 
macrophages. Altogether, a functional role for DCs in the pathogenesis of 
these diverse inflammatory vasculopathies remains to be established, as 
studies are of rather descriptive nature. 
 
A functional role for dendritic cells in atherosclerosis 
 
In human atherosclerotic plaques, fully mature DCs (CD83+ CD86+) 
accumulate within the rupture-prone atherosclerotic plaque shoulder where 
they produce T cell chemotactic (CCL19 and CCL21), and pro-inflammatory 
cytokines (interleukin-12 (IL-12), IL-23 and tumor necrosis factor α (TNF-α)).(41) 
Mapping of plaque-residing DCs revealed a close contact between DCs and 
activated T and NKT cells, suggesting that DCs tune or even orchestrate 
immune responses relevant to atherosclerosis.(41) Of note, many of the 
histology studies are thwarted by the moderate/poor specificity of most DC 
markers, rendering DC’s immunohistochemical detection a delicate issue. The 
additional use of other techniques, such as flow cytometric cell isolation, could 
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help here to better appreciate DC presence and phenotype in different stages 
of atherosclerosis. 
Mouse models have been very insightful in elucidating DC functions in 
atherosclerosis. For instance, lipid accumulation in the initial stages of 
atherosclerosis was recently shown to be directed and regulated by intimal 
CD11c+ DCs, residing in the atherosclerotic-prone lesser curvature of the aortic 
arch.(42) The impact of lipid uptake by resident vascular DCs on their 
functionality remains a controversial subject. Dyslipidemia was seen to lead to 
a retention of DCs and macrophages in the atherosclerotic plaque.(43, 44) 
However, as reported in several studies antigen-presentation and T cell 
priming ability by DC remains unaffected under hyperlipidemic conditions, 
even after excessive lipid-loading.(45, 46) In a transgenic mouse model with cDC 
specific overexpression of the anti-apoptotic gene hBcl-2, the induced 
enhanced lifespan and immunogenicity of circulating cDCs  was associated 
with enhanced T cell activation, elevated levels of T helper 1 (Th1) and Th17 
cytokines and increased production of Th1-driven IgG2c antibodies under 
hyperlipidemic conditions.(45) This major functional DC expansion did not 
aggravate lesion formation, as it was compensated for by decreased plasma 
cholesterol levels. Further support for a link between DC function and lipid 
metabolism was derived from the augmented plasma cholesterol levels after 
cDC depletion in hyperlipidemic ApoE-/- mice crossed to CD11c diphtheria toxin 
receptor (CD11c-DTR) transgenic mice.(45) Precise mechanisms that underlie 
cDC involvement in cholesterol homeostasis have only scarcely been explored. 
Cholesterol lowering by DCs is suggested to occur in the periphery where DCs 
are amongst others exposed to lipoproteins. The behavior of circulating cDCs 
in patients with familial hypercholesterolemia has not yet been analyzed. Such 
data will allow to elucidate whether DCs are involved in lipoprotein clearance 
and how this is influencing DC functionality. Several lines of evidence suggest 
that oxLDL, present in the plaque, can impact DC maturation already in the 
initial stages of atherosclerosis. In vitro exposure to oxLDL during 
differentiation of human monocytes resulted in phenotypically mature DCs 
with upregulated HLA-DR, CD40 and CD86 and induced capacity to T cell 
activation.(33, 47) However, incubation with high concentrations of oxLDL 
attenuated DC function and induced apoptosis.(33) A strong inhibition of oxLDL 
on expression of CCR7 and its ligand CCL21 by monocyte-derived DCs was 
recently reported by Nickel et al., which likely will impact their migratory 
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capacity in plaque.(48) As shown by Kopf and coworkers, dyslipidemia also 
affects CD8α- cDC function, impairing their response to Toll-like receptor (TLR) 
stimulation in vitro and in vivo during Leishmania major infection. OxLDL 
appeared to be directly responsible for this effect, as it uncoupled TLR-
mediated signaling in DCs, leading to decreased DC activation and dampened 
Th1 responses.(49) Similarly, Blueml et al. have shown that oxidized 
phospholipids impair DC maturation by blocking TLR3 and TLR4 mediated up-
regulation of co-stimulatory molecules and induction of pro-inflammatory 
cytokines in human DCs.(50) These data are in line with previous studies, 
showing an anti-inflammatory effect of oxLDL in LPS-stimulated 
macrophages.(51, 52) 
Taken together, considerable controversy exists on DC function(s) in 
hyperlipidemia-associated atherosclerosis. The still ongoing characterization of 
classical DC subsets within the vasculature(30, 53) makes it even more complex to 
comprehend DC (subset) contribution to plaque burden. It will be of 
importance to uncover how early and more advanced stages of hyperlipidemia 
impair DC (precursor) homeostasis, including their development in the bone 
marrow, DC mobilization into the circulation, peripheral phenotype, and 
migratory routes. In addition, extensive knowledge about DC actions within a 
lipid-rich environment such as the atherosclerotic plaque is lacking. How lipid 
uptake and prolonged intracellular storage interfere with signaling pathways 
responsible for DC activation is still controversial and will require further study.  
 
A functional role for plasmacytoid dendritic cells in atherosclerosis 
 
The group of Weyand and coworkers has recently shown the presence 
of CD123+ pDCs in human carotid atherosclerotic plaques, mainly located in 
the shoulder region that was also enriched in interferon-α (IFN-α) positive 
cells, thus associating pDC presence with IFN-α production.(54) Furthermore, 
pDC numbers were significantly increased in unstable compared to stable 
human lesions. In vitro CpG-induced IFN-α release by pDCs induced a 10-fold 
up-regulation of tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL) expression on CD4+ T cells, thus promoting apoptosis of vascular 
smooth muscle cells (vSMC) and endothelial cells (ECs), processes that 
tremendously contribute to plaque destabilization.(54) However, these data 
leave unaddressed whether pDCs are functional in the atherosclerotic plaque 
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in vivo. We and others have recently shown that CD123 displays only moderate 
specificity for human pDCs, being co-localized also with CD68+ macrophages 
and with ASMA+ vSMC.(10, 55) Use of the human pDC specific marker blood 
dendritic cell antigen 4 (BDCA-4) by our group revealed the scanty and 
equivalent presence of pDCs in human stable and unstable plaques. Moreover, 
we demonstrated that expression of IFN-α in human unstable versus stable 
carotid endarterectomy tissue specimens did not differ, suggesting that in 
chronic low grade inflammatory processes, such as atherosclerosis, pDC 
activation may not be a prominent feature.(55)  
Our group has recently shown that selective depletion of pDCs by 120G8 
monoclonal antibody administration in Ldlr-/- mice fed a high fat diet (HFD) 
exacerbated lesion size in the carotid artery and the aortic roots, and 
promoted plaque T cell accumulation as well as peripheral CD4+ T cell 
activation. pDCs isolated from atherosclerotic mice suppressed CD4+ T cell 
proliferation in an indoleamine-2,3-dioxygenase (IDO)-dependent manner, 
pleading for an athero-protective role for pDCs in atherosclerosis.(55) In 
contrast to our study, Doering et al. and MacRitchie et al. reported significantly 
decreased diet-induced lesion formation in the aortic root and the aorta of 
pDC-depleted ApoE-/- mice, while plaques showed a more stable phenotype. 
Both groups investigated the impact of pDC depletion by use of the PDCA-1 
depletion antibody on early lesion development (4 weeks of HFD feeding).(29, 56) 
These controversial findings are intriguing. A seeming paradox was in the 
presence of pDCs in the atherosclerotic plaque. While pDCs could barely be 
detected in mouse atherosclerotic lesions in Ldlr-/- mice(55), Doering et al. 
showed the presence of pDCs in lesions of ApoE-/- mice, mainly in the plaque 
shoulder, at which pDC abundance was increased with HFD feeding and lesion 
progression.(29) Conversily, MacRitchie et al. described the constitutive 
presence of mostly immature pDCs in non-inflamed aortic tissue of 
normolipidemic mice, at numbers similar to those seen in atherosclerotic 
ApoE-/- mice. Nevertheless, antigen presentation capacity of aortic pDCs from 
ApoE-/- mice was enhanced.(56) In line, Doering et al. showed that sorted aortic 
pDCs from hyperlipidemic mice, ex vivo primed, were capable to trigger T cell 
stimulation in vivo.(29) Finally, baseline IFN-α levels were below detection levels 
or not affected by pDCs in our study and the study of MacRitchie et al.,(55, 56) 
whereas Doering et al. demonstrated elevated IFN-α levels in plaque (mRNA) 
and serum in HFD fed ApoE-/- mice, being reduced after pDC depletion.(29) It has 
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to be noted that the groups employed different methodologies, such as the 
use of the depletion antibody, administration regimen and mouse models. As 
instance, ApoE-/-, the model used by Doering et al. and MacRitchie et al., 
displays more aggressive atherosclerosis than the Ldlr-/-, which may favor pDC 
switching to an immunogenic mode. Regarding the complex pathophysiology 
of atherosclerosis, pDCs could well exert dual functions in early and advanced 
stages of disease, dependent on their microenvironmental context. During 
episodes of fulminant plaque inflammation pDCs acquire pro-atherogenic 
functions by rapid secretion of type I IFNs and pro-inflammatory cytokines, 
while during low grade chronic inflammatory stages, pDCs may act tolerogenic 
by inhibiting proliferation of CD4+ T cells. Indeed, pDCs are involved in the 
pathogenesis of a range of autoimmune diseases characterized by a type I IFN-
signature,(57) whereas alternatively activated pDCs are considered to contribute 
to tolerance induction.(57) Further studies are warranted to elucidate the actual 
pathways that are activated in pDCs during different stages of atherosclerosis 
by using more advanced animal models, such as conditional E2-2 knockout.(57, 
58) Nevertheless, the above findings clearly identify this cell type as an 
interesting new target for future therapeutic intervention studies in the 
treatment of atherosclerosis. 
 
5. CVD risk factors: contribution of DCs? 
 
Type 2 diabetes mellitus (T2D) and hypertension are major risk factors 
for the development of atherosclerosis and its cardiovascular complications. 
Chronic inflammation is thought to accelerate the progression of these 
pathological conditions.(59, 60) DCs are likely to contribute here by triggering 
cell-mediated immune responses. The following two sections outline the 
current knowledge on potential DC functions in T2D and hypertension. 
 
A role for DCs in type 2 diabetic patients with atherosclerotic complications 
 
Insulin resistance and hyperglycemia in T2D are associated with a 
systemic pro-inflammatory state (increase in pro-inflammatory cytokines such 
as IL-6, activation of immune cells) that facilitate the development of 
atherosclerosis.(52) In vitro studies have shown that advanced glycosylation end 
products (AGEs)(61) and hyperinsulinemia(62) enhance DC maturation and induce 
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an antigen-specific T cell activation, thus supporting a contributory role of DC 
(subsets) on the immune reactions in diabetic atherosclerosis. Yao et al. 
recently reported a significant decline in circulating cDCs in T2D patients with 
unstable angina pectoris (UAP) vs. healthy controls and T2D patients, while 
pDC numbers remained mainly unaltered.  cDCs showed a more mature and 
activated phenotype, evidenced by the up-regulation of CD86 and the 
enhanced capability to stimulate T cell proliferation in vitro.(63) Reduced 
circulating DC numbers in T2D patients with atherosclerotic complications was 
attributed to an increased trafficking into the inflamed vulnerable plaque or to 
neighbouring lymph nodes as patients had significantly increased levels of 
fractalkine, an important chemokine for DC attraction to sites of 
inflammation.(63) In contrast to these findings, Orfao and coworkers showed 
both quantitatively and functionally impaired pro-inflammatory cytokine 
response by circulating DCs from T2D patients with atherosclerotic 
complications.(64) Conceivably, the increased plasma TNF-α levels observed in 
patients with diabetic atherosclerosis may underlie this impairment, as it can 
tone blood DC differentiation.(65) This notion is encouraged by studies, 
describing an inverse correlation between blood DC numbers and plasma TNF-
α concentrations in T2D.(66, 67) Of note, medication employed for glycemic 
control and/or for the treatment of diabetes-related comorbidities (ACE 
antagonists, angiotensin receptor blockers, or statins) could be partly causal in 
the altered blood DC abundance.(60) Altogether, although DC function is clearly 
perturbed in T2D, the present state of knowledge does not allow to segregate 
atherosclerosis from T2D intrinsic DC effects. 
 
A role for DCs in hypertension 
 
T cells have been described to contribute to hypertension,(68) a process 
that likely involves their priming by APCs, such as DCs, with the capacity to 
present neoepitopes, generated by necrotic and apoptotic cells.(59) However, 
less is known regarding the role of DCs in hypertension. DC accumulation in 
alveolar lesions of human and experimental pulmonary arterial hypertension 
has been described.(69) Recently, Vinh et al. have shown that the CD28 blocking 
agent Abatacept prevents angiotensin II (Ang II)-induced hypertension in mice, 
supporting a contributory role for DCs as APCs in hypertension.(70) Additionally, 
they observed increased activated DC numbers in spleen and lymph nodes of 
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hypertensive mice.(70) However, these data leave unaddressed whether DCs 
are the primary cell type responsible for antigen presentation. The more 
abundant vascular macrophages in the vessel wall might as well function as 
APCs. Interestingly, the renin-angiotensin-aldosterone system can by itself 
initiate/ modulate innate and adaptive immune responses and inflict target-
organ damage as shown by the group of Mueller and coworkers in a 
compound transgenic rat model harboring human renin/angiotensin genes.(59) 
Activation of the AT-IA receptor, amongst others expressed on DCs, promoted 
DC migration to the kidneys and their activation, potentially inducing renal 
damage.(59) Moreover, Id2-/- mice – lacking Langerhans cells (LC) and CD8+ DCs - 
infused with Ang II remained normotensive and failed to develop albuminuria 
and renal damage, firmly establishing a role for LCs and CD8+ DCs in Ang II-
induced hypertension.(59) These data support the idea that Ang II itself can 
influence T cell ‘fate’ both directly or indirectly.  
 
6. DC contribution to ischemic stroke: friend, foe or bystander? 
 
Only recently immune mechanisms were recognized to contribute to 
the pathophysiology of ischemic stroke, and involve both the innate and 
adaptive immune system.(4) A potential role for DCs as potent mediators of 
inflammation in stroke has not been investigated extensively. Yilmaz et al. 
have shown that circulating cDC as well as pDC numbers were transiently 
reduced in patients with acute stroke.(11) They postulated that circulating DCs 
are recruited into the infarcted brain to elicit antigen-specific immune 
responses through T cell activation. Indeed, HLA-DR expressing cDCs co-
localized with T cells in dense infiltrates around cerebral vessels in the stroke 
area.(60) The pro-oxidant conditions of ischemia-reperfusion may give rise to 
the formation of neoepitopes, which can well be presented by APCs, such as 
HLA-DR expressing residential microglia or recruited DCs. It cannot be excluded 
that other factors, such as increased cell apoptosis may contribute to the 
declined circulating DC numbers, as it has been shown for lymphocytes after 
stroke.(71) Interestingly, Gelderblom et al. revealed in a rodent stroke model 
(temporary middle cerebral artery occlusion) the early accumulation of DCs, 
peaking on day 3 after reperfusion.(72) DCs showed strong and sustained up-
regulation of MHC class II, but an absent concomitant up-regulation of co-
stimulatory molecules, possibly leading to disrupted T cell activation. While 
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such a phenotype is conceivable, this warrants further study on whether DCs 
are active contributors to local immune responses after stroke, either in an 
immunogenic or immunosuppressive way.  
 
7. DC involvement in the diseased heart 
Circulating DCs in heart failure patients  
 
The association between circulating DCs and heart failure has only 
been subject of a few scattered studies and study outcomes are rather 
divergent. Athanassopoulos et al. have revealed an increase in total blood DCs 
in patients with chronic heart failure (non-ischemic dilated cardiomyopathy) 
compared to controls due to an increase in the mature fraction of the cDC 
subset (CD83+ CCR7+), suggesting a possible Th1 response in end-stage heart 
failure.(73, 74) In seeming contrast, Sugi et al. showed that total circulating DC 
numbers were transiently declined, but residual DCs appeared more activated 
during the acute decompensated phase of heart failure.(12) Comparable to the 
decline in circulating DC counts in CAD patients, the authors associate 
diminished DC numbers in heart failure with DC recruitment from systemic 
circulation into the damaged tissue in response to released DAMPs. Clearly, 
other confounders with the potential to modify circulating DC counts (e.g. 
development in the bone marrow and release into the circulation, cell 
apoptosis, trafficking routes) have to be taken into account. To conclude, a 
direct involvement of DCs in the pathophysiology of heart failure, while 
plausible, remains elusive. Moreover, further studies are warranted to 
precisely define the cause of systemic DC modifications, taking different 
disease stages (acute versus chronic) into account.  
 
Myocardial Ischemia and Reperfusion 
 
A role for DCs in the pathogenesis of cardiac ischemia/ reperfusion 
injury (IRI) is not well-established. In 1993, Zhang et al. demonstrated the rapid 
accumulation of interstitial DCs in the border zones 7 days post myocardial 
infarction (left coronary artery ligation) in the rat heart.(75) DCs tended to be 
assembled in small clusters with CD4+ T cells, which disappeared 21 days after 
coronary ligation. It is assumed that these DCs are involved in post-ischemic 
short-term cytoprotective responses through TLR2 and TLR4 stimulation by 
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tissue released DAMPs.(76) Maekawa et al. on the contrary demonstrated in a 
murine myocardial infarction model (left coronary artery ligation) that deletion 
of interleukin-1 receptor-associated kinase-4 (IRAK-4), a downstream effector 
of the TLR/MyD88 axis, had beneficial effects on survival and function after 
myocardial infarction by blunting DC mobilization into the heart and 
attenuating local inflammatory processes.(77) Of note, cardiomyocytes and 
residential macrophages also express TLR2 and TLR4, and are able to respond 
to endogenous DAMPs, thereby contributing to inflammatory processes after 
myocardial infarction.(3)  
Altogether, the presence of DCs in the heart and their post-ischemic 
accumulation has been demonstrated. Concerning their role as professional 
APCs in parallel to phagocytes and cardiomyocytes, DCs likely exert functions 
in acute myocarditis by steering cell-mediated immune responses.  
 
Viral myocarditis  
 
Even less is known about a contribution of DCs to the pathogenesis of 
viral myocarditis. Virus infections can inflict significant damage on 
cardiomyocytes by (1) immune-response mediated, (2) autoimmune-mediated, 
or (3) direct virus-induced myocardial injury, which can cause myocarditis and 
dilated cardiomyopathy. Many animal studies have been performed in this 
field using models of myocarditis caused by coxsackievirus B3 (CVB3).(78) In 
response to viral infections, immune cells, such as cardiomyocytes, endothelial 
cells, fibroblasts, and DCs were reported to infiltrate up to five days 
postinfection, supposed to limit viral replication by the release of pro-
inflammatory cytokines (IL-1α, IL-1β, IL-6, IL-18, TNF-α, TNF-β, and IFN-γ).(79, 80) 
In the subacute phase (within two weeks after viral infection) the release of 
progeny virus into the interstitium stimulates the infiltration of pro-
inflammatory natural killer (NK) cells and macrophages, followed by a 
considerable influx of antigen-specific CD4+ Th and cytotoxic CD8+ T cells, which 
recognize viral antigens presented via MHC molecules on the surface of 
infected cardiomyocytes.(80, 81) Interestingly, in a mouse model of 
Coxsackievirus myocarditis it has been shown that CD8+ DCs, next to 
cardiomyocytes, are implicated in CD8+ T cell priming, thereby curtailing viral 
infection in the acute phase (within 8 days postinfection).(82) Whether or not 
DCs are implicated in low-grade inflammation during chronic myocarditis (days 
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15-90 postinfection) remains unclear. In particular pDCs, the major type I IFN 
producers in response to viral infection, have not received much attention so 
far, but may be likely mediators in anti-viral defense in the heart, although 
endogenous type I IFN release by infected cardiomyocytes could as well limit 
viral replication in the heart.  
 
 
 
 
Figure 1. Schematic overview representing the possible impact of DCs in CVDs. (A) Risk factors 
critically contributing to ischemic stroke and heart failure can directly interfere with the 
activation state of DCs. (B) Epitopes released from necrotic tissue or dying cells of the damaged 
organs could additionally induce phenotypic changes in DCs (indirect effect), thus finally leading 
to (C) DC immunogenicity or tolerance. (D) Chronic DC activation potentially constitutes 
detrimental effects due to release of pro-inflammatory cytokines and the activation of CD4+ and 
CD8+ T cells, which in turn causes further organ damage. Otherwise, (E) induction of tolerance by 
DCs may thwart immunogenic responses by eliciting T cell anergy/ apoptosis and the generation 
of regulatory T cells. (F) Pathogen-derived signals, and (G) the local environment most likely 
impair DC functionality sustained through (a) or (b), thereby boosting or abating DC-mediated 
immune responses. 
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8. DC targeted therapeutic opportunities in cardiovascular disease 
Targeting DCs in cardiac transplantation: contributors to graft rejection or 
useful tools in tolerance induction 
 
The role of DCs as modulators of alloreactive and autoreactive T cell 
responses after transplantion has been extensively studied.(83) DCs hold 
promise as therapeutic tools to ameliorate or prevent graft rejection or graft-
versus-host disease (GVHD), and to treat autoimmune diseases.(84, 85) DCs are 
implicated in the recognition of allo-antigens by the host’s immune system. As 
Larsen et al. demonstrated, mature donor-derived DCs are homing to T cell 
areas in the draining lymph nodes in the first days after transplantation, where 
they trigger naïve T cells by presenting graft-derived epitopes. Thus potentially 
contributes to acute rejection of cardiac allografts.(86) Similarly, Kofler et al. 
reported pronounced infiltration of recipient DCs into the cardiac allograft, 
picking up and processing the donor antigens, and activating the recipient’s 
adaptive immune system in the first postoperative year after human heart 
transplantation.(87) Summarized, DCs appear to be main culprits in organ 
rejection, but have otherwise been shown to mediate transplant tolerance by 
preventing T cell-mediated immunity. Ochando et al. have demonstrated an 
essential role for pDCs as phagocytotic APCs in tolerance induction in 
vascularized cardiac grafts, in that adoptive transfer of tolerized pDCs induced 
regulatory T cell development and prolonged graft survival in mice.(88) Likewise, 
a single pre-operative infusion of donor-mobilized immature pDCs in 
combination with anti-CD154 monoclonal antibody was able to effectively 
suppress allograft rejection and prolonged graft survival in mice.(89) These 
findings are concordant with a recent study in human that examined total 
peripheral blood DC numbers in patients with clinical heart transplantation 
(HT), revealing significantly diminished DC frequency one week post HT, which 
probably reflects immunological quiescence through adequate 
immunosuppression.(90)  
In summary, adoptive transfer of pre-primed (tolerogenic) DCs seems to hold 
great promise for preventing graft rejection after cardiac transplantation. For 
all that, a better understanding of how graft-infiltrating DCs function, may also 
help to appreciate their contributory roles in chronic heart failure and post-
myocardial infarct healing. At first glance these processes seem unrelated, but 
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similar immune pathways activated in the different disease settings may help 
to refine DC’s contribution to certain CVD. 
 
DCs as potential therapeutic tools in the treatment of atherosclerosis  
 
As alluded to, DC-based vaccination and immunization strategies, 
based on application of ex vivo antigen loaded or genetically engineered 
autologous DCs to tune T cell responses have meanwhile evolved into a viable 
therapeutic option for cancer.(91) This success has inspired several groups to 
explore the potential of DC-based vaccination for atherosclerosis. Studies in 
animal models so far are at least encouraging and support the notion that DC-
based vaccination and immunization hold promise for therapeutic 
immunomodulation of atherosclerosis.(92) Kuiper and coworkers have shown 
that transferred oxLDL-pulsed mature DCs into Ldlr-/- mice reduce 
atherosclerotic lesion size. DC vaccination led to quenched Th1 responses and 
elevated oxLDL-specific IgG titers indicating that oxLDL-pulsed DCs may confer 
protection against atherosclerosis, by favoring humoral immune responses to 
oxLDL.(93) Other groups have shown that repeated injection of antigen-loaded 
immunogenic DCs (oxLDL or malondialdehyde modified LDL (MDA-LDL)) 
aggravated atherosclerosis.(94) A recent study proposed immunotherapy with 
DCs, pulsed with apolipoprotein B100 in the presence of IL-10 to render them 
immunosuppressive, as an effective strategy to attenuate atherosclerosis. DC 
immunotherapy resulted in reduced proliferation of effector T cells, dampened 
Th1 and Th2 immunity and diminished atherosclerotic lesion formation in 
mice.(95) Taken together, the outcome of these studies indicates that DC 
vaccination emerges as a new, potentially powerful approach in the treatment 
of atherosclerosis, although translation of these largely animal experimental 
findings to human disease needs further investigation. A second thwart will be 
the establishment of exclusively atherosclerosis-specific antigens to avoid 
systemic immunity.  
Furthermore, therapy timing and the immunological status of the patient are 
additional important issues that need to be considered carefully, given that 
atherosclerosis mainly affects the elderly. Indeed, age-dependent alterations in 
expression and function of innate immune receptors and signal transduction 
pathways may translate in defective DC activation, thus diminishing the DC-
based vaccination efficacy.(96) Nevertheless, promising developments in the 
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cancer field, where ex vivo pulsed DC have been successfully applied in phase 
I/II clinical trials, stem hopeful and prompt to further investigations in DC 
therapy for CVD treatment.  
 
9. Concluding remarks 
 
This review summarizes the current state of knowledge on the role of 
different DC subsets in the pathogenesis of CVDs, pinpoints shortcomings/gaps 
and delineates the future perspectives for DCs as therapeutic target in CVDs. 
By now several DC subsets have been reported to accumulate not only in 
atherosclerotic or hypertensive vessels, but also in failing, cardiomyopathic or 
ischemic heart tissue and in ischemic brain, suggestive of a role in the 
underlying pathophysiology. DC (precursor) numbers and functionality in blood 
of patients with CVD have been embraced as measure of DC association with 
disease onset and progression, although cause and implications of these 
disease-associated changes in DC homeostasis still are subject of discussion. 
Moreover, the actual value of circulating DCs as biomarkers in CVDs needs to 
be established, but it is fairly improbable that DC subset numbers will offer the 
precision, specificity and discriminative power to be useful as biomarkers. Of 
all cardiovascular disorders, atherosclerosis is by far most extensively studied 
for impact of DC subsets in its disease ontogenesis, albeit that the majority of 
these studies involve murine animal models. Much less is known about the 
contribution of DCs to cardiovascular pathologies such as stroke, heart failure 
and myocardial diseases. Conceivably, also here injury associated DAMP 
release will lead to the recruitment and subsequent activation of DCs with T 
cell priming ability at the inflamed locus, skewing the adaptive immune system 
towards Th1/17-like immune responses or towards a state of tolerance, 
dependent on disease stage and environmental context.  
Recent findings in mice plead for a beneficial role for pre-primed DCs as 
therapeutic agents in the treatment of atherosclerosis. Nevertheless, the 
efficacy of DC immunotherapy for preventing plaque progression and 
destabilisation in humans remains to be seen. In this regard, it will be vital to 
target the relevant disease-associated antigens for DC pulsing. Donor-
mobilized DCs could be otherwise cultured in vitro without further adjuvants, 
as the use of non-pulsed immature DCs has been proven to be an attractive 
approach to induce tolerance. Alternatively strategies could be employed to 
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instruct endogenous DCs in situ, f.e. by receptor-specific manipulation, albeit 
that the options for targeting DC subset specific surface receptors are rather 
limited.  
Summarizing, despite the limitations in our current understanding in DC 
functions in various CVDs, the recently shown efficacy of DC-based tolerance 
and immunization strategies in ameliorating murine atherosclerosis and 
diminishing allograft rejection, in combination with the current dynamics in 
this rapidly progressing research field inspire confidence that (some of) these 
approaches will evolve into viable modalities for the treatment and may be 
even prevention of human cardiovascular disorders. 
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 The main goal of the following two studies presented here (Chapter 3 
and 4) was to explore the impact of plasmacytoid dendritic cells (pDCs) in 
atherosclerosis.  
pDCs are a rare innate immune cell population that circulates in the 
blood and is present in peripheral lymphoid organs. Upon stimulation through 
Toll-like receptor 7 (TLR7) and TLR9, pDCs release large amounts of type I 
interferons (IFN), which are critically involved in anti-viral defense 
mechanisms. Chronic pDC activation and type I IFN release in the absence of 
viral infections results in autoimmune diseases such as systemic lupus 
erythematosus (SLE), psoriasis vulgaris and multiple sclerosis. Several host 
factors have been shown to activate pDCs, thus breaking down innate 
tolerance. Of note, both SLE and psoriasis are associated with an increased risk 
of atherosclerosis. Otherwise, several reports have indicated that immature or 
alternatively activated pDCs can induce T cell tolerance, primarily through the 
induction of regulatory T cells. Thus, pDCs are capable to function dually. 
Priming of immunogenic or tolerogenic immune responses depends largely on 
the microenvironment in which pDCs get activated.  
A potential role for pDCs in atherosclerosis has not been identified yet. 
pDCs were described to be present in inflammatory regions in the human 
atherosclerotic plaque, supposed to trigger CD4+ T cells and to boost 
conventional dendritic cell responses within the lesion. In the following two 
chapters we made use of different pDC depletion models to characterize a 
potential contributory role for pDCs to lesion formation; (1) pDC ablation by 
use of a specific depletion antibody resulted in significantly deteriorated lesion 
formation, suggestive of a protective role for pDCs in mouse atherosclerosis 
(Chapter 3). Furthermore, we examined the impact of pDCs in murine 
atherosclerosis by (2) use of a pDC depletion model, in which pDC ablation was 
based on the transgenic diphtheria toxin receptor (DTR) expression under the 
pDC-specific human BDCA-2 promoter (Chapter 4). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contribution to the manuscript (Chapter 3): 
Anette Christ was next to Dr. Daissormont and Prof. Biessen critically 
involved in the study design, the performance of experiments and data 
discussions/ interpretations. Anette Christ was responsible for the 
accomplishment and analysis of the immunohistochemical and RT-PCR data on 
human plaque tissue samples, and the blood samples received from healthy 
controls and patients with carotid entarterectomy. Besides, Dr. Daissormont 
and Anette Christ mainly performed the in vivo pDC depletion studies, 
including optimization of the used depletion antibody (120G8), in vivo antibody 
administration, sacrifice of the animals, flow cytometry experiments (analysis 
of leukocyte populations, sorting of plasmacytoid dendritic cells and T cell 
subsets for RT-PCR analysis), and histology of mouse atherosclerotic lesions 
(immunohistochemistry, quantification and data analysis). Additionally, Anette 
Christ contributed crucially to the revision of the written manuscript by Dr. 
Daissormont. 
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Abstract 
 
Unlike conventional dendritic cells (cDCs), plasmacytoid DCs (pDCs) are poor in antigen 
presentation and critical for type I interferon response. While proposed to be present 
in human atherosclerotic lesions, their role in atherosclerosis remains elusive. We 
show that pDCs are scarcely present in human atherosclerotic lesions, and almost 
absent in mouse plaques. Surprisingly, pDC depletion by 120G8 mAb administration 
was seen to promote plaque T cell accumulation and exacerbate lesion development 
and progression in low-density lipoprotein receptor deficient (Ldlr-/-) mice. pDC 
depletion was accompanied by increased CD4+ T cell proliferation, IFN-γ expression by 
splenic T cells and plasma IFN-γ levels. Lymphoid tissue pDCs from atherosclerotic mice 
showed increased indoleamine 2,3-dioxygenase (IDO) expression and IDO blockage 
abrogated the pDC suppressive effect on T cell proliferation. In conclusion, our data 
reveal a protective role for pDCs in atherosclerosis, possibly by dampening T cell 
proliferation and activity in peripheral lymphoid tissue, rendering pDCs an interesting 
target for future therapeutic interventions. 
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Introduction 
 
Plasmacytoid dendritic cells (pDCs) are a subset of dendritic cells derived 
from both myeloid and lymphoid precursors in bone marrow, and constitute 
only 0.1-0.5% of the total leukocyte pool in blood and peripheral lymphoid 
tissue. As the main type I interferon (IFN) producing cells, pDCs have a critical 
role in detection of and host defense against bacterial and viral infection, but 
also in sensing RNA/DNA and immune complexes. Upon stimulation, pDCs 
produce large amounts of type I interferons (IFN-α, IFN-β, IFN-ω and IFN-λ) in a 
toll-like receptor (TLR) 7 and 9 dependent manner, thereby inducing effector T 
and natural killer (NK) cell activation and linking innate and adaptive 
immunity.(1) pDCs differ from conventional dendritic cells (cDCs) in that they 
are poor T cell activators due to low expression of major histocompatibility 
complex class-II (MHC-II) and co-stimulatory molecules.(2,3)  
The presence of pDCs in human atherosclerotic lesions has been 
documented in 1995(4) and was subsequently confirmed by C. Weyand and co-
workers.(5) pDCs (CD4+CD45RA+IL-3α(CD123)+ILT3+ILT1-CD11-) were reported to 
be expressed in the shoulder region of human plaques where they are believed 
to regulate T cell function, even in the absence of antigen recognition. CpG-
induced IFN-α release by pDCs effected a 10-fold up regulation of tumor 
necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on CD4+ T 
cell surface, thereby promoting vascular smooth muscle cell (vSMC) and 
endothelial cell (EC) apoptosis, processes that are generally deemed 
deleterious for plaque stability. However, these in vitro data leave 
unaddressed whether pDCs are instrumental in plaque destabilization in vivo. 
While viral infection associated acute pDC activation results in massive 
type I IFN release, chronic activation of pDCs in the absence of infection was 
reported to cause severe autoimmune diseases. For instance, in experimental 
autoimmune encephalomyelitis pDCs were shown to exert overt pathogenic 
activity, mainly by enhancing T helper 17 (Th17) dependent immune 
responses.(6) In patients with systemic lupus erythematosus, pDC activity and 
IFN-α/β release correlated with disease activity and severity.(7,8) Conversely, 
evidence is culminating that immature and alternatively activated pDCs have 
the capacity to dampen chronic low grade inflammation and autoimmune 
diseases, including diabetes type I, asthma and transplant rejection, possibly 
by suppressing CD8+ effector T cell and inducing CD4+CD25+ regulatory T cell 
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(Treg) function by the release of tolerogenic molecules such as indoleamine 
2,3-dioxygenase (IDO) or programmed death-ligand 1 (PD-L1).(9-13) Altogether, 
these observations show that pDCs are very plastic cells with the capacity to 
produce high levels of type I IFN and activate the adaptive immune system in 
infection on the one hand and to regulate inflammation by inhibiting effector T 
cell and inducing regulatory T cell responses on the other hand. 
In this study, we addressed the actual role of pDCs in atherosclerosis 
by a loss-of-function approach, providing evidence for an IDO-dependent T cell 
suppressive activity of pDCs in human and mouse atherosclerosis. 
 
 
Methods 
 
Atherosclerosis induction and pDC depletion in mice 
Female Ldlr-/- mice, obtained from The Jackson Laboratoy and 
backcrossed at least 11 times to C57Bl/6, were placed on high fat diet 
containing 0.25% cholesterol (Special Diets Services, Witham, Essex, UK). Two 
weeks later, atherosclerotic lesions were induced in the carotid artery by 
bilateral placement of semi-constrictive collars.(14) To study effects of pDC 
depletion on atherosclerosis development, a pDC depleting antibody, 120G8 
(250µg/mouse/injection, Bioceros, Utrecht, the Netherlands), was 
administered 4 times per week i.p. for 3,5 weeks starting at the time of collar 
placement (n=19) after which mice were sacrificed. From these mice, also the 
aortic root was analyzed to study effects of pDC depletion on natural 
atherosclerosis development. To study effects of pDC depletion on progression 
of atherosclerosis, 120G8 (250µg/mouse/injection, Bioceros, Utrecht, the 
Netherlands) was administered 4 times per week i.p for 3 weeks starting at 4 
weeks after collar placement, once initial lesions had formed (n=17). As control 
antibody, an isotype control (GL113) was used. All animal work was approved 
by the regulatory authority of Maastricht University and performed in 
compliance with the Dutch government guidelines. 
 
Histology of mouse atherosclerotic lesions 
Mice were euthanized by an overdose pentobarbital (115mg/kg) and 
perfused through the left cardiac ventricle with phosphate buffered saline 
(PBS) (NaCl/Na2HPO4/KH2PO4, pH 7.4) containing sodium nitroprusside 
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(0.1mg/ml, Sigma) and 1% paraformaldehyde (PFA). The right common carotid 
artery and the heart were removed, fixed overnight in 1% PFA and paraffin-
embedded sections (4 µm) were cut. To determine plaque volume in the 
carotid artery, plaque area was measured for consecutive cross sections at 100 
µm intervals over a carotid artery segment that covered the entire plaque. To 
measure plaque volume in the aortic root, plaque area was measured for each 
valve for consecutive sections at 20 µm intervals that covered the entire lesion. 
Collagen content was detected by sirius red staining and expressed as a 
percentage of plaque area.(15) Slides were analyzed in a blinded manner using a 
Leica DM3000 light microscope (Leica Microsystems) coupled to a 
computerized morphometric system (Leica Qwin 3.5.1).  
 
Immunohistochemistry 
Immunohistochemical stainings were performed on paraffin carotid 
artery sections for CD3 (DAKO), Siglec-H/440c (Hycult Biotechnology) and α-
smooth muscle actin (ASMA) (DAKO). Slides were analyzed blindly using Leica 
Qwin program. The number of positive cells was measured and expressed as a 
percentage of total number of cells in the plaque. For ASMA, the number of 
positive cells was expressed as a percentage of plaque area.  
 
Flow cytometry 
Blood, spleen and peripheral lymph nodes (LN) were removed before 
perfusion and used for FACS analysis of pDCs (CCR9high PDCA-1high, eBioscience), 
cDCs (CD11chigh, eBioscience), T cells (CD3e+, Miltenyi), T helper cells (CD4+, 
BD), cytotoxic T cells (CD8a+, BD), effector T cells (CD44high, eBioscience), 
regulatory T cells (CD4+CD25+Foxp3+, eBioscience), B cells (B220+, BD), 
monocytes (CD11bhigh Ly6G-, BD), granulocytes (Ly6Ghigh CD11bhigh) and NK cells 
(NK1.1+ CD3-). For pDC and cDC analysis, spleen and peripheral LN were 
enzyme treated (liberase (0.032mg/ml, Roche) and DNAse (0.8μg/ml, Roche)) 
for 30 minutes in RPMI medium, before antibody incubation to release DCs 
from the tissue. FACS analysis was performed with FACS Canto II (BD).  
 
Plasma cytokine and lipid analysis 
Plasma cholesterol levels were measured in duplicate using a 
colorimetric assay (CHOD-PAP, Roche). Mouse and human plasma levels of 
IFN-α were measured by sandwich ELISA (PBL Interferon Source). Cytokine 
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analysis of mouse IFN-γ was performed using the Bio-Plex Pro assay (Bio-Rad). 
To verify functional ablation of pDCs after 120G8 treatment, control and 
120G8 treated mice (n=5 per group) received subcutaneous injection with CpG 
(CpG-ODN 1585, type A, 40 µg/mouse, Invivogen) and were sacrificed 6 hours 
later to measure IFN-α plasma levels. ELISA plates were used from Greiner Bio-
One (Alphen a/d Rijn, the Netherlands). 
 
Mouse pDC and T cell isolation by Fluorescence Activated Cell Sorting (FACS) 
Splenic pDCs (PDCA-1high CCR9high) and T cells (CD3+) were isolated from 
Ldlr-/- mice, either on high fat diet (0,25% cholesterol) (group of atherosclerotic 
mice, n=8) or on normal diet (group of non-atherosclerotic mice, n=8), by 
FACSAria. The purity of the sorted pDCs (PDCA-1high CCR9high) was 98.3%, for 
the CD3+ T cells 95%. 
 
RNA isolation and Quantitative real-time PCR 
RNA from sorted cells was isolated using the ®Trizol (Invitrogen) 
method. Isolated pDCs were analyzed for gene expression of mouse PD-L1 (5’-
ccatcctgttgttcctcattg-3’ and 3’-gttcactcttacgatctacacct-5’), mouse IDO (5'-
actgtgtcctggcaaactggaag-3’ and 3'-gagataaccacctttagcgtcgaa-5') and mouse 
IFN-α (5’-cattctgcaatgacctccac-3’ and 3’-cacgtccttaaaggggact-5’). Isolated CD3+ 
T cells were analyzed for expression of mouse IFN-γ (5'-tggctgtttctggctgttactg-
3' and 3'-actgtacttttaggacgtctcg-5'). Isolated human pDCs from blood were 
analyzed for gene expression of human IFN-α (5’-aatggccttgacctttgctt-3’ and 
3’-cgttcagttcgacgagacac-5’). 
 
BrdU labeling and cell analysis 
Ldlr-/- mice on high fat diet treated either with 120G8 (n=4) or GL113 
(n=4) received BrdU intraperitoneal (i.p.) injections (0.8mg/day) for 5 
consecutive days. BrdU incorporation in CD4+ and CD8+ T cells was assessed 
using a FITC BrdU flow kit (BD) according to manufacturer’s instructions. Cells 
were analyzed using FACS CANTO II (BD). 
 
OT-1 and OT-2 antigen specific T cell proliferation experiment 
Ldlr-/- recipient mice (n=4 120G8 versus n=4 GL113 treated mice) on 
high fat diet received intravenous (i.v.) 1x106 CFSE-labeled purified OVA-
specific OT-1/CD45.1 or OT-2/CD90.1 cells together with 2x106 non-transgenic 
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purified CD8+/CD90.1 or CD4+/CD45.1 T cells that served as an internal control. 
The next day, mice received i.v. 106 irradiated (1500 rad) Kb-/--actmOVA or 
C3H-actmOVA cells. Three days later, OT-1/CD90.1 and OT-2/CD45.1 
proliferation and expansion were determined based on CFSE dilution and the 
ratio of OT-1/CD45.1 to CD90.1 control CD8+ T cells and OT-2/CD90.1 to 
CD45.1 control CD4+ T cells. In parallel, 5x106 splenocytes were restimulated 
with OVA 257-264 or OVA 323-339 peptide (A&A labs, San Diego, CA) in the 
presence of Brefeldin A for 5 hours. Surface staining for CD8/CD4 (BD) and 
CD45.1/CD90.1 (eBioscience) was performed.  
 
pDC-T cell co-culture 
pDCs were isolated from spleen from a Bl6 Flt3L (3x106) treated Ldlr-/- 
mouse on high fat diet using PDCA-1 microbeads (Miltenyi). CD3+ T cells were 
isolated from spleen of a pDC depleted Ldlr-/- mouse on high fat diet by staining 
T cells with a biotinylated CD4 (Biolegend) and CD8 (Biolegend) antibody and 
using a biotin isolation kit (Miltenyi). pDC and CD3+ T cells were co-cultured in 
a 96 well plate coated with anti-CD3/ CD28 (0.1µg/ml) in a 1:6 ratio (1x105 pDC 
and 6x105 T cells, respectively) for 3 days in iDMEM medium supplemented 
with either 1-MT (Sigma Aldrich, 100µM) or anti-PD-L1 (20µg/ml, Bioceros). 
Seventy-two hours later, CD3+ T cell proliferation was assessed by 3[H]-
thymidine incorporation and plotted as relative proliferation index, being the 
ratio of T cell proliferation in the presence and absence of pDCs. In parallel, 
purified CD4+ T cells were CFSE labeled prior to stimulation and proliferation 
was determined by flow cytometry 72 hours later upon. 
 
Human plaque analysis 
For microarray analysis, total RNA was extracted from carotid artery 
sections obtained from autopsy (Department of Pathology, University Hospital 
Maastricht, Maastricht, the Netherlands) (early (n=13) and advanced stable 
(n=16) lesions) and surgery (Department of Surgery, Maasland Hospital Sittard, 
Sittard, the Netherlands) (advanced stable (n=21) and advanced unstable 
(n=23) lesions). For quantitative real-time PCR analysis, RNA was isolated from 
carotid artery sections obtained from surgery (Department of Surgery, 
Maasland Hospital Sittard, Sittard, the Netherlands) (advanced stable (n=12) 
and advanced unstable (n=12) lesions). Plaques were staged by histological 
analysis of adjacent slides according to Virmani et al. at which intimal 
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thickening (IT) were characterized as early, thick fibrous cap atheroma (TkfcA) 
as advanced stable, and intraplaque hemorrhaged lesions (IPH) as advanced 
unstable lesions, respectively.(16) Immunohistochemical stainings were 
performed on paraffin carotid artery sections from advanced stable (n=22) and 
ruptured lesions (n=22) from surgery for CD123 (Sigma Prestige), BDCA-4 (R&D 
Systems), ASMA (Dako) and CD68 (Dako). The purity of the BDCA-4 antibody 
was checked by flow cytometry by comparing mean fluorescence intensity 
(MFI) of BDCA-4 expression on pDCs versus B cells, T cells and monocytes. 
Double-stained slides were analyzed with the Nuance spectral imaging system 
(Caliper Life Science / Cambridge Research Instrumentation, Woburn, MA, 
USA). Spectral imaging data sets were taken from 420-720 nm at 20 nm 
intervals using a DM-5000 Leica microscope system at 20x (plan apo). Spectral 
libraries of single-red (Vector Red), single-blue (Vector Blue), and natural 
occurring iron pigments were obtained from the control slides. The resulting 
library was applied to the double stained slides to spectrally dissect/unmix 
them into individual component images using the Nuance™ 3.0 software.(17) 
Pseudo-color images showing co-localization, as well as an exclusive image of 
co-localization, were generated with the Nuance 3.0 software. Quantitative 
assessment of co-localization and pixel-based measurement of the individual 
markers per microscopic field was done with the same software. 
 
Microarray analysis of human atherosclerotic lesions 
RNA was isolated using the Guanidine Thiocyanate (GTC)/CsCl gradient 
method and a NucleoSpin RNA II kit (Macherey-Nagel GmbH & Co. KG).(18) RNA 
concentration was determined using the Nanodrop ND-1000 and the RNA 
quality obtained using the RNA 6000 Nano/Pico LabChip (Agilent 2100 
Bioanalyzer) where the RIN (RNA integration number) was determined. 
Samples, where the RIN number was lower than 5.6, were excluded from the 
study. The mean RIN was 7.2±0.49. Samples from autopsy were individually 
hybridized to HGU133 2.0 Plus arrays (Affymetrix, Santa Clara, California, USA) 
and samples from surgery to Illumina Human Sentrix-8 V2.0 BeadChip® 
(Illumina Inc., San Diego, California, USA). Analysis has been performed in R.(19) 
For autopsy samples, pre-processing was performed with affy using the Robust 
MultiArray (RMA) normalization.(20) For surgery samples, pre-processing was 
performed by lumi using the Variance Stabilizing Transform (VST) 
normalization.(21) Differential expression has been assessed separately for the 
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two sets of data by fitting each gene against a linear model across the given 
arrays with limma.(22) Empirical Bayesian shrinkage of the standard errors have 
been used to moderate t-statistics, F-statistics, and log-odds of differential 
expression. The resulting ordered dataset has been queried for the set of 
genes of interest and their results are hereby presented. The adjusted p-values 
presented in the results are corrected according to the Benjamini and 
Hochberg False Detection Rate method.(23) 
 
pDC isolation from human blood 
pDCs were collected from healthy controls (n=15) and patients with 
carotid endarterectomy (n=14). pDCs were isolated from blood (LymphoprepTM 
Isolation). From this, the B220 positive fraction was depleted with magnetic 
beads (Miltenyi Biotec) after which pDCs were isolated from the negative 
fraction using a BDCA-4 isolation kit (Miltenyi Biotec). The purity for BDCA-4+ 
pDCs, as assessed by flow cytometry (CD123high BDCA-2high) was 96%. RNA was 
isolated using the Trizol method. Gene expression profile was analyzed by 
quantitative real-time PCR. Patients for this study were recruited at the 
Department of Cardiology, University Hospital Oslo, Oslo, Norway. The study 
included 14 patients (7 male, 7 female, average age of 67) with high-grade 
internal carotid stenosis (≥70%), diagnosed and classified by precerebral color 
duplex and CT angiography according to consensus criteria. For comparison, 
blood was collected from 15 healthy controls, comparable to the patient group 
for age, sex and smoking habits. The controls were health care workers, 
consecutively recruited from the same area of Norway as the patients. All 
human work was approved by the Ethical Committee of the University Hospital 
Oslo. Signed informed consent for participation in the study was obtained from 
all individuals.  
 
Statistical analysis 
Data are expressed as mean ± SEM and Mann-Whitney U test was used 
to compare individual groups of animals. Data are considered statistically 
significant at p<0.05.  
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Results  
 
pDCs are scarce in human and mouse atherosclerotic lesions  
Concordant with previous observations,(5) CD123+ pDCs were seen to 
be present in human atherosclerotic lesions and their presence increases with 
plaque progression (P<0.05) (Figure 1A). Of note, CD123 stained cells were 
found to show considerable co-localization with macrophages (Figure 1B) and 
vSMC (Figure 1C), supporting earlier findings from van Vré et al. showing that 
CD123 is not a specific marker for human pDCs.(24) Next, we considered BDCA-4 
as a more selective human pDC marker.(25) Flow cytometry on human whole 
blood samples confirmed the high specificity of this marker for human pDCs, as 
it was virtually absent on circulating monocyte, B cell, T cell and granulocyte 
subsets (data not shown). Surprisingly, BDCA-4+ staining revealed the scanty 
presence of pDCs in human plaques. Moreover, BDCA-4+ cell expression did 
not differ between stable and unstable advanced atherosclerotic lesions 
(Figure 1D). In agreement, microarray (Figure 1E) and quantitative real-time 
PCR analysis (data not shown) failed to demonstrate differential expression of 
established pDC markers during plaque progression. Likewise, pDCs were 
almost absent in mouse carotid and aortic artery lesions of Ldlr-/- and ApoE-/- 
mice as well (data not shown), although we did observe few scattered pDCs in 
the adventitia (Figure 1F). 
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Figure 1. pDCs are scarce in human and mouse atherosclerotic lesions. Microscopic analysis of 
human atherosclerotic lesions. (A) Immunohistochemistry for CD123 and quantitative 
measurement of CD123+ pDCs in early (intimal thickening, n=12), stable advanced (thick fibrous 
cap atheroma, n=13) and unstable advanced (intraplaque hemorrhage, n=10) human carotid 
artery atherosclerotic lesions. (B) Co-localization for CD123 (blue) and CD68+ macrophages (red). 
Slides were analyzed with MultiSpectral Imaging and each set of two pictures on the right side 
represents a composite fluorescent-like image in pseudo-colors of the left picture and was 
obtained after unmixing the individual colors red and blue with spectral imaging. Co-localization 
of fluorescent red and green is represented in yellow. Spectral imaging analysis of this double-
stained series clearly shows co-localization of CD123+ cells and macrophages. (C) Co-localization 
for CD123 (red) and aSMA+ smooth muscle cells (blue). (D) Immunohistochemistry for BDCA-4 
and quantitative measurement of BDCA-4+ cells in advanced stable (n=16) and unstable (n=19) 
human carotid artery lesions. (E) Microarray analysis on human carotid artery lesions (early 
(n=13) vs advanced stable (n=16) and advanced stable (n=21) vs vulnerable (n=23)) (F) 
Immunohistochemistry for Siglec-H (440c) in mouse carotid lesions. pDCs were detected in the 
adventitia where they were present in small clusters near to vasa vasora, showing a typical 
plasmacytoid morphology. *p<0.05; **p,0.01; ***p,0.001. 
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Effective and selective depletion of pDCs in mice by 120G8 antibody 
treatment 
Next, we addressed the specificity of pDC depletion by 120G8 mAb, 
which recognizes PDCA-1 (also referred to as bone marrow stromal cell antigen 
2 (BST2)), a marker specifically expressed on mouse pDCs. 120G8 significantly 
depleted (>90%) pDC numbers in blood and spleen (P<0.05) (Figure 2A). pDC 
repopulation started already 24 hours after a single 120G8 administration and 
full recovery was obtained after 72 hours (Figure 3A), necessitating an every 
two daily 120G8 dose regimen for effective and persistent pDC depletion. It 
has been reported that in vitro PDCA-1 expression is up-regulated at mRNA 
level in other cell types in response to viral infection or exposure to 
inflammatory stimuli, which theoretically could thwart the depletion 
specificity.(26) In our study, 120G8 treatment did neither affect cDC (Figure 2B), 
nor B cell numbers (Figure 2C). Also monocyte and granulocyte levels were 
unchanged (Figure 3B-C). Moreover, assessment of PDCA-1 expression by flow 
cytometry showed that in high fat diet fed Ldlr-/- mice PDCA-1 expression is 
completely restricted to pDCs (Figure 2D). These data demonstrate that in our 
mouse model of atherosclerosis pDC depletion by 120G8 mAb was effective 
and specific. To investigate whether prolonged antibody administration by 
itself could modulate immune responses, we compared the T cell activation 
status between GL113 and PBS-treated mice and did not find a difference in 
the number of CD44high T cells (Figure 3D). At a functional level 120G8 
treatment almost abrogated CpG-induced pDC activation in vivo, as judged by 
the 6-fold attenuated induction in plasma IFN-α release upon CpG injection in 
120G8 treated versus control mice (P<0.05; Figure 2E). While pDC activity and 
TLR7/9 function appear to be intact, under conditions of hyperlipidemia, 
baseline plasma IFN-α levels remained unchanged after pDC depletion, both in 
the plaque initiation and progression study. This suggests that an atherogenic 
stimulus per se does not increase IFN-α release by peripheral pDCs and/or that 
pDCs are under these conditions not the major source of circulating IFN-α.  
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Figure 2. Effective and selective depletion of pDCs in Ldlr-/- mice by 120G8 administration. 
Depicted are the results of flow cytometry from Ldlr-/- mice on high fat diet treated with GL113 
(n=6) or 120G8 (n=6) for 3 weeks. (A) pDC (PDCA-1+CCR9+) numbers in blood and spleen. (B) cDC 
(CD11chigh) and (C) B cell (B220+) numbers in spleen and peripheral lymph nodes. (D) PDCA-1 
expression on pDCs, T cells (CD3+), B cells (B220+), monocytes (CD11bhighLy6G-), granulocytes 
(CD11bhighLy6Ghigh), cDCs (CD11chigh) and NK cells (NK1.1highCD3-) from spleen. (E) CpG 
stimulation in GL113 (n=5) versus 120G8 (n=5) treated mice. *p<0.05; **p,0.01; ***p,0.001. 
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Figure 3. Efficiency and specificity of pDC depletion by 120G8 mAb. (A) Time-span of pDC 
depletion by 120G8 mAb. Ldlr-/- mice on high fat diet received one single dose of 120G8 
(250μg/mouse) via i.p. injection and pDC recovery was analyzed 24, 48 and 72 hours later in 
blood (n=3 per group). (B) Flow cytometry analysis of circulating monocytes (CD11bhighLy6G-), (C) 
granulocytes (CD11bhighLy6Ghigh) and (D) activated (CD44high) CD4+ and CD8+ T cells from Ldlr-/- 
mice on high fat diet treated with GL113 (n=6) versus 120G8 (n=6) for 3 weeks. *p<0.05; 
**p,0.01; ***p,0.001. 
 
Depletion of pDCs accelerates atherosclerosis in Ldlr-/- mice 
To address the role of pDCs in atherosclerosis, we examined lesion 
development and progression in Ldlr-/- mice fed a high fat diet. For plaque 
initiation, 120G8 treatment was started at time of collar placement, whereas 
for plaque progression, it was started at week 4 after collar placement, once 
initial lesions had formed. 120G8 treatment did not affect body weight, nor did 
it lead to overt pathogenic responses. 120G8 treatment tended to decrease 
plasma cholesterol levels initially (1384 ± 78.53 vs 1126 ± 46.28 mg/dl in 
control and 120G8 treated mice, respectively), but this effect was blunted at 
later stages of plaque development (1097 ± 44.83 vs 1231 ± 72.31 mg/dl in 
control and 120G8 treated mice, respectively) (Table 1).  
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Table 1. Body weight and plasma cholesterol levels  
  Control Ab 120G8 mAb 
Body weight initiation study (g)  
Body weight progression study (g)                                            
    21.10 ± 0.23 
    21.90 ± 0.43  
    20.11 ±  0.42 
    22.75 ± 0.31 
Plasma cholesterol levels initiation study (mg/dl)     1384 ± 78.53     1126 ± 46.2* 
Plasma cholesterol levels progression study (mg/dl)     1097± 44.83     1231 ± 72.31 
                                                                                                                                                         
(* P<0.05) 
 
 
To our surprise, atherosclerosis considerably deteriorated after pDC 
depletion. Plaque volume was 2-fold increased in the plaque initiation study 
(1.4x107 ± 2.6x106 vs 2.7x107 ± 4.7x106 µm3 in control and 120G8 treated mice, 
respectively) (P<0.05) (Figure 4A), while we observed a 3-fold increase in 
plaque progression compared to plaques at baseline (1.4x107 ± 2.5x106 vs 
5.4x107 ± 7.2x106 µm3 in control baseline and 120G8 treated mice, 
respectively) (P<0.0005) versus only 2-fold for the GL113 Ab-treated mice 
(1.4x107 ± 2.5x106 vs 3.3x107 ± 7.5x106 µm3 in control baseline and GL113 
treated mice, respectively) (p<0.05) (Figure 4B). Likewise, pDC depletion 
induced a more unstable plaque phenotype in the progression study, 
characterized by necrotic core expansion (Figure 4C) and diminished cap vSMC 
content (Figure 4D). There was no difference in plaque collagen content (data 
not shown). In addition to the carotid artery, we also examined atherosclerosis 
development in the aortic root, showing an essentially similar aggravation of 
lesion formation after pDC depletion (P<0.05; Figure 4E).  
Thus our data point to an unexpected protective role of pDCs in 
atherosclerosis, which is in contrast to the prevailing notion that pDCs might 
promote atherosclerosis by activating T cells in a type-I IFN dependent 
manner.(5,27) Moreover, given the fact that atherosclerotic lesions are virtually 
devoid of pDCs, they most likely exert their athero-protective effect by 
modulating immune responses in the periphery and/or adventitia. 
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Figure 4. pDC depletion significantly deteriorates atherosclerotic plaque development and 
progression in Ldlr-/- mice. (A) Effects of pDC depletion on atherosclerosis development (collar 
model) (GL113 (n=9) vs 120G8 (n=10) treated mice). Right carotid artery was stained with 
hematoxylin and eosin (HE) to analyze the extent of atherosclerosis (plaque volume, μm3). (B) 
Effects of pDC depletion on atherosclerosis progression (collar model) (GL113 baseline (n=9), 
GL113 (n=8) and 120G8 (n=9) treated mice). GL113 baseline group represents plaque formation 
at start of antibody treatment. Right carotid artery was stained with HE and atherosclerotic 
lesion burden was analyzed (plaque volume, μm3). (C) Necrotic core area is represented as the 
percentage of lipid core area over plaque area. Data are represented for the plaque progression 
study. (D) ASMA content is presented as the percentage of ASMA-positive cells per plaque area. 
Data are represented for the plaque progression study. (E) Effects of pDC depletion on 
atherosclerosis development in the aortic root (GL113 (n=9) vs 120G8 (n=10) treated mice). The 
aortic root was stained with HE to analyze the extent of atherosclerosis (plaque area, µm2). 
*p<0.05; **p,0.01; ***p,0.001. 
 
pDCs exert their athero-protective effect by regulating CD4+ T cell 
proliferation and function in lymphoid tissue 
As a next step, we examined effects of pDC depletion on plaque 
composition to address the potential mechanisms responsible for the 
protective effects of pDCs in atherosclerosis. We found that pDC depletion led 
to an increase in lesional T cell accumulation (P<0.05; Figure 5A and Figure 
3 | Plasmacytoid dendritic cells in atherosclerosis 
88 
6A). The scarce presence of pDCs in mouse atherosclerotic lesions suggests 
that the increased T cell infiltration into the lesions most likely reflects 
peripheral modulation of T cell function. Indeed, blood and spleen T cell 
content was increased in pDC-depleted mice (P<0.05; Figure 5B), suggesting 
that pDCs interfere with T cell homeostasis. 
 
 
 
Figure 5. pDC depletion results in increased CD4+ T cell proliferation. (A) CD3+ T cell content in 
mouse atherosclerotic lesions (collar model) (GL113 (n=9) vs 120G8 (n=10) treated mice). Data 
are represented for the plaque initiation study. (B) Flow cytometry analysis for CD3+ T cells in 
blood and spleen. (C) BrdU staining of CD4+ T cells in spleen from GL113 (n=4) vs 120G8 (n=4) 
treated Ldlr-/- mice on high fat diet. (D) OT-2 CD4+ T cell proliferation in spleen in response to 
ovalbumin challenge (OVA323-339) in GL113 (n=4) versus 120G8 (n=4) treated Ldlr
-/- mice on high 
fat diet. (E) IFN-γ plasma levels (n=8 GL113 vs n=8 120G8). (F) IFN-γ gene expression by splenic 
CD3+ T cells isolated from GL113 (n=8) versus 120G8 (n=8) treated mice. *p<0.05; **p,0.01; 
***p,0.001. 
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As pDCs have been reported to induce regulatory T cell (Treg) 
expansion,(11,28) we investigated whether the increase in plaque CD3+ T cell 
content is owing to decreased Treg numbers or function and an associated 
failure to control T cell responses. However, we did not observe a difference in 
blood and spleen Treg numbers between 120G8 and GL113 treated Ldlr-/- mice 
(Figure 6B). In keeping, IL-10 plasma levels did not differ as well (Figure 6C). To 
address whether the increase in T cells resulted from increased proliferation or 
survival, we examined T cell proliferation in vivo. Spleens of pDC-depleted mice 
were enriched in BrdU+ CD4+ (P<0.05; Figure 5C) but not CD8+ T cells (Figure 
6D). Moreover, T cell proliferation appeared to be antigen-dependent in that 
ovalbumin (OVA) challenge led to augmented proliferation of OT-2 CD4+ T cells 
(P<0.05; Figure 5D) but not OT-1 CD8+ T cells (Figure 6E) in pDC-depleted 
versus non-depleted mice. In addition, these findings also show that the 
increased proliferation is not due to intrinsic T cell effects, as both innate and 
administered T cell proliferation was increased, but to changes in the 
environment in pDC-depleted mice. In parallel to increased T cell proliferation, 
IFN-γ (P<0.0005; Figure 5E) as well as IL-6 and MCP-1 plasma levels (Figure 6F) 
were seen to be increased after pDC depletion. FACS sorted CD3+ T cells (purity 
95%) from spleens of pDC-depleted Ldlr-/- mice tended to have increased IFN-γ 
expression (P=0.07; Figure 5F). In addition, CD3+ T cells isolated from 
atherosclerotic (high fat diet fed) Ldlr-/- mice expressed higher levels of GATA-3 
(Th2 marker) as well as of T-bet (Th1 marker) compared to T cells isolated from 
non-atherosclerotic mice (chow diet fed) (Figure 6G). pDC depletion abrogated 
this effect for GATA-3 but not T-bet, suggesting that pDCs might help to 
dampen the high fat diet induced Th1 shift in Ldlr-/- mice. Overall, these data 
further substantiate a tolerogenic activity of pDCs under atherogenic 
conditions, probably by suppressing T cell proliferation and function. 
 
 
 
 
 
 
 
 
 
3 | Plasmacytoid dendritic cells in atherosclerosis 
90 
 
 
Figure 6. T cell analysis of atherosclerotic mice treated with GL113 versus 120G8. (A) CD3+ T 
cell content in mouse atherosclerotic lesions (aortic root) (GL113 (n=9) vs 120G8 (n=10) treated 
mice, P=0.08). Data are represented for the plaque initiation study. (B) Depicted are the results 
of flow cytometry analysis for regulatory T cell numbers in blood and spleen from Ldlr-/- mice on 
high fat diet treated with GL113 (n=9) and 120G8 (n=10). (C) IL-10 plasma levels. (D) BrdU 
staining of CD8+ T cells in spleen from Ldlr-/- mice on high fat diet treated with GL113 (n=4) 
versus 120G8 (n=4). (E) OT-1 CD8+ T cell proliferation in spleen in response to ovalbumin 
challenge (n=4/group). (F) IL-6 and MCP-1 plasma levels (n=8 GL113 vs n=8 120G8). (G) 
Quantitative real-time PCR analysis of CD3+ T cells sorted from spleen from Ldlr-/- mice on chow 
diet (n=5) and high fat diet treated with GL113 (n=5) and 120G8 (n=5). 
 
pDCs suppress CD4+ T cell proliferation in an IDO-dependent manner  
To address the underlying mechanism for the T cell suppressive 
capacity of pDCs in atherosclerosis, we compared the expression of known key 
regulators of pDC tolerogenicity, such as indoleamine 2,3-dioxygenase (IDO), 
IL-10, programmed death ligand-1 (PD-L1) and inducible co-stimulator-ligand 
(ICOS-L), by pDCs isolated from chow (non-atherosclerotic mice) versus high fat 
diet (atherosclerotic mice) fed Ldlr-/- mice (purity 98.3%). Expression of PD-L1 
and IDO (P<0.05; Figure 7A), but not IL-10 and ICOS-L (data not shown), was 
significantly elevated in pDCs from high fat diet versus chow fed mice. 
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Importantly, CD3+ T cells isolated from spleen of pDC-depleted atherosclerotic 
mice, co-cultured with pDCs in the presence of 1-methyl-trypthophan (1-MT), 
an IDO blocker, but not anti-PD-L1, displayed markedly induced T cell 
proliferation (P<0.05; Figure 7B), suggesting that pDCs suppress T cell 
proliferation in an IDO-dependent manner. The 1-MT induced CD4+ T cell 
mitogenic response was confirmed by flow cytometry (Figure 7C), showing a 
similar increment in CD4+ T cell proliferation after co-culture with pDCs in the 
presence of 1-MT. Baseline levels of IFN-α in plasma of high fat diet versus 
chow fed Ldlr-/- mice were unaltered (Figure 7D), as well as IFN-α expression by 
pDCs (Figure 7E), firmly establishing that in mice pro-atherogenic conditions 
per se do not promote IFN-α release and immunogenic activity. Moreover, we 
extend these findings to the human context, as like in Ldlr-/- mice, IFN-α plasma 
levels were also seen to be unchanged (Figure 7F) and IFN-α expression by 
pDCs even significantly lowered in atherosclerotic patients versus healthy 
controls (P<0.05; Figure 7G). Altogether, our data indicate that both in mice 
and man, conditions of chronic atherosclerosis do not trigger pDC 
immunogenic activity, IFN-α release and ensuing T cell activation and 
proliferation. Rather, this milieu may even consolidate pDC’s innate 
tolerogenic capacity to suppress T cell proliferation.(29) 
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Figure 7. pDCs suppress CD4+ T cell proliferation in an IDO-dependent manner. (A) PD-L1 and 
IDO gene expression by pDCs isolated from spleen from atherosclerotic (high fat diet, n=8) and 
non-atherosclerotic mice (chow diet, n=8). (B) In vitro co-culture of pDCs and CD3+ T cells (in 
quatro) isolated from spleen from Ldlr-/- mice on high fat diet in the presence or absence of 1-
MT (100µM) or anti-PD-L1 (20µg/ml). T cell proliferation was assessed by 3[H]-thymidine 
incorporation and plotted as relative proliferation index, being the ratio of T cell proliferation in 
the presence and absence of pDCs. This experiment was reproduced twice and gave similar 
results. (C) In vitro co-culture of pDCs and CFSE labeled CD4+ T cells (in duplo) isolated from 
spleen from Ldlr-/- mice on high fat diet in the presence or absence of 1-MT (100µM). (D) IFN-α 
plasma levels and (E) IFN-α pDC gene expression in atherosclerotic (high fat diet, n=8) versus 
non-atherosclerotic (chow diet, n=8) Ldlr-/- mice. (F) IFN-α plasma levels and (G) IFN-α pDC gene 
expression in atherosclerotic patients (carotid endarterectomy (CEA), n=14) versus healthy 
controls (n=15). 
 
 
Discussion 
 
In this study, we are the first to demonstrate a contributory role for pDCs 
in atherosclerosis. Despite the scarce presence of pDCs in mouse 
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atherosclerotic lesions, depletion of pDCs in Ldlr-/- mice by 120G8 mAb 
aggravated atherosclerosis development and progression. Lesions of pDC-
depleted mice were characterized by increased T cell accumulation and a more 
unstable plaque phenotype, which, as we show, is likely linked to a deficiency 
in pDC-associated epitope specific dampening of T cell response. 
We demonstrate selective and almost complete pDC depletion by the use 
of 120G8 mAb in Ldlr-/- mice. PDCA-1 expression was exclusively restricted to 
the pDC population and no other leukocyte subsets other than pDCs were 
depleted. These findings confirm previous reports which highlight the 
specificity of the 120G8 mAb, all showing selective depletion of pDCs in blood, 
bone marrow, LN, thymus and non-lymphoid organs of C57Bl/6 mice but not of 
CD4/CD8 T cells, DX5+ NK en CD19+ B cells.(30-33) Alternative pDC ablation or 
depletion models currently available such as IKAROS and IRF8 (mutant) all 
suffer from major effects on non-pDC subsets, while the CD11c.CRExE22
f/- and 
the BDCA-2.hDTR mice are interesting new models for future ablation studies. 
Our data point to an unexpected athero-protective activity of pDCs, which 
is in contrast to previous findings pointing towards a pro-atherogenic 
function.(5) This notion was largely based on guilt by association, in that (1) 
plaques were seen to express CD123+ and IFN-α+ cells, in particular when 
progressed to an unstable phenotype, (2) CpG-induced pDC activation in vitro 
led to type I IFN release, and (3) type I IFN were recently reported to 
contribute to atherosclerosis in ApoE-/- and Ldlr-/- mice by stimulating 
macrophage recruitment.(27) The data presented in this study justify a minor 
adjustment of this assumption. First, unlike BDCA-4, CD123 staining may not 
be entirely reflective of the plaque’s pDC content as macrophages and vSMCs 
appear to express this marker as well and as CD123+ cells often lack 
characteristic plasmacytoid morphology. This observation concurs with recent 
findings by van Vré et al., showing that CD123 is not a specific pDC marker 
staining also for endothelial cells in human atherosclerotic lesions.(24) As a 
result, the actual plaque pDC content may not only be lower than originally 
envisioned, but also does not markedly increase with progression of disease. 
This also implies that pDC effects may be precipitated primarily in the 
periphery rather than within the plaque itself. Second, we show here that pDCs 
are not the prime source of plasma IFN-α at baseline, and that IFN-α release by 
pDCs into the circulation is boosted by CpG treatment, however not by 
atherogenic conditions. Apparently, atherogenic stimuli per se do not induce 
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pDC activation. Moreover, in atherosclerotic mice, circulating IFN-α originates 
from other cell types than pDCs but may be derived from macrophages. Third, 
we failed to demonstrate progressively increased expression of IFN-α by 
microarray or real-time PCR analysis by circulating pDCs from atherosclerotic 
mice and by human pDCs from patients with stable versus unstable disease 
and by unstable versus stable endarterectomy lesions, confirming that in 
chronic inflammatory processes such as atherosclerosis TLR7/9 activation of 
pDCs is not very prominent. Collectively, our data indicate that pDCs exert 
their athero-protective effect primarily by modulating extravascular immune 
responses. 
Our studies also provide a plausible mechanism by which pDCs suppress 
CD4+ T cell proliferation under conditions of atherosclerosis. pDCs isolated 
from spleens from atherosclerotic mice had a 2-fold increase in expression of 
tolerogenic molecules IDO and PD-L1 compared to pDCs isolated from non-
atherosclerotic mice. IDO is an intracellular tryptophan catabolizing enzyme 
which has been attributed suppressive activity on cDCs and stimulatory activity 
on Tregs.(34) PD-L1 is an inhibitory co-stimulatory molecule which interacts with 
programmed death-1 (PD-1) on CD8+ T cells to suppress their viability and 
activity.(35)  
Moreover, co-culture of pDCs with T cells in the presence of 1-MT, an IDO 
blocker, but not anti-PD-L1, showed increased T cell proliferation, suggesting 
that pDCs suppress T cell proliferation in an IDO dependent manner. These 
observations correspond with previous reports in which pDCs were shown to 
induce tolerance in other low grade chronic inflammatory and autoimmune 
diseases.(9,10,34-36) The tolerogenic function of pDCs was seen to depend on 
cytokine/ligand activation. For instance, B7-1 (CD80) engagement by cytotoxic 
T-lymphocyte Antigen-4 (CTLA-4Ig), that of CD200R1 by CD200Ig and B7-1/B7-
2 (CD80/CD86) by CD28Ig all have been shown to be able to induce the release 
of IDO by pDCs, leading to the suppression of T cells.(37) It remains to be 
established which activation pathway is involved in atherosclerosis. Thus, in 
analogy, during atherosclerosis pDCs not only maintain their immature 
tolerogenic state, but even invigorate their inborn dampening activity so that 
they can control T cell activity. If the same also holds for brief episodes of 
fulminant plaque inflammation (acute myocardial infarction), remains to be 
established.  
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In conclusion, this manuscript is the first to unveil a protective role for 
pDCs in an established mouse model of atherosclerosis, throughout disease 
progression. Given the virtual absence of pDCs in the plaque itself, pDCs most 
likely exert their activity extravascularly, by dampening T cell proliferation and 
function in an IDO dependent manner. While these findings identify pDCs as an 
interesting new target for therapeutic intervention studies, they warrant 
further study to elucidate the actual pathways underlying the augmented 
tolerogenic activity of pDCs under conditions of atherosclerosis. 
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Plasmacytoid dendritic cell ablation 
by diphtheria toxin administration 
in Ldlr-/- mice expressing the BDCA2-
DTR induces granulocytosis and 
over signs of pneumonia. 
 
 
   
 
 
 
Abstract 
 
Plasmacytoid dendritic cells (pDCs) play a pivotal role in orchestrating immunity and 
tolerance, and as such, they are key targets for immunotherapy. It has been shown 
that pDCs populate the inflamed human atherosclerotic plaque, proposing a pro-
inflammatory role through release of type I interferons (IFNs). Studying a functional 
role of pDCs in atherosclerosis by use of pDC-specific depletion antibodies showed 
controversial results, with pDCs seen to inhibit or promote lesion development. 
Therefore, alternative animal models are necessary to elucidate the involvement of 
pDCs in atherosclerosis. The use of the inducible pDC ablation model based on the 
transgenic diphtheria toxin receptor (DTR) expression under the pDC specific human 
blood dendritic cells antigen 2 (BDCA-2) promoter may be more revealing. Here, we 
depleted pDCs in high fat diet fed low-density lipoprotein receptor deficient (Ldlr-/-) 
mice that were reconstituted with BDCA-2 DTR derived bone marrow by 
administration of diphtheria toxin (DT) for 3 weeks. A subset of mice additionally 
received a CD4+ T cell depleting antibody to address the contribution of CD4+ T cells to 
pDC immunity in atherosclerosis. Unexpectedly, next to pDC depletion, repeated DT 
administration induced immune cell modulations, shown by peripheral granulocytosis 
and significant reductions in B cell and cDC numbers. Beside, DT caused systemic 
toxicity, featured by gradual body weight loss, generalized weakness, sudden death 
and over signs of pneumonia. We can conclude from our study that the BDCA-2 DTR 
model is not applicable to study the impact of pDCs in atherosclerosis due to 
undesirable side effects, pointing to a major limitation of this otherwise technically 
interesting approach. 
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Introduction 
 
Plasmacytoid dendritic cells (pDCs) represent a rare leukocyte 
population present in blood and peripheral lymphoid organs. In response to 
viruses, and subsequent activation of the Toll-like receptor 7 (TLR7) and TLR9 
pathways, pDCs secrete large amounts of type I interferons (IFNs), making 
pDCs refractory to viral infections.(1-4) Additionally, immature or alternatively 
activated pDCs are also equipped to trigger regulatory T cell (Treg) expansion, 
thereby inhibiting acute graft-versus host disease(5) or mediating oral tolerance 
to vascularized grafts.(6) pDC-mediated control of inflammation was in some 
studies reported to depend on the type I IFN induced release of indoleamine-
2,3-dioxygenase (IDO),(7, 8) while other studies implicated IL-10, ICOS-L and PD-
L1 dependent mechanisms in pDC tolerogenic capacity.(9, 10) Thus, pDCs are 
essentially involved in both the control of anti-viral immune responses, 
characterized by a type I IFN-signature, and in tolerance induction at sites of 
infection in order to prevent immunopathology.  
In recent years the presence of pDCs has been described in human 
atherosclerotic lesions, predominantly in the plaque shoulder region in close 
vicinity with IFN-α+ cells, conventional DCs (cDCs) and activated T cells.(11-14) It 
is believed that plaque pDCs regulate the functional activity of cDCs and 
augment adaptive immune responses by CD4+ T cell activation through release 
of type I IFNs.(11, 14) However, we failed to demonstrate co-localization of BDCA-
4+ pDCs and IFN-α+ cells in advanced human plaques, encouraging that pDC 
activation is not very prominent in atherosclerosis.(15) Results from animal 
models, studying a functional role of pDCs in atherosclerosis, are 
controversial.(15-17) We have recently shown, that selective depletion of pDCs 
by 120G8 monoclonal antibody (mAb) administration(18) in low-density 
lipoprotein receptor deficient (Ldlr-/-) mice fed a high fat diet protected against 
atherosclerosis by tuning T cell proliferation and activation.(15) In contrast, two 
other groups have exhibited that pDC presence contributes significantly to 
diet-induced lesion formation in the aortic root and the aorta by their ability to 
prime and stimulate CD4+ T cells. Selective pDC depletion resulted in a more 
stable plaque phenotype and decreased systemic immune cell activation 
accompanied by reduced pro-inflammatory cytokine levels.(16, 17) 
Recapitulatory, a functional contribution of pDCs to the pathogenesis of 
atherosclerosis needs to be further investigated in more advanced animal 
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models such as knock-out models in which the genetic deletion of transcription 
factors, crucial for pDC development, would specifically block pDC 
differentiation. An alternative strategy to address pDC function in vivo is based 
on genetic pDC ablation models, such as mice expressing the diphtheria toxin 
receptor (DTR) under the control of the highly specific human pDC gene 
promoter BDCA-2.(19, 20) Indeed, administration of diphtheria toxin (DT) to 
BDCA-2 DTR transgenic mice has been shown to lead to an almost complete 
and selective depletion of pDCs.(21) 
To address the impact of pDCs on atherosclerotic plaque progression 
and inflammation, we used bone marrow transplantation to generate Ldlr-/- 
chimeras with hematopoietic BDCA-2 driven DTR expression for conditional 
pDC ablation. To dissect potential pDC-CD4+ T cell crosstalk in atherosclerosis, 
we additionally depleted CD4+ T cells in a subset of mice. Unexpectedly, long-
term DT administration induced generalized body infirmness, and caused a 
dramatic increase in granulocyte numbers in the periphery, accompanied by 
tremendous immune cell infiltration in lung. We thus conclude that the BDCA-
2 DTR model is not suitable to study pDC functions in atherosclerosis, due to 
the ectopic side-effects associated with long-term DT administration. 
 
 
Methods 
 
Animals 
All animal work was approved by the regulatory authority of 
Maastricht University and performed in compliance with the Dutch 
government guidelines. BDCA-2 DTR (= diphtheria toxin receptor) transgenic 
mice(21) on a C57Bl/6J background, maintained as heterozygotes, were 
provided by M. Colonna (Department of Pathology and Immunology, 
Washington University School of Medicine). Ldlr-/- mice were bred at the local 
animal breeding facility (Maastricht University, The Netherlands). All mice 
were fed a standard fat diet (Cat# V1535, sniff Spezialdiäten GmbH, Soest, 
Germany), had ad libitum access to food and water, and were housed under a 
12 hour light-dark cycle.  
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Bone marrow transplantation 
Female Ldlr-/- mice (n=37), 12 weeks of age, were housed under filter 
top cages and given antibiotics supplemented water (Neomycin (100mg/L; 
Gibco, Carlsbad, CA, USA) and Polymyxin B sulfate (60.000 U/L; Gibco), starting 
2 weeks before until 6 weeks after bone marrow transplantation. To induce 
bone marrow aplasia, Ldlr-/- mice were exposed to a single dose of 9Gy 
(0.5Gy/min, Philips MU15F/225kV, Hamburg, Germany) total body irradiation 
one day before bone marrow transplantation. Irradiated recipients were 
injected via the tail vein with bone marrow cell suspensions (107 cells/mouse), 
prepared from BDCA-2 DTR donor mice by tibia/ femur lavage. Six weeks after 
bone marrow transplantation, mice were placed on a western type diet (0.25% 
cholesterol and 15% cacao butter; Special Diets Services, Witham, Essex, UK) 
for another 6 weeks to induce atherosclerosis development. To study effects of 
pDC depletion on atherosclerosis development, diphtheria toxin (DT, Sigma-
Aldrich, Seelze, Germany; 120 ng/mouse/injection) was injected 
intraperitoneally (i.p.) three times per week over a period of three weeks 
before animals were sacrificed. A nontoxic diphtheria toxin mutant (DTM 
CRM197, Sigma-Aldrich, Seelze, Germany) served as control. To study effects 
of CD4+ T cell depletion in control mice compared to pDC-depleted mice, a 
CD4+ T cell depleting antibody, αCD4 (150μg/mouse/injection, Biocerus, 
Utrecht, The Netherlands), was administered 3 times per week i.p. over a 
period of three weeks before sacrifice. As control antibody, an isotype control 
(GL113, Biocerus, Utrecht, The Netherlands) was used. 
 
Atherosclerosis experiments 
Mice were euthanized by an overdose of pentobarbital (115 mg/kg) 
and perfused through the left cardiac ventricle with PBS 
(NaCl/Na2HPO4/KH2PO4; pH 7.4) containing sodium nitroprusside (0.1mg/ml; 
Sigma-Aldrich, Seelze, Germany) and 1% paraformaldehyde (PFA). The aortic 
arch and the heart were removed, fixed overnight in 1% PFA and paraffin-
embedded sections (4 μm) were cut. To measure plaque volume and necrotic 
core size in the aortic root, plaque area was measured for each valve for 
consecutive sections at 20μm intervals that covered the entire lesion. Plaque 
collagen content was quantified based on Sirius Red staining under polarized 
light. Slides were analyzed in a blinded manner using a Leica DM3000 light 
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microscope (Leica Microsystems, Wetzlar, Germany) coupled to a 
computerized morphometric system (Leica Qwin 3.5.1, Wetzlar, Germany). 
 
Immunohistochemistry 
Immunohistochemical stainings were performed on paraffin sections 
of murine heart, lung, liver and kidney: CD45 polyclonal antibody (1:5000 
dilution, BD Bioscience, Bedford, MA, USA) to detect total leukocytes, CD3 
polyclonal antibody (1:200 dilution, DAKO, Glostrup, Denmark) to detect T 
lymphocytes, Mac3 monoclonal antibody (1:30 dilution, BD Bioscience, 
Bedford, MA, USA) to detect macrophages, Ly6G monoclonal antibody (1:200 
dilution, BD Bioscience, Bedford, MA, USA) to detect Ly6G positive 
granulocytes and Caspase 3 polyclonal antibody (1:20 dilution, Cell Signaling, 
Danvers, MA, USA) to detect apoptotic cells. Slides were analyzed using Leica 
Qwin program.  
 
Plasma cytokine and cholesterol analysis 
Plasma cholesterol levels were measured in duplicate using a 
colorimetric assay (CHOD-PAP, Roche, Mannheim, Germany). Plasma cytokine 
levels of IFN-γ, IL-10, IL-12p70, IL-1β, IL-6 and TNF-α were determined with 
Multi-Spot assay system (Meso Scale Discovery, Rockville, MD, USA). 
 
Flow cytometry 
Blood, spleen, thymus, mesenteric lymph nodes (MLN), peripheral 
lymph nodes (a mixture of mandibular and axillary lymph nodes) (LN), liver and 
small intestines were isolated before perfusion, processed and stained for total 
T cells (CD3e+, Miltenyi Biotech, Bergisch-Gladbach, Germany), T helper cells 
(CD4+, BD Bioscience, Bedford, MA, USA), cytotoxic T cells (CD8a+, BD 
Bioscience), regulatory T cells (CD4+ CD25+ Foxp3+, eBioscience, San Diego, CA, 
USA), effector T cells (CD44high, eBioscience), B cells (B220+, BD Bioscience), 
monocytes (CD11bhigh Ly6Glow, BD Bioscience), granulocytes (CD11bhigh Ly6Ghigh, 
BD Bioscience), NK cells (NK1.1+ CD3-), conventional DCs (CD11chigh, 
eBioscience) and plasmacytoid DCs (PDCA-1high CCR9high, eBioscience). For cDC 
and pDC analysis, spleen, peripheral LN, mesenteric LN, liver and intestines 
were pretreated for 30 minutes with a cocktail of liberase (0.032mg/ml, Roche, 
Carlsbad, CA, USA) and DNase (0.8μg/ml, Roche, Basel, Switzerland) in RPMI 
medium. Cell counts were estimated by absolute counting beads (BD 
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Bioscience, Bedford, MA, USA). All flow cytometry analysis was performed on a 
BDCanto II (BD Bioscience, Bedford, MA, USA). 
 
Statistical analysis 
Data were analyzed with the use of Graph Pad Prism 5 (Graph Pad 
Software Inc San Diego, CA, USA). All data are expressed as mean ± SEM. To 
compare individual groups, a 2-tailed Student’s t test was used; nonparametric 
data were analyzed using a Mann-Whitney U-test. Values of p< 0.05 were 
considered statistically significant. 
 
 
Results  
 
DT administration induces effective depletion of pDCs but also influences cDC 
numbers in Ldlr-/- mice on high fat diet 
We generated Ldlr-/- hematopoietic chimeras reconstituted with bone 
marrow from transgenic mice for the human diphtheria toxin receptor (DTR) 
under control of the highly pDC specific human blood dendritic cell antigen 2 
(BDCA-2) (Figure 1A). To verify the efficacy of DT-induced pDC depletion in the 
chimeras, we examined pDC numbers in secondary lymphoid organs. DT 
administration resulted in an almost complete ablation of pDCs in spleen, 
peripheral and mesenteric lymph nodes (p<0.01) (Figure 1B). Treatment with 
DT mutant (DTM CRM197), used as control, did not affect PDCA1+ CCR9+ pDC 
numbers (relative to a PBS control), establishing DTR involvement in pDC 
ablation (Figure 1C). The group of Colonna has previously shown that DT-
induced pDC depletion persists for at least 2-3 days,(21) corresponding with the 
pDC half life. However, pDCs could be depleted for several days by repeated 
DT administration. DT administration to BDCA-2 DTR transgenic C57Bl/6J mice 
resulted in selective depletion of pDCs, whereas classical cDCs as well as other 
leukocyte subsets were left intact.(21) To investigate whether DT administration 
for a period of 3 weeks in Ldlr-/- on high fat diet could modulate cDC numbers 
we compared percentages of cDCs between DTM and DT-injected mice. DT 
administration significantly diminished (~ 40-50%) the relative cDC content in 
peripheral and mesenteric lymph nodes (p<0.01), while splenic cDC numbers 
were left intact (Figure 1D). Thus, long term DT administration in Ldlr-/- mice 
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expressing the BDCA2-DTR leads to effective depletion of pDCs, but influences 
also peripheral cDC numbers.  
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Figure 1. DT administration induces effective depletion of pDCs, but has also significant impact 
on the cDC subset in high fat diet fed Ldlr-/- mice. (A) The construct for BDCA-2 DTR includes a 
5kb fragment upstream of the ATG of the BDCA-2 gene, a cDNA fragment encoding DTR, and the 
human growth hormone (hGH) gene polyadenylation signal.(21) (B) Flow cytometry analysis of 
spleen, peripheral lymph nodes (LN) and mesenteric lymph nodes (MLN) from high fat diet fed 
Ldlr-/- mice treated for 3 weeks with diphtheria toxin mutant (DTM; n=10) or diphtheria toxin 
(DT; n=11) revealed a significant decrease of pDC (PDCA-1+ CCR9+) numbers in all three lymphoid 
organs. (C) Treatment with DTM, used as control, does not affect PDCA1+ CCR9+ pDC numbers, 
relative to a PBS control. (D) Percentage of cDCs (CD11chigh) in spleen, LN and MLN indicates a 
significant decrease in cDC numbers in LN and MLN in DT-treated compared to control mice.  
* p< 0.05, ** p< 0.01, *** p< 0.001. 
 
 
Effective and selective depletion of CD4+ T cells in Ldlr-/- mice by 
administration of an anti-CD4 depletion antibody (αCD4) 
Next, we addressed the specificity of CD4+ T cell depletion by αCD4 
mAb, which recognizes the CD4 co-receptor expressed on T cells. 
Intraperitoneal administration of αCD4 mAb (but not GL113 isotype control) 
three times per week over three weeks gave almost quantitative (>95%) 
depletion of CD4+ T cell numbers in blood, spleen, peripheral and mesenteric 
lymph nodes (p<0.001) (Figure 2A-C). Depletion of CD4+ T cells resulted in 
approximately 60% reduction in absolute blood CD3+ T cell counts (p<0.001) 
compared to GL113 treated controls (Figure 2D). In line with the quantitative 
CD4+ T cell depletion, CD3+ T cells were highly enriched in CD8+ T cells (Figure 
2E). Anti-CD4+ T cell treatment did not affect numbers of NKT cells, NK cells, B 
cells, monocytes, granulocytes, cDCs and pDCs (Figure 2F). Thus, the αCD4 
mAb gave complete and specific CD4+ T cell depletion. 
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Figure 2. Effective and selective depletion of CD4+ T cells in Ldlr-/- mice by administration of an 
anti-CD4 depletion antibody (αCD4). Depicted are the results of flow cytometry from high fat 
diet fed Ldlr-/- mice treated with GL113 (n=11) or αCD4 (n=8). (A), (B) Absolute numbers of CD4+ 
T cells in blood are significantly decreased in high fat diet fed Ldlr-/- mice treated for 3 weeks 
with αCD4 depletion antibody. (C) Percentage of CD4+ T cells in spleen, LN and MLN are 
significantly declined in αCD4 treated mice. (D) Absolute numbers of CD3+ T cells in blood. (E) 
Absolute numbers of CD8+ T cells in blood. (F) Percentage of NKT cells (NK1.1low CD3low), NK cells 
(NK1.1+), B cells (B220+), monocytes (CD11b+ Ly6G-), granulocytes (CD11b+ Ly6G+), cDCs 
(CD11chigh) and pDCs (PDCA1+ CCR9+)  in spleen. * p< 0.05, ** p< 0.01, *** p< 0.001. 
 
 
Long-term DT injection alters B cell and granulocyte numbers in Ldlr-/- mice 
on high fat diet 
To investigate whether prolonged DT administration by itself could 
modulate immune responses, we compared leukocyte subset distribution 
between DTM and DT treated Ldlr-/- mice. Absolute CD45+ leukocyte counts in 
blood were unaffected (Figure 3A), as well as NK cell, NKT cell and monocyte 
levels in blood and spleen (Figure 3A-B; Supplemental Figure 1A-B). 
Comparing the T cell activation status between DTM and DT treated Ldlr-/- mice 
we did not find a difference in the number of CD44high effector-memory T cells 
(Figure 3C). Surprisingly, DT administration led to a significant decrease in 
absolute blood and, albeit to a lesser extent, relative spleen B cell numbers 
(p<0.01; Figure 3D-E), which was not in line with results previously 
described.(21) Likewise, absolute numbers of blood B1 and B2 B cell subsets 
were significantly decreased in DT-treated Ldlr-/- mice (Supplemental Figure 
S1C-D). In addition, granulocyte numbers were significantly increased 
(p<0.001) in blood (Figure 3F, H) and spleen (Figure 3G) after 3 weeks of DT 
administration. This suggests that prolonged DT treatment in high fat diet fed 
Ldlr-/- mice is associated with B cell lymphocytopenia and granulocytosis. In 
parallel to granulocytosis, IL-6 plasma levels were seen to be significantly 
increased (p<0.05) in DT-treated Ldlr-/- mice. Additionally, IFN-γ (Figure 4A) and 
CXCL1 (mKC) (Figure 4B) plasma levels tended to be elevated in DT treated 
compared to control mice (Figure 4C) pointing towards a systemic 
inflammatory status in Ldlr-/- mice that received DT administration over a 
period of 3 weeks. Interestingly, plasma IL-10 levels were also significantly 
augmented (p<0.05) in DT-treated Ldlr-/- mice (Figure 4D). 
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Figure 3. B cell and granulocyte numbers are altered in Ldlr-/- mice treated with DT. Flow 
cytometry analysis on blood and spleen leukocyte patterns in Ldlr-/- mice on high fat diet treated 
with DTM (n=10) or DT (n=11). (A) Absolute numbers of CD45+ leukocytes, NK cells (NK1.1+), NKT 
cells (NK1.1low CD3low) and monocytes (CD11b+ Ly6G-) in blood. (B) Percentage of NK cells, NKT 
cells and monocytes in spleen. (C) Numbers of effector memory CD4+ T cells (CD44high CD62Llow) 
in blood and spleen. (D) Absolute numbers of B220+ B cells in blood and (E) percentage of B cells 
(B220+) in spleen decreased significantly in high fat diet fed Ldlr-/- mice treated with DT for 3 
weeks compared to controls. (F) Absolute numbers of circulating Ly6Ghigh granulocytes and (G) 
percentage of Ly6Ghigh granulocytes in spleen. DT treatment for 3 weeks induced granulocytosis 
shown by the significantly increased granulocyte numbers. (H) FACS plot showing monocytes 
(CD11b+, Ly6G-) and granulocytes (CD11b+, Ly6G+) populations in blood of DT- and DTM-treated 
LDLr-/- mice. * p< 0.05, ** p< 0.01, *** p< 0.001. 
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Figure 4. Long-term DT treatment induces a systemic inflammatory status in Ldlr-/- mice. 
Measurement of plasma cytokine levels in high fat diet fed Ldlr-/- mice treated for 3 weeks with 
DTM (n=10) or DT (n=11). (A) IFN-γ, (B) CXCL1 (mKC), (C) IL-6, and (D) IL-10 plasma levels.  
* p< 0.05. 
 
Administration of DT, αCD4 antibody or DT/αCD4 antibody does not reduce 
atherosclerotic plaque development in Ldlr-/- mice 
To address the role of pDCs and the possible crosstalk of pDCs and 
CD4+ T cells in atherosclerosis, we examined lesion development in DT-treated, 
αCD4 mAb-treated, DT- and αCD4 mAb-treated, and control Ldlr-/- mice. DT 
administration and/or αCD4 mAb injection were launched three weeks after 
start of high fat diet, once initial lesions had formed. DT treatment per se did 
not influence plasma cholesterol levels (1360 ± 83.82 mg/dl vs 1266 ± 114 
mg/dl in DTM and DT treated mice, respectively), whereas αCD4 mAb 
treatment was seen to increase plasma cholesterol levels (1360 ± 83.82 mg/dl 
vs 1641 ± 67.2 in DTM/ GL113 and DTM/ αCD4 treated mice; 1266 ± 114 mg/dl 
vs 1647 ± 163 in DT/ GL113 and DT/ αCD4 treated mice, respectively; p<0.05) 
(Table 1). To our surprise, atherosclerosis development was unchanged in the 
aortic root after DT-aided pDC as well as CD4+ T cell depletion (Figure 5A). 
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Unexpectedly, treatment with αCD4 mAb induced a more unstable plaque 
phenotype, characterized by necrotic core expansion, regardless of the pDC 
status of the mice (Figure 5B). However, collagen content was not affected in 
αCD4 mAb treated Ldlr-/- mice (Figure 5C). These data did not corroborate our 
previous observations in mice, showing that pDCs function athero-protective in 
that they dampen peripheral CD4+ T cells activation and proliferation.(15) 
However, given the fact that prolonged DT administration is accompanied by 
pronounced granulocytosis, and diminished cDC and B cell numbers in the 
periphery, it is conceivable that these ectopic effects have overruled the pDC 
intrinsic impact on atherosclerosis.  
 
 
 
Figure 5. DT treatment in Ldlr-/- mice conceivably overrules the intrinsic impact of pDCs and 
CD4+ T cells on atherosclerosis. (A) Effects of DT aided pDC ablation in the presence (GL113 
isotype control) or absence of CD4 T cells (αCD4 mAb on atherosclerosis development in the 
aortic root; control mice were treated with inactive DTM instead of DT (DTM/GL113, n=10; 
DT/GL113, n=11; DTM/αCD4, n=8; DT/αCD4, n=6). Aortic roots were stained with hematoxylin 
and eosin (HE) to analyze plaque burden (plaque area, μm2). (B) Plaque necrotic core size of the 
different treatment groups. Necrotic core is defined as percentage of lipid core size over total 
plaque area. (C) Plaque collagen content is expressed as the percentage of collagen over plaque 
area. Scale bars represent 100 μm. * p< 0.05. 
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DT administration causes significant body weight loss, body infirmity, and 
induces lung inflammation in Ldlr-/- mice 
As further indication of peripheral side effects of DT treatment, Ldlr-/- 
mice exhibited severe progressive weight loss of up to 25% of the total body 
weight after 3 weeks of DT injection, both in GL113 and αCD4 mAb treated 
mice (Figure 6, Table 1) In addition, these animals exhibited generalized 
infirmity, reduced mobility/agility, sudden death after 18-21 days after 
repeated DT injection, and over signs of pneumonia. 
 
 
 
 
Figure 6. DT administration causes significant body weight loss and body infirmity in Ldlr-/- 
mice. Effects of DT administration on total body weight. Intraperitoneal DT application for 3 
weeks caused a gradual loss of 25% body weight in Ldlr-/- mice fed a high fat diet.  
* p< 0.05, ** p< 0.01. 
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Therefore, we analyzed the immune cell content in different organs in 
DT- an DTM-treated animals. Organ histopathology did not reveal any 
abnormalities in heart and kidney (data not shown) in DT-treated compared to 
control animals. Livers of DT-treated animals showed less fat accumulation 
which was in line with their weight loss (Figure 7A). However, lung histology 
demonstrated increased influx of inflammatory cells, mainly Ly6G+ 
granulocytes, Mac3+ macrophages and CD3+ T cells in the alveoli of DT-treated 
animals (Figure 7A, C). In keeping with the granulomatous lung inflammation, 
apoptosis was increased in lung alveoli and bronchii of DT-treated compared to 
control animals, as shown by Caspase 3 staining (Figure 7D). In conclusion, our 
results demonstrate that prolonged DT administration is associated with 
alveolar immune cell infiltration and apoptosis. It still needs to be analyzed, 
whether immune cells in lung of DT-treated animals display a more activated 
phenotype. 
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Figure 7. DT administration is accompanied by immune cell infiltration in lung. Microscopic 
analysis of mouse liver and lung. (A) Hematoxylin and eosin (HE) staining reveals regular 
histology for mouse liver of DT- versus DTM-treated animals. In contrast, lung tissue of DT- but 
not DTM-treated Ldlr-/- mice shows overt features of granulomatous inflammation. (B) 
Immunohistochemistry for Ly6G (granulocytes) on mouse liver. (C) Immunohistochemistry for 
Ly6G+ granulocytes, Mac3+ macrophages and CD3+ T cells in lung of DTM- versus DT-treated 
mice to analyze leukocyte infiltration. DT-treated mice show increased influx of immune cells. 
(D) Immunohistochemistry for Caspase 3 to show content of apoptotic cells in lung in DTM- 
versus DT-treated mice. 
 
 
Discussion 
 
pDCs play an important role in orchestrating immunity and tolerance in 
a variety of diseases.(22-26) In recent years pDCs gained more attention in the 
context of atherosclerosis. Hitherto, antibody depletion models have been 
used in vivo to uncover a functional role for pDCs in the pathophysiology of 
atherosclerosis. However, results are controversial, with pDCs seen to act 
tolerogenic or immunogenic, thus attenuating or promoting lesion 
formation.(15-17) 
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In the present study we used the BDCA-2 DTR model to unravel the 
impact of pDCs in atherosclerosis. A subset of mice additionally received a 
CD4+ T cell depleting antibody to address the contribution of CD4+ T cells to 
pDC immunity in atherosclerosis. Here, we could confirm, using the BDCA-2 
DTR model that PDCA-1+ CCR9+ pDCs were indeed efficiently depleted after 
repeated DT administration in spleen, lymph nodes and liver of Ldlr-/- mice fed 
a high fat diet. Surprisingly, under hyperlipidemic, potentially pro-
inflammatory conditions in Ldlr-/- mice, prolonged application of DT-induced 
systemic toxicity, manifested through elevated levels of pro-inflammatory 
cytokines, progressive weight loss, generalized body infirmity and sudden 
death between days 18 and 21 of DT administration. Moreover, DT-treated 
mice showed lung infiltration by inflammatory cells - mainly granulocytes, 
macrophages and T cells, which is not induced under conditions of 
hyperlipidemia.(27) Collectively, these features point to DT treatment associated 
acute pneumonia. This notion was supported by the elevated numbers of 
granulocytes and granulocyte progenitors in blood and spleen in DT-treated 
animals, thus reflecting inflammation elicited release of granulocyte 
(progenitors) from the bone marrow into the periphery. In line, plasma CXCL1 
levels were markedly increased in DT-treated mice compared to control mice, 
promoting augmented neutrophil mobilization from the bone marrow into the 
circulation, most likely to lung.(27, 28) 
Our results are in seeming contrast with findings of Swiecki et al. 
showing that specific pDC depletion is not accompanied by overt systemic 
abnormalities.(21) It has to be remarked that in the study of Swiecki et al., mice 
received DT twice before viral challenge and splenic immune cell composition 
was analyzed on day 7 post-infection. Of note, they did not examine effects of 
prolonged DT administration. Otherwise, the potentially pro-inflammatory 
milieu in Ldlr-/- mice may have favored ectopic side-effects of DT treatment 
and/or pDC ablation on other leukocyte subsets in our study.  
Interestingly, another study has shown that the use of DT per se was 
seen to confer (sublethal) toxicity, even in toxin-resistant wild-type mice when 
administered during active immunization, irrespective of the immunogenic 
peptide applied. Respectable, DT-treated mice in this study also showed 
mononuclear lung infiltration.(29) In a different study, LysM-DTR mice were 
generated to specifically deplete myelomonocytic cells.(30) Although peritoneal 
macrophages were efficiently depleted after DT injection, expression of the 
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DTR by alveolar epithelial cells resulted in apoptosis of these cells and lethal 
respiratory failure. To overcome systemic toxicity and lethality in mice 
receiving prolonged DT administration due to DTR expression on some 
alternative cell subsets, bone marrow chimeras in which the DTR expression is 
restricted to the hematopoietic compartment, should be generated. 
Another important limitation of the BDCA2-DTR model for 
atherosclerosis studies was the observation that during prolonged DT 
administration in Ldlr-/- mice, numbers of CD11chigh DCs in lymph nodes as well 
as B cell numbers in blood and spleen were markedly decreased. These data do 
not correspond with previous findings of Swiecki et al. in which DT 
administration specifically depleted pDCs, leaving other immune cell subsets 
intact.(21) We did not examine whether the BDCA2 promoter contains target 
sequences for transcription factors others than E2-2, that are important for B 
cell or cDC development, such as the zinc finger transcriptional regulator 
Ikaros(31-33) or the interferon regulatory factor 8 (IRF-8),(34, 35) but it should be 
investigated to confirm specificity of the BDCA-2 DTR model. Interestingly, a 
recent study has described the direct involvement of E2-2 together with the 
HeLa E-box binding protein E2A in the early B cell development as well as in 
the selection of peripheral B cell subsets. Transfer of E2-2-deficient cells into 
irradiated mice could reconstitute all B cell subpopulations, albeit with a 
reduction in cellularity, requiring E2-2 for the optimal expansion of pro-B 
cells.(36) This could explain a direct effect on peripheral B cell (subset) numbers 
in our study. 
By analyzing the atherosclerotic plaque size in DT-treated Ldlr-/- mice, 
we could not confirm the results received from our previous study, in which 
we have shown an athero-protective role for pDCs in atherosclerosis.(15) 
However, given the fact that prolonged DT administration is accompanied by 
pronounced granulocytosis, and diminished cDC and B cell numbers in the 
periphery, it is possible that these ectopic effects have overruled the pDC 
intrinsic impact on atherosclerosis.  
In conclusion, our study has shown that the BDCA-2 DTR model is not 
appropriate to study pDC functions in atherosclerosis, due to systemic toxicity 
and undesirable modulations of leukocyte subsets others than pDCs after 
prolonged DT administration. Given the limitations of the BDCA2-hDTR model 
for prolonged pDC depletion, alternative models, such as the E2-2+/- or E2-2-/-
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(37) should be considered for conditional pDC depletion studies in these chronic 
inflammatory disorder. 
 
 
Supplemental Figures  
 
 
Supplemental Figure 1. Number of B cell subsets are altered in Ldlr-/- mice treated with DT. 
Flow cytometry analysis on blood and spleen leukocyte patterns in Ldlr-/- mice on high fat diet 
treated with DTM (n=10) or DT (n=11). (A) Absolute numbers of monocyte subsets (Ly6C-, Ly6C+) 
in blood, and (B) percentage of monocyte subsets (Ly6C-, Ly6C+) in spleen reveal that DT 
treatment did not affect peripheral monocyte subset numbers. (C, D) Long-term DT 
administration induced a significant decrease in circulating B cell subsets. * p < 0.05. 
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  Dendritic cells (DCs) are specialized antigen-presenting cells that are 
thought to be involved in atherosclerosis adaptive immune responses. 
Maturation and activation of DCs induced by danger signals derived from 
pathogenic agents or damaged tissue via pattern-recognition receptors such as 
Toll-like receptors, is a crucial step in DC innate and adaptive immune actions. 
Hypercholesterolemia, a major risk factor in atherosclerosis development, may 
influence signaling pathways relevant to DC immune functions, thereby 
screwing host immune responses against invading pathogens. Indeed, 
hyperlipidemia has been shown to abrogate the activation of certain murine 
DC subsets, due to uncoupling of Toll-like receptor-mediated signaling, thus 
affecting host resistance to microbial infections. 
In the following two studies (Chapter 5 and 6) we investigated the 
influence of a hyperlipidemic environment on DC precursor development, 
peripheral DC subset phenotype (when lipid-laden), their activation status, and 
functionality. In Chapter 5 we focused on the effect(s) of hyperlipidemia on 
human plasmacytoid dendritic cells (pDCs), isolated from peripheral blood 
mononuclear cells. We indicated that excessive lipoprotein exposure led to 
impaired functionality of human pDCs in vitro. Such association might have 
profound implications for the host’s pathogen defense capacity in 
hyperlipidemic patients. In Chapter 6 we investigated the effects of early and 
later time points of dietary-induced hypercholesterolemia on murine DC 
(precursor) homeostasis, as well as the phenotype of lipid-laden peripheral DC 
subsets, and their T cell priming capability. In accordance with our results 
purchased in Chapter 5, we demonstrated in Chapter 6 that DCs were affected 
in their T cell priming capability upon lipoprotein uptake. These data 
strengthen the idea that a cholesterol-rich environment potentially interferes 
with DC responses to host immunity. 
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Abstract 
 
Maturation and activation of plasmacytoid dendritic cells (pDCs) induced by danger 
signals derived from invading pathogens or damaged tissue via pattern-recognition 
receptors, is a pivotal step in pDC innate and adaptive immune functions. Exposure to 
factors, such as lipoproteins, may well influence signaling pathways relevant to pDC 
immune functions, thereby tuning host immune responses against endogenous, 
bacterial and viral pathogens. In this study, we have investigated the effect of a 
hyperlipidemic environment on human pDC activation, cytokine response and capacity 
to prime CD4+ T cells. We show that exposure to pro-atherogenic lipoproteins (LDL and 
oxidized LDL (oxLDL)), induced pDC lipid accumulation, ablated Toll-like receptor 9 
(TLR9)-induced production of pro-inflammatory cytokines, including interferon (IFN)-α, 
interleukin (IL)-6, tumor necrosis factor (TNF)-α, CCL3 and CCL4, as well as up-
regulation of the pDC maturation markers CD40, CD83, CD86 and HLA-DR. Additionally, 
oxLDL induced blunting of pDC activation and profoundly impaired their CD4+ T helper 
(Th) cell stimulatory capacity. These results show that a hyperlipidemic environment 
does interfere with pDC responses to pathogen-derived signals through abrogating 
pDC activation. 
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Introduction 
 
Dendritic cells (DCs) are specialized antigen-presenting cells (APCs), 
and therefore pivotal in mediating adaptive immune responses, either inducing 
immunity or a state of tolerance.(1, 2) Under healthy steady-state conditions 
DCs reside as immature sentinels in peripheral tissue and lymphoid organs to 
scan and respond to changes in their environment.(3, 4) Upon stimulation by 
danger signals derived from invading pathogens and/or injured tissue through 
pattern-recognition receptors (PRRs), such as Toll-like receptors (TLRs), DCs get 
activated.(5, 6) This process is characterized by major phenotypic changes, 
including the up-regulation of maturation markers, such as CD40, CD80, CD86 
and major histocompatibility complex (MHC) molecules, and the release of a 
range of cytokines, critically implicated in the activation of naïve T cells.(7, 8) 
Plasmacytoid DCs (pDCs), an unconventional DC subset, are highly 
specialized in sensing viral and certain microbial infections, which is based on 
their expression of TLR7 and TLR9.(9) TLR receptor activation leads to the 
unique ability of pDCs to release large amounts of type I interferons (IFNs; IFN-
α, -β, -λ, -ω), which notably influences several immune responses, for example. 
Th1/2 differentiation, conventional DC (cDC) maturation, and stimulation of B 
cells to differentiate into antibody secreting plasma cells(9, 10) Thus, pDCs are 
important players in initiating innate as well as adaptive immune responses. 
Otherwise, pDCs have also been shown to be involved in the pathophysiology 
of certain autoimmune diseases, such as systemic lupus erythematosus (SLE) 
or psoriasis, through the indeliable production of type I IFNs, which stimulate 
autoreactive T and B cells.(11) However, immature pDCs are also contributing to 
peripheral T cell tolerance, as has been shown in cardiac transplantation and in 
oral tolerance.(12, 13) 
Interstitial fluids, lymph, and plasma compose the environment in 
which certain DC subsets are exposed to danger signals and they might thus 
steer immune responses. Lipoproteins, laden with bioactive lipids, may be 
particularly potent in this regard, and a perturbation of lipoprotein 
homeostasis by environmental or genetic factors may therefore impact (p)DC 
function.(14, 15) Whether or not DC subsets are fully functional under 
dyslipidemic conditions is still subject to controversy. Hypercholesterolemia 
was seen to lead to impaired DC migration,(16) but also to the maintenance of 
antigen-presentation and T cell priming ability by several DC subsets.(17-19) At a 
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functional level, dyslipidemia was recently reported to directly affect murine 
CD8- cDCs, impairing their response to TLR stimulation, and compromising host 
resistance to Leishmania major.(20) In keeping, overt TLR3 and 4 dependent 
immuno-inhibitory effects were observed for oxidized phospholipids (oxPLs) on 
LPS-induced DC maturation and cytokine release.(21) However, no studies thus 
far have addressed whether a hyperlipidemic environment interferes with pDC 
responses to (pathogen-derived) danger signals and anti-viral host immunity.  
In this study we have investigated the effect of hyperlipidemia on 
human pDC activation and CD4+ Th cell polarization capability in vitro. We 
show that modified lipoproteins impair pDC maturation and functionality. This 
subsequently leads to abated cell-mediated immune responses by pDCs.  
 
 
Methods 
 
Isolation and culture of pDCs 
Peripheral blood mononuclear cells (PBMCs) were prepared from 
heparinised whole blood of healthy donors by standard Ficoll-Paque (Sigma-
Aldrich, Seelze, Germany) density gradient centrifugation. pDCs were isolated 
from PBMCs using the BDCA-4 Cell Isolation Kit (Miltenyi Biotec, Bergisch-
Gladbach, Germany) and phosphate buffered saline (PBS)/ EDTA Buffer 
(Miltenyi Biotec) supplemented with 0.5% bovine serum albumine (BSA; 
Sigma-Aldrich). Labeled cells were enriched using permanent magnets yielding 
a high-gradient magnetic field (midiMACS separators, Miltenyi Biotec). The 
positively sorted pDC fraction was analyzed by flow cytometry on a BD Canto II 
(BD Bioscience, Bedford, MA, USA) according to their BDCA-2+, CD123+, CD11c-, 
CD3-, CD14-, CD19-, CD20- and CD56- phenotype and reached > 85% purity. 
Isolated pDCs were seeded in round-bottomed 96-well cell culture plates at a 
density of 5x104 cells/ well in AIM-V medium (Invitrogen, Darmstadt, 
Germany), and cultured in the presence of 10µM CpG (CpG-ODN 2216, type A; 
Invivogen, San Diego, CA, USA), CpG (10µM) plus LDL (50µg/ml), CpG (10µM) 
plus oxLDL (10µg/ml or 50µg/ml), LDL (50µg/ml) or oxLDL (10µg/ml or 
50µg/ml) for 24 hours at 37°C and 5% CO2.  
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OxLDL preparation 
Low-density lipoprotein (LDL) (1.006 ≤ d ≤ 1.063 g/ml) was isolated 
from human plasma of normolipidemic healthy individuals by 
ultracentrifugation. The plasma density was raised to 1.055 g/ml using KBr. 
After ultracentrifugation at 32,000 rpm at 4°C for 16 hours using a SW41Ti 
rotor Beckman Instrument, the light fraction, containing LDL, was collected and 
stored under nitrogen. LDL concentration was determined using the 
bicinchoninic acid (BCA) protein kit (Thermo Scientific, Rockford, IL, USA). LDL 
concentration was adjusted to 0.5 mg/ml of protein by dilution in PBS. Cu2+-
mediated oxidation was conducted at 37°C for 24h against 0.32mM 
CuSO4/PBS. The reaction was stopped by addition of 50µM ethylene-diamid-
tetraacetate (EDTA) and extensive dialysis at 4°C against PBS containing 0.5M 
EDTA for 24 hours. LDL or modified LDL were tested for endotoxin using a 
Limulus Amebocyte Lysate (LAL) assay (Hycult Biotechnology, Uden, The 
Netherlands), according to the manufacturer’s instructions. Endotoxin 
concentration of all samples was below 5pg/ml. 
 
Labeling of LDL and oxLDL with DiI 
LDL and oxLDL were labeled with the fluorescent lipid 1,1'-dioctadecyl-
3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI; Invitrogen, Darmstadt, 
Germany), by incubating 3mg/ml DiI per ml of LDL or oxLDL, overnight and in 
the dark, while continuously stirring in a 37˚C water bath. Free DiI was 
removed by size exclusion chromatography using PD-10 columns (GE 
Healthcare, Uppsala, Sweden). DiI-labeled LDL and oxLDL uptake was 
determined by flow cytometry on a BD Canto II (BD Bioscience, Bedford, MA, 
USA). 
 
Oil-Red-O staining 
5x104 pDCs were cytospun at 700rpm for 5 minutes on glass slides. 
After drying slides for 1 hour, sections were incubated in PBS for 5 minutes, 
dipped 10x in 60% 2-propanol and stained with Oil-Red-O solution for 20 
minutes. After dipping 10x in 60% 2-propanol, sections were cleared under tap 
water. Cell nuclei were stained with haematoxylin. Sections were mounted 
with IMSOL and covered. 
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Flow cytometry 
Isolated pDCs were stained with fluorescein isothiocyanate (FITC)-
conjugated CD3 (1:100, DAKO, Glostrup, Denmark), CD14 (1:100, eBioscience, 
San Diego, CA, USA), CD16 (1:100, DAKO), CD19 (1:100, DAKO), CD56 (1:100, 
eBioscience), CCR7 (1:20, BD Bioscience, Bedford, MA, USA) and CD40 (1:100, 
BD Bioscience), R-phycoerithrin (PE)-conjugated CD86 (1:500, BD Bioscience) 
and CD83 (1:20, BD Bioscience), PerCP-Cy5.5-conjugated CD123 (1:50, BD 
Bioscience), allophycocyanin (APC)-conjugated BDCA-2 (1:50, Miltenyi Biotec, 
Bergisch-Gladbach, Germany), phycoerithrin-Cyanine7 (PE-Cy7)-conjugated 
CD11c (1:20, eBioscience), allophycocyanin-H7 (APC-H7)-conjugated HLA-DR 
(BD) and Pacific Blue-conjugated CD4 (1:20, eBioscience) monoclonal antibody 
(mAb). Life-dead cell staining was accomplished using 7-AAD, a marker that is 
intercalating in non-vital cell DNA. All flow cytometry analyses were performed 
on a BD Canto II (BD Bioscience). 
 
Mixed leukocyte reaction 
Autologous naïve CD4+ T cells were isolated from pDC-depleted PBMCs 
by use of the human naive CD4+ T Cell Isolation Kit (Miltenyi-Biotec, Bergisch-
Gladbach, Germany). As determined by staining with V500-conjugated CD3 
mAb, APC-H7-conjugated CD4 mAb, FITC-conjugated CD8 mAb, PE-conjugated 
CD45RO mAb, V450-conjugated CD45RA mAb and APC-conjugated CD25 mAb 
(BD Bioscience, Bedford, MA, USA), populations containing 99,9% CD3+ CD4+ 
CD45RA+ CD45RO- CD8- T cells were routinely obtained. For the mixed 
leukocyte reaction (MLR), autologous purified naïve CD4+ T cells (5x105 cells/ 
well) were incubated in 96-well cell culture plates with 1x105 pDCs, pre-
cultured for 24 hours as described above and pre-incubated 1 hour before 
adding the T cells with Staphylococcus Enterotoxin B (SEB; 10ng/ml). MLRs 
were cultured for 7 days. The assay was performed in duplicate. 
 
Cytokine measurement 
pDCs were treated as indicated, and cytokine concentrations of IFN-α, 
IL-6, IL-12p70, IL-10, TNF-α, RANTES (CCL5), MIP-1α (CCL3), MIP-1β (CCL4) and 
CXCL10 (IP10) in cell-free supernatants were measured after 24 hours using 
the Cytometric Bead Array (CBA) human soluble protein kit (BD Bioscience, 
Bedford, MA, USA), according to the manufacturers instructions. For the T cell 
polarization assay, MLR supernatants were harvested at day one to seven of 
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co-culture and analyzed for IFN-γ, TNF-α (T helper 1 cytokines), IL-4, IL-5, IL-13 
(T helper 2 cytokines), IL-17A (T helper 17 cytokine), and IL-10 (Treg cytokine) 
by CBA kit. ELISA plates were used from Greiner Bio-One (Alphen a/d Rijn, The 
Netherlands). 
 
Statistical analysis 
Data were analyzed with the use of Graph Pad Prism 5 (Graph Pad 
Software Inc., San Diego, CA, USA). All data are expressed as mean ± SEM. To 
compare several groups, a one-way ANOVA with multiple testing correction 
was used. Values of p< 0.05 were considered statistically significant.Values of 
p< 0.05 were considered statistically significant. 
 
 
Results  
 
Human pDCs are able to engulf lipoproteins 
First we examined whether pDCs, freshly isolated from human PBMCs 
by BDCA-4 magnetic beads, are able to take up oxLDL. Enrichment of isolated 
immature pDCs was confirmed by flow cytometry according to the surface 
marker expression of BDCA-2 and CD123 and reached >85%, represented by 
flow cytometry (Figure 1A). Immature, as well as CpG-matured pDCs were 
incubated for 24 hours in the absence or presence of DiI-labeled oxLDL (10 and 
50μg/ml). DiI-oxLDL exposed pDCs exhibited modest lipoprotein uptake, as 
assessed by flow cytometry (p<0.05; Figure 1B, C). CpG-stimulated pDCs 
showed markedly increased DiI-oxLDL uptake (p<0.001; Figure 1B, C). OxLDL 
accumulation by pDCs could be confirmed by Oil-Red-O staining, showing the 
characteristic presence of Oil-Red-O stained vacuoles in oxLDL exposed pDCs 
(Supplemental Figure 1). Overnight incubation of immature pDCs with oxLDL 
did not lead to increased cell death (Supplemental Figure 2A, B), and average 
cell viability amounted 25-30%. pDCs stimulated for 24 hours with CpG and 
oxLDL (10 and 50 μg/ml) showed much less cell death (10-15%) (Supplemental 
Figure 2A, B). 
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Figure 1. Human pDCs take up lipoproteins. pDCs, isolated from human PBMCs, were cultured 
for 24 hours with CpG-ODN 2216, CpG-ODN 2216 plus DiI-oxLDL (10μg/ml or 50μg/ml), or DiI-
oxLDL alone (10μg/ml or 50μg/ml). Non-supplemented medium was used as control, and DiI 
fluorescence was determined by flow cytometry as a measure of oxLDL uptake. Results are 
representative of five independent experiments. (A) Enrichment of CD123+ BDCA-2+ pDCs from 
isolated PBMCs by BDCA-4 positive magnetic beads. Purity was determined by flow cytometry. 
(B) FACS plots demonstrating oxLDL uptake by pDCs. (C) Mean fluorescence intensity (MFI) of 
DiI+ pDCs. *p< 0.05, **p< 0.01, ***p<0.001. 
 
Lipoproteins inhibit CpG-induced up-regulation of maturation markers and 
cytokine production by pDCs 
 To test the impact of oxLDL accumulation on pDC maturation, we 
incubated human pDCs for 24 hours with oxLDL (0, 10 and 50μg/ml) in the 
absence or presence of CpG. CpG-activated pDCs acquired a characteristic 
mature phenotype compared to non-stimulated controls, as demonstrated by 
the significantly increased expression of maturation markers, including CD83, 
CD86, HLA-DR and the lymphoid-homing receptor CCR7 (Figure 2A). BDCA-2, a 
pDC specific type II C-type lectin,(22) is expressed on immature pDCs, but abated 
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on mature pDCs, rendering it a useful marker of immature pDCs. As expected, 
CpG-stimulated pDCs showed significantly decreased BDCA-2 expression 
(p<0.001; Figure 2A). OxLDL treated pDCs exhibited a low surface expression of 
CD83, CD86, HLA-DR and CCR7, comparable to that of immature pDCs (Figure 
2A). Interestingly, co-incubation of pDCs with oxLDL dose-dependently 
inhibited CpG-induced pDC maturation (Figure 2A). BDCA-2 surface expression 
remained unexpectedly low in CpG/oxLDL co-stimulated pDCs (Figure 2A). 
Bioactive oxidized lipids, such as oxidized phospholipids, are present in oxLDL, 
and can profoundly modify the course of an immune response,(23) as has also 
been observed for pDC activation. To test the impact of LDL on pDC 
maturation, human pDCs were incubated for 24 hours with CpG, in the 
absence or presence of LDL (50 μg/ml), with LDL alone (50 μg/ml), or in non-
supplemented medium (control). While treatment with LDL did not influence 
pDC maturation status, it abrogated CpG-induced pDC maturation as was 
indicated by the significant down-regulation of CD83, CD86, HLA-DR and CCR7, 
as well as the concomitant up-regulation of BDCA-2 (Supplemental Figure 3A). 
 The oxLDL and LDL associated inhibition of CpG-induced pDC 
maturation led us to test their impact on pDC cytokine production. In the 
context of systemic viral or bacterial infections pDCs rapidly release large 
amounts of type I IFNs, as well as other pro-inflammatory cyto- and 
chemokines, which promote lymphocyte recruitment to sites of infection.(24, 25, 
27, 28) Here, simultaneous treatment of immature pDCs with LDL or oxLDL 
(50μg/ml) and CpG for 24 hours almost completely prevented the CpG-induced 
production of the pro-inflammatory cytokines IFN-α, TNF-α and IL-6. 
Additionally, the release of the chemokines CCL3, CCL4 and CXCL10 was nearly 
entirely abrogated, when stimulated with the lipoproteins and CpG (p<0.01; 
Figure 3A). Concentrations of IL-10, IL-12p70, and CCL5 were not measurable 
under all conditions tested (data not shown). 
 Altogether, these data reveal that the presence of lipoproteins do not 
induce in vitro maturation of human pDCs. Moreover, CpG-induced pDC 
activation is abrogated when co-cultured with LDL or oxLDL. 
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Figure 2. OxLDL inhibits CpG-induced expression of maturation markers in pDCs. Freshly 
isolated human pDCs were stimulated with 10μg/ml CpG-ODN 2216 either with or without 
oxLDL (10 and 50μg/ml) (oxLDL and CpG-ODN 2216 were added simultaneously). Non-stimulated 
pDCs were used as control. After 24 hours, cells were harvested and the surface expression 
levels of the indicated markers were measured by flow cytometry. (A) Induction of maturation 
markers (CD83, CD86, HLA-DR, CCR7, BDCA-2) on pDCs shown as MFI. The presence of oxLDL 
dose-dependently inhibits the up-regulation of pDC maturation markers. (B) Maturation marker 
expression on non-stimulated pDCs (grey peak), CpG-ODN 2216 stimulated pDCs (red peak), or 
CpG-ODN 2216 plus oxLDL stimulated pDCs (10μg/ml: green peak; 50μg/ml: blue peak). Data are 
shown as mean ± SEM of five independent experiments using different donor pDCs.  
*p< 0.05, **p< 0.01, ***p<0.001. 
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Figure 3. LDL and oxLDL inhibit CpG-induced pro-inflammatory cytokine production by pDCs. 
(A) Freshly isolated human pDCs were stimulated with 10μg/ml CpG-ODN 2216 either with or 
without LDL (50μg/ml) or oxLDL (50μg/ml). Non-stimulated pDCs were used as control. After 24 
hours, cell supernatants were analyzed for the indicated cytokines by use of the CBA kit. Data 
are shown as mean ± SEM of three independent experiments using different donor pDCs.  
*p< 0.05, **p< 0.01, ***p<0.001. 
 
Prior lipoprotein treatment inhibits CpG-induced pDC maturation 
Next, we addressed the question whether lipoproteins inhibit CpG 
effects by preventing CpG-uptake, or by shielding CpG to interact with TLRs. 
pDCs express TLR7 and TLR9, which recognize single-stranded RNA and double-
stranded DNA, respectively.(29) Upon TLR stimulation, pDCs undergo major 
phenotypic changes, including the up-regulation of maturation markers. Pre-
treatment of pDCs with the lipoproteins prevented CpG-induced up-regulation 
of maturation markers, including CD40, CD86, HLA-DR, and CCR7 (Figure 4A). 
BDCA-2 surface expression remained up-regulated in CpG-stimulated pDCs, 
pretreated with lipoproteins. In contrast, CpG-induced pDC activation was not 
affected by post-treatment with LDL or oxLDL. Cells displayed elevated 
expression levels of the aforementioned pDC maturation markers (Figure 4A), 
and increased IFN-α production (data not shown). To conclude, pre-incubation 
of pDCs with LDL or oxLDL ablates TLR9-induced activation by CpG. 
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Figure 4. Lipoprotein treatment inhibits TLR9-induced pDC maturation. Freshly isolated human 
pDCs were stimulated for 4 hours with (ox)LDL (50μg/ml), and subsequently for 16 hours with 
10μg/ml CpG-ODN 2216 (red bars), or conversely (blue bars). As controls, pDCs were stimulated 
with 10μg/ml CpG-ODN 2216 (positive control) or incubated in non-supplemented medium. 
Subsequently, cells were harvested and the surface expression levels of the indicated markers 
were measured by flow cytometry. (A) Induction of maturation markers (CD40, CD86, HLA-DR, 
CCR7, BDCA-2) on pDCs shown as MFI. Data are shown as mean ± SEM of three independent 
experiments using different donor pDCs. *p < 0.05, **p<0.01, ***p<0.001. 
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OxLDL treatment suppresses TLR9-induced pDC activation and T cell 
stimulation capacity 
 To analyze the effect of LDL and oxLDL on T cell stimulatory capacity of 
pDCs, activated with CpG, we performed autologous mixed leukocyte 
reactions. Non-activated pDCs were used as control. As expected CpG-
activated pDCs augmented Th1 polarization of naïve CD4+ T cells after 7 days of 
co-culture, as judged by the markedly increased IFN-γ and TNF-α cytokine 
release (Figure 5A). Similarly, CpG-matured pDCs also enhanced cytokine 
induced Th2 polarization, illustrated by significantly elevated IL-13 production 
on day 7 of co-culture (Figure 5B). Of note, Th2 cytokine levels of IL-5 and IL-4 
remained unaffected in CpG-matured pDC co-cultures (Figure 5B). Importantly, 
T cell stimulatory capacity of CpG-stimulated pDCs was almost or completely 
blunted by co-treatment with oxLDL (Figure 5A, B), consistent with the 
observed impaired maturation and activation capacity of (ox)LDL treated pDCs. 
Surprisingly, pDCs, pre-treated with LDL, were able to induce a Th1 polarization 
of naïve CD4+ T cells (Figure 5 A), comparable to the Th1 response elicited by 
CpG-activated pDCs. IL-17A and IL-10 cytokine levels in the cell supernatants 
were nearly or completely undetectable in all conditions (Figure 5C, D), except 
for IL-10 cytokine concentrations that were significantly up-regulated on day 7 
of co-culture with immature pDCs (control). This might reflect a preferential T 
cell differentiation into regulatory T cells (Treg’s) (Figure 5D). 
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Figure 5. OxLDL inhibits T cell stimulatory capacity of CpG-activated pDCs. Human autologous 
naïve CD4+ T cells were stimulated with immature, CpG-ODN 2216 pre-incubated (with or 
without 25μg/ml LDL or oxLDL), or lipoprotein pre-incubated (25μg/ml LDL or oxLDL) pDCs, and T 
cell polarization capacity (Th1, Th2, Th17 or Treg) was analyzed on day 1, 3, 5 and 7 of co-culture 
by measuring T cell cytokines in the cell supernatant (CBA kit). (A) Measurement of Th1 
cytokines IFN-γ and TNF-α; (B) measurement of Th2 cytokines IL-5, IL-4 and IL-13; (C) 
measurement of Th17 cytokine IL-17A; (D) measurement of Treg cytokine IL-10. Data are shown 
as mean ± SEM of two independent experiments using different donor pDCs and T cells. 
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Discussion 
 
 DC activation, induced by receptor-mediated recognition of pathogen-
derived and endogenous danger signals is a crucial step during infections to 
trigger innate and adaptive immunity. Hyperlipidemia has been shown to 
impair host immune responses against yeast, bacterial, and viral infections.(30-
33) However, the underlying mechanisms are not well understood. pDCs have a 
critical role in anti-viral defense through production of large amounts of type I 
IFNs. Additionally, pDCs are fully capable to present endogenous antigens to 
naïve T cells, thereby inducing effective T cell responses.(34, 35) Here, we address 
the question whether a hyperlipidemic environment affects pDC activation and 
their T cell stimulatory capacity. We demonstrate that human pDCs are hypo-
responsive after (ox)LDL exposure, and fail to induce Th cell polarization in 
vitro. These effects might have striking implications for pDC-mediated 
pathogen responses, as well as general immunity in vivo under pathological 
conditions such as atherosclerosis or obesity, which are strongly associated 
with dyslipidemia.(14) 
As we show, human pDCs are able to take up and accumulate 
lipoproteins. Lipoprotein (LDL or oxLDL) accumulation dose-dependently 
dampened the CpG-induced IFN and cytokine response. Additionally, the 
hyperlipidemic environment abrogated the up-regulation of co-stimulatory 
molecules, such as CD40, CD83 and CD86, as well as HLA-DR, markers which 
are pivotal for T cell priming.(4) As a consequence, CD4+ T cell polarization was 
completely quenched. This is in keeping with the recently reported ability of 
murine pDCs to incorporate oxLDL.(19) Interestingly, in vitro oxLDL exposure 
enhanced the phagocytic efficiency of murine pDCs, but did neither alter 
surface expression of the maturation markers CD86 and MHC II, nor secretion 
of IFN-α protein.(19) Surprisingly, ex vivo ovalbumin-pulsed pDCs, additionally 
pre-treated with oxLDL, were able to induce strong antigen-specific OT-II CD4+ 
T cell proliferation in vivo.(19) One explanation might be that additional in vivo 
stimuli have boosted pDCs to trigger T cell proliferation. Otherwise, it needs to 
be determined how long pDCs were pre-treated ex vivo with oxLDL in the 
referred study. Long-term lipoprotein exposure possibly quenches pDC 
activation, whereas short incubation times preserve their antigen processing 
and presenting capability. 
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Moreover, we demonstrated that lipoprotein treatment (LDL and 
oxLDL) markedly decreased surface expression of the lymphoid-homing 
receptor CCR7 in CpG-stimulated pDCs. Down-regulation of this receptor may 
limit pDC migration from injured tissue to secondary lymphoid organs, thereby 
impairing the induction of effective T cell responses.(36, 37) Then again, other 
chemokine receptors may regulate pDC trafficking.(38) pDC migration in the 
steady-state is mediated through the expression of L-Selectin, CXCR4 and 
ChemR23.(38) Under inflammatory conditions this chemokine receptor 
repertoire is enlarged by the expression of CCR5, CXCR3 and CCR7.(22) Next to 
the latter, the ChemR23/chemerin axis seems to play a key role in pDC 
migration towards secondary lymphoid organs, especially under inflammatory 
conditions.(39) It remains to be demonstrated, whether a hyperlipidemic 
environment will impact the surface expression of other chemokine receptors 
on pDCs, thereby interfering their trafficking routes. 
Additionally, lipoprotein treatment potently quenched CpG-induced 
IFN-α production by pDCs. Moreover, the release of IL-6 and TNF-α, as well as 
of the T cell attracting chemokines CCL3 and CCL4 was impaired by lipoprotein 
exposure, identifying LDL and oxLDL as strong negative regulators of 
inflammatory cytokine and chemokine production in human pDCs.(27, 28 ) In line, 
we have previously shown that CpG-induced IFN-α release by pDCs into the 
circulation was dampened in high fat diet fed low-density lipoprotein deficient 
(Ldlr-/-) mice, suggesting that hyperlipidemia dampens murine pDC 
activation.(40) At least two studies in humans also observed an impaired 
functionality of circulating pDCs, isolated from patients with carotid 
endarterectomy (CEA),(40) or from coronary artery disease (CAD) patients, 
revealed by the derogated expression and secretion of IFN-α.(41) Nevertheless, 
data interpretation has to be considered cautious, since hyperlipidemia was 
present only in a minor fraction of included patients. It will be of interest in 
future studies to analyze phenotype and functionality of pDCs, isolated from 
patients with familial hypercholesterolemia. 
The actual mechanism underlying (ox)LDL mediated interference with 
TLR9 activation remains elusive. (Ox)LDL may act by interfering with CpG-
binding to TLR9, thereby inhibiting TLR9-induced NF-κB, and IRF7 activation.(42-
44) Alternatively, oxLDL could bind to other surface receptors, such as BDCA-2, 
dendritic cell immuno-receptor (DCIR), or immunoglobulin-like receptor 7 
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(ILT7), which potently suppress IFN-α/ β production upon ligand binding.(22, 45, 
46)  
Previous studies corroborate the idea that oxidized lipoproteins 
directly affect TLR-ligand binding. For instance, Kopf and coworkers 
demonstrated that dyslipidemia inhibits murine CD8α- cDC activation. OxLDL 
appeared to be responsible for this effect, as it uncoupled TLR2, 3, 4, 7-
mediated signaling in cDCs, and inhibited NF-κB binding to DNA.(20) Similarly, 
Blueml et al. have shown that oxidized phospholipids (oxPLs) negatively 
regulate LPS-induced maturation of human monocyte-derived DCs, and their 
lymphocyte stimulatory capacity.(21) The authors suggest a direct interaction of 
oxPLs with TLR4, thereby blocking LPS binding to its receptor.(47) A similar 
mechanism may apply for TLR9 as well. 
Our data suggest that hyperlipidemia could induce immuno-tolerance 
in pDCs. This may require the production of anti-inflammatory cytokines, such 
as IL-10 or TGF-β, crucial for such immuno-suppression by dampening 
immunogenic T cell responses, and favoring Treg differentiation.(48, 49) We were 
however unable to detect elevated levels of IL-10 or TGF-β after lipoprotein 
exposure, nor did lipoprotein treatment induce the generation of Treg’s. As we 
have previously shown, hyperlipidemia can also induce tolerogenic pDCs in 
mice by dampening T cell proliferation in an IDO-dependent manner, an option 
that requires further study.(40) 
Taken together, our data show that a hyperlipidemic environment 
inhibits TLR9-dependent maturation and cytokine production by human pDCs. 
Moreover, the presence of oxLDL abrogates the ensuing Th cell responses in 
vitro. It will be of importance to dissect the lipoprotein uptake associated 
culprit pathways and the downstream lipid metabolites responsible for the 
inhibitory effect of (ox)LDL. Additionally, it remains elusive, whether 
hyperlipidemia renders pDCs functionally impaired and non-responsive to 
pathogen-derived signals in vivo. 
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Supplemental Figures  
 
 
  
 
Supplemental Figure 1. Human pDCs are able to take up oxLDL. pDCs, isolated from human 
peripheral blood mononuclear cells, were cultured for 24 hours with CpG-ODN 2216, CpG-ODN 
2216 plus oxLDL (10μg/ml), with oxLDL (50μg/ml)) alone (10 and 50μg/ml) or in non-
supplemented medium (control). Oil-Red-O staining confirmed oxLDL accumulation by pDCs (red 
droplets). Cell nuclei were counterstained with haematoxylin. 
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Supplemental Figure 2. OxLDL does not affect pDC viability. Depicted are the results of flow 
cytometry analysis of isolated human pDCs, cultured with CpG-ODN 2216, CpG-ODN 2216 and 
oxLDL (10μg/ml or 50μg/ml), oxLDL alone (10μg/ml or 50μg/ml) or in non-supplemented 
medium (control), and stained with 7-AAD for the presence of dead/ apoptotic cells. (A) 
Percentage of viable (white bars) versus dead (black bars) pDCs. (B) Histograms representing 
viability (red histograms) versus cell death (green histograms) in pDCs. Results are 
representative of five independent experiments. 
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Supplemental Figure 3. LDL inhibits CpG-induced expression of pDC maturation markers. 
Freshly isolated human pDCs were stimulated with 10μg/ml CpG-ODN 2216 in the absence or 
presence of LDL (50 μg/ ml). Non-stimulated pDCs were used as control. After 24 hours, the cells 
were harvested and the surface expression levels of the indicated markers were measured by 
flow cytometry. (A) Induction of maturation markers on pDCs shown as MFI. The presence of 
LDL inhibits up-regulation of maturation markers on pDCs. Data are shown as mean ± SEM of 
three independent experiments using different donor pDCs. *p< 0.05, **p< 0.01, ***p<0.001. 
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Murine lipid-laden peripheral 
dendritic cell subsets display an 
immature phenotype and are 
impaired in their capability to prime 
naïve T cells. 
 
  - in preparation - 
 
 
 
Abstract 
 
Immune cell activation, proliferation and recruitment are key mechanisms in the 
onset and progression of hypercholesterolemia-associated atherosclerosis. 
Dendritic cells (DCs), highly professional antigen-presenting cells (APCs), are 
thought to contribute to atherosclerosis related adaptive immune responses. 
However, their functionality under hypercholesterolemic conditions, a major risk 
factor in disease development, remains to be established. Here, we addressed the 
immediate impact of high fat diet-induced hypercholesterolemia in low-density 
lipoprotein receptor deficient (Ldlr-/-) mice on DC subset patterns, their 
compartmentalization and functionality. Hypercholesterolemia induced a 
significant rise in bone marrow myeloid and dendritic cell (MDP) frequency and 
proliferation rate after 5 weeks of high fat diet feeding. DC subset numbers in 
peripheral compartments, such as blood and lymphoid organs, remained largely 
unchanged. Hypercholesterolemia led to augmented granularity of pDCs, CD8+ and 
CD8- DCs, which for the cDC subsets correlated with intracellular lipoprotein 
accumulation. Lipid loading did not affect DC maturation levels, as witnessed by an 
unaltered co-stimulatory molecule expression. Remarkably, lipid-laden CD8- cDCs 
displayed a profoundly reduced capacity to stimulate naïve T cells. Conclusively, 
our data provide evidence that under conditions of hypercholesterolemia 
peripheral CD8- and CD8+ cDC subsets engulf lipoproteins in situ. In addition, lipid-
laden cDCs, while maintaining their trafficking capacity, show sharply impaired T 
cell priming ability, a finding that may have repercussions for host defense against 
pathogens and/or endogenous (neo) antigens.______________________________
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Introduction 
 
An established risk factor in atherosclerosis related cardiovascular 
diseases (CVD), hypercholesterolemia, was seen to trigger a range of effects 
that contribute to its pro-atherogenic activity. Amongst others it was seen to  
activate not only endothelial cells, but also myeloid lineage subsets relevant to 
disease, and to induce an expansion of circulating inflammatory monocytes in 
atherosclerosis mouse models.(1, 2) The causal contribution of this subset to 
plaque formation, due to their permanent recruitment to the growing lesion, 
where they differentiate into macrophages, has been studied extensively.(3-6) 
Recent evidence from mouse atherosclerosis models has proven that dietary-
induced hypercholesterolemia can also modify neutrophil homeostasis and 
phenotype, rendering them more prone to infiltrate the lesion during early 
stages of atherosclerosis.(7-9) Hypercholesterolemia-associated myelocytosis 
may be linked to an ablated high-density lipoprotein (HDL) or apolipoprotein E 
(ApoE)-mediated suppression on stem and multipotential progenitor cell 
proliferation in the bone marrow.(6, 10) Additionally, hypercholesterolemia was 
seen to promote extramedullary myelopoiesis resulting in continuous ectopic 
production of inflammatory cells that potentially contribute to plaque 
burden.(11)   
Several bodies of evidence from patient studies as well as from murine 
atherosclerosis models suggest a significant contribution of another myeloid 
subset, dendritic cells (DCs), to atherosclerotic lesion formation.(12-14) DCs are 
present in non-diseased arteries,(15, 16) and accumulate within atherosclerotic 
plaques.(17-19) In mice, hypercholesterolemia has been shown to elicit rapid 
lipoprotein incorporation by vascular resident DCs, which initiates their foam 
cell formation,(20) while conventional DCs (cDCs) were reported to favor 
cholesterol clearance, possibly from the circulation.(14) Whether lipid-laden DCs 
are able to present antigens and prime T cells remains controversial. 
Hypercholesterolemia was seen to inhibit the activation of particular DC 
subsets,(21-23) but did not alter DCs capacity to prime naive T cells.(13, 14) 
Altogether, systematic investigation of how hypercholesterolemia impacts 
bone marrow and peripheral DC (progenitor) counts, phenotype, migratory 
behaviour, as well as functionality is largely lacking. 
In the present study, we addressed temporal effects of diet-induced 
hypercholesterolemia in Ldlr-/-mice on DC (precursor) homeostasis, on DC lipid 
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accumulation and its consequences for phenotype and T cell priming 
capability, analyzing cell composition, cell proliferation, and cell activation 
status in bone marrow and peripheral lymphoid organs at different time points 
after diet change. 
 
 
Methods 
 
Animals 
All animal work was approved by the regulatory authority of 
Maastricht University and performed in compliance with the Dutch 
government guidelines. Female age-matched C56BL/6J Ldlr-/- mice (originally 
obtained from The Jackson Laboratory) were bred at the local animal breeding 
facility (Maastricht University, The Netherlands). Mice were fed a standard fat 
diet (SFD; Cat# V1535, sniff Spezialdiäten GmbH, Soest, Germany) unless 
indicated otherwise, had ad libitum access to food and water, and were 
housed under a 12 hour light-dark cycle. To study early adaptation responses 
to diet induced hypercholesterolemia on DC development, homeostasis, and 
phenotype in peripheral lymphoid organs, Ldlr-/- mice were placed for 0,5 
weeks (n=6), 1 week (n=6), 3 weeks (n=6) or 5 weeks (n=6) on high fat diet 
(HFD; 0.25% cholesterol and 15% cacao butter; Special Diets Services, Witham, 
Essex, UK). Standard fat diet fed mice served as controls (n=6). At sacrifice 
mice were euthanized by an overdose of pentobarbital. Blood was 
subsequently obtained from the left cardiac ventricle and plasma was used for 
cholesterol measurements and cytokine profiles. Bones, blood, spleen, a pool 
of peripheral (a mixture of mandibular and axillary lymph nodes) and 
mesenteric lymph nodes, and small intestines were used for flow cytometric 
analysis. 
 
Plasma cytokine and cholesterol analysis 
Plasma cholesterol levels were measured in duplicate using a 
colorimetric assay (CHOD-PAP, Roche, Mannheim, Germany). Plasma cytokine 
levels of IL-10, IL-12p70, IL-1β, IL-6 and mKC (CXCL10) were determined with a 
Multi-Spot assay system (Meso Scale Discovery, Rockville, MD, USA). 
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Flow cytometry 
Bone marrow, blood, spleen, mesenteric lymph nodes, peripheral 
lymph nodes (a mixture of mandibular and axillary lymph nodes), and small 
intestines were isolated, processed and stained for total leukocytes (CD45+, 
BioLegend, Uithoorn, The Netherlands), total T cells (CD3+, eBioscience, San 
Diego, CA, USA), T helper cells (CD4+, BD Bioscience, Bedford, MA, USA), 
cytotoxic T cells (CD8a+, BD Bioscience), B cells (B220+, BD Bioscience), NK cells 
(CD3- NK1.1+, BD Bioscience) monocytes (CD11bhigh Ly6Glow, BD Bioscience; or 
CD115+, BioLegend), granulocytes (CD11bhigh Ly6Ghigh, BD Bioscience), 
conventional dendritic cells (cDCs; CD11chigh, CD8- or CD8+, eBioscience) and 
plasmacytoid dendritic cells (pDCs; PDCA-1high B220+, eBioscience). DC 
maturation was analyzed performing cell surface staining on CD40 
(eBioscience), CD86 (eBioscience), and major histocompatibility complex 
(MHC-) II (eBioscience). For cDC and pDC analysis, spleen, peripheral lymph 
nodes, mesenteric lymph nodes, and small intestines were pretreated for 30 
minutes with a cocktail of liberase (32μg/ml; Roche, Basel, Switzerland) and 
DNase (0.8μg/ml; Roche, Basel, Switzerland) in RPMI medium. Absolute cell 
numbers in blood were calculated by use of Trucount tubes (BD Bioscience, 
Bedford, MA, USA). All flow cytometry analysis was performed on a BDCanto II 
(BD Bioscience, Bedford, MA, USA) using FACS Diva Analysis Software.  
 
BrdU labeling and cell analysis 
Ldlr-/- mice on standard fat diet (n=6) or high fat diet (0,5 weeks, 1 
week, 3 weeks, or 5 weeks; n=6 per group) received two 5-bromo-2’-
deoxyuridine (BrdU; Sigma-Aldrich, Seelze, Germany) i.p. injections (1mg/twice 
per day every 12 hours) for 1 day before sacrifice (last injection 12 hours 
before sacrifice). BrdU incorporation in various leukocyte (precursor) subsets, 
isolated from bone marrow, blood and spleen, was assessed using an 
allophycocyanin (APC) BrdU flow kit (BD Bioscience, Bedford, MA, USA) 
according to the manufacturer’s instructions. Cells were analyzed using the 
BDCanto II. 
 
Reactive oxygen species (ROS) activity measurement 
Splenic DC subsets, isolated from standard or high fat diet (3weeks) fed 
Ldlr-/- mice (n=11 per group), were stained for 20 minutes at 37°C with 20μm 
2′,7′-dichlorofluorescein diacetate (DCFDA), which is first deacetylated and 
Effects of hypercholesterolemia on peripheral DC phenotype and functionality | 6 
 
161 
after oxidized by ROS to 2’, 7’ –dichlorofluorescin (DCF), visible as a fluorescent 
signal at 525nm. Fluorescently labeled cells were analyzed using the BDCanto 
II. 
 
Mouse DC isolation by Fluorescence Activated Cell Sorting (FACS) 
Splenic DC subsets, including cDCs (lin- CD11chigh CD8- or CD8+) and 
pDCs (lin- CD11clow PDCA-1high B220+) were sorted by FACSAria from Ldlr-/- mice, 
either on high fat diet (n=3) or on normal standard fat diet (control, n=3). The 
purity of the isolated DC subsets was > 98%, assessed by flow cytometry. 
 
Oil-Red-O staining 
DC subsets, sorted as described above from different lymphoid organs 
(spleen, peripheral lymph nodes, mesenteric lymph nodes) and small intestines 
from standard fat diet fed (n=3) and high fat diet fed (n=3; 3 weeks of high fat 
diet) Ldlr-/- mice were cytospun at 700 rpm for 5 minutes on glass slides. After 
drying slides, sections were incubated in phosphate buffered saline (PBS) for 5 
minutes, dipped 10x in 60% 2-propanol and stained with Oil-Red-O solution for 
20 minutes. Subsequently, sections were cleared under tap water. Cell nuclei 
were stained with haematoxylin. Images were analyzed by ImageJ. 
 
Nile Red lipid staining 
 DC subsets (cDCs and pDCs), isolated from spleen and peripheral 
lymph nodes from standard fat diet fed (n=3) and high fat diet fed (n=3; 3 
weeks of high fat diet) Ldlr-/- mice were stained with Nile Red (AdipoRedTM; 
Lonza, Walkersville, MD, USA) to quantify intracellular lipid droplet 
accumulation. Cells were incubated with AdipoRed (1:1000 dilution in PBS) for 
10 minutes at room temperature, washed twice in PBS, and were immediately 
analyzed using the BDCanto II (BD Bioscience, Bedford, MA, USA). 
 
cDC-T cell co-culture 
Low and high granular cDC subsets (CD8- and CD8+) were sorted from 
spleen from Ldlr-/- mice, either fed a standard (n=3) or a high fat diet for 3 
weeks (n=3). DC subsets were gated as described above, but additionally 
low/high granular DC subsets were separated, by gating for side scatter (SSC). 
Naïve CD4+ and CD8+ T cells were sorted from spleen from Ldlr-/- mice on 
standard fat diet (n=3). The purity of the isolated cDC and T cell subsets was > 
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98%, assessed by flow cytometry. Subsequently, purified cDC and T cell subsets 
were co-cultured in a 96 well plate in a 1:5 ratio (1x105 cDCs and 5x105 T cells, 
respectively) for 3 days in complete RPMI medium (Hepes, glutamax, 
Pen/Strep) (Gibco LifeTechnologies, Carlsbad, CA, USA) supplemented with 
10% heat-inactivated fetal calf serum (Gibco), 2ng/ml β-mercaptoethanol, and 
0,5μg/ml anti-CD3 beads (Bioceros, Utrecht, The Netherlands). Purified T cell 
subsets were CFSE labeled prior to co-culture, according to the manufacturer’s 
instructions (Invitrogen, Carlsbad, CA, USA), and proliferation was determined 
by flow cytometry 72 hours later using the BDCanto II (BD Bioscience, Bedford, 
MA, USA). 
 
Statistical analysis 
Data were analyzed with the use of Graph Pad Prism 5 (Graph Pad 
Software Inc., San Diego, CA, USA). All data are expressed as mean ± SEM. To 
compare individual groups, a 2-tailed Student’s t test was used (if normally 
distributed); nonparametric data were analyzed using a Mann-Whitney U-test. 
To compare several groups, a one-way ANOVA with multiple testing correction 
was used. Values of p< 0.05 were considered statistically significant. 
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Results  
 
Hypercholesterolemia alters myeloid and dendritic cell precursor 
homeostasis in the bone marrow  
 Hypercholesterolemia has been shown to affect counts and phenotype 
of circulating cells of the myeloid lineage, however systemic investigation on 
how a cholesterol-rich environment affects DC (precursor) behaviour is 
lacking.(4, 7, 24, 25) In this study we examined whether very early and more 
advanced stages of hypercholesterolemia alter DC (precursor) homeostasis,  
DC maturation status and DC functionality.   
We primarily made a temporal analysis of abundance of DC subsets in 
bone marrow and peripheral lymphoid organs from Ldlr-/- mice in response to 
shift from standard fat diet (SFD) to high fat diet (HFD). As expected, plasma 
cholesterol levels rapidly increased upon the diet change to reach plateau 
values after 1 week (Figure 1A). This was accompanied by a consistent increase 
in body weight (Table 1). Plasma levels of relevant inflammatory cytokines, 
such as IL-6, IL-12p70, IL-1β, and IL-10 remained largely unchanged during HFD 
feeding (Supplemental Figure 1A-D). Congruent with previous studies,(7) 
plasma levels of CXCL1 (mKC), a neutrophil chemoattractant,(26, 27) significantly 
increased with HFD feeding (Supplemental Figure 1E). Next, we assessed 
whether diet-induced hypercholesterolemia influences bone marrow content 
of myeloid and dendritic cell precursors (MDP), the most differentiated 
clonogenic precursors of conventional DCs (cDCs), plasmacytoid DCs (pDCs), 
and monocytes (CD115+ CD135+ CX3CR1
+ within the lin- IL7Ra- and CD117low 
population).(28, 29) Bone marrow MDP numbers were increased two fold after 5 
weeks of HFD feeding (Figure 1B, D). In contrast to previous findings,(11) we 
were unable to detect the presence of splenic MDPs in hypercholesterolemic 
Ldlr-/- mice (data not shown). Next, we examined whether MDP expansion was 
associated with increased cell proliferation. Cell cycle analysis as assessed by 5-
bromo-2’-deoxyuridine (BrdU) incorporation, revealed a slight, but significant 
increase in bone marrow MDP proliferation upon diet change  (Figure 1C). 
To summarize, HFD feeding leads to an MDP expansion in bone marrow, 
possibly due to increased cell proliferation. 
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Figure 1. Hypercholesterolemia induces an augmentation in bone marrow MDP numbers. 
Effects of standard (SFD; n=6) versus high fat diet feeding (HFD; 0.5 weeks, 1 week, 3 weeks, or 5 
weeks; n=6 per group) on (A) plasma cholesterol levels. Depicted are the results of flow 
cytometry analysis on bone marrow from Ldlr-/- mice on SFD or HFD. (B) Relative MDP 
abundance (lin-, c-kit+, CD115+, CD135+) in bone marrow is significantly increased after 5 weeks 
of HFD. (C) BrdU staining on bone marrow isolated MDPs shows a slight increase in proliferating 
cells in HFD fed animals. *p< 0.05, **p<0.01, ***p<0.001. 
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Table 1. Body weight 
 
 SFD 3 days HFD 1 wk HFD 3 wks HFD 5 wks HFD 
Body weight (g) 26.0 ± 0.43 26.2 ± 0.59 27.1 ± 0.55 27.8 ± 0.57* 28.2 ± 0.61* 
 
* p < 0.05, ** p < 0.01 
 
 
Early adaptive response to hypercholesterolemia does not alter peripheral 
DC subset patterns 
 As HFD feeding resulted in increased MDP numbers in bone marrow, 
we sought to investigate whether this was associated with raised DC frequency 
in peripheral lymphoid organs and/ or small intestines. Splenic pDCs as well as 
CD8- and CD8+ cDCs, were unaltered under hypercholesterolemic conditions 
(Figure 2A, E; Supplemental Figure 3A). Similarly, we did not observe any 
effects on DC numbers in peripheral lymph nodes, except for an initial 
transient 2-fold decline in total cDCs (Figure 2B, E). Peripheral lymph node 
CD8- cDC numbers increased slightly immediately after onset of HFD feeding. 
In contrast, CD8+ cDC frequency was significantly decreased after 0.5 and 1 
week of HFD, but normalized to control values as seen in SFD fed Ldlr-/- mice 
afterwards (Supplemental Figure 3B). In line with these results, we did not 
observe an increase in proliferating splenic and peripheral lymph node DC 
subsets (data not shown). Interestingly, HFD feeding resulted in a 2-fold 
significant decrease in small intestinal cDC and pDC counts, which reverted 
with prolonged HFD feeding to numbers seen in normolipidemic mice (Figure 
2D, E). This effect was paralleled by a significant increase in mesenteric lymph 
node pDC numbers after 0,5 weeks of HFD feeding (Figure 2C, E)  
We next investigated whether acute hypercholesterolemia affects 
peripheral T and B cell content. CD45+ leukocyte counts in blood and spleen, as 
well as T cell (subset), and B cell levels in bone marrow, blood and spleen were 
essentially unaffected throughout the high fat diet adaptation phase (0,5-5 
weeks; Supplemental Figure 2A-C), contrary to previously reported data in 
ApoE-/- mice.(4, 24, 25) As expected,(4) we observed a mild monocytosis in 
response to high fat diet exposure (data not shown).  
Collectively our data show that early stages of HFD-induced 
hypercholesterolemia in Ldlr-/- mice do not modify peripheral DC subset 
patterns, as well as T and B cell levels in bone marrow and periphery. 
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Figure 2. Hypercholesterolemia leads to a rapid decline in DC subset content in small intestine 
but not lymphoid organs. To study immediate adaptation response of peripheral DCs to 
hypercholesterolemia, Ldlr-/- mice were placed for 0-5 weeks on HFD (n=6 per group) or left on 
SFD (control; n=6). Depicted are the results of flow cytometry analysis on spleen, peripheral 
lymph nodes (LN), mesenteric lymph nodes (mesenteric LN) and small intestines. (A) Absolute 
numbers of conventional DCs (cDCs; lin-, CD11chigh MHC II+) and plasmacytoid DCs (pDCs; PDCA-
1+, B220+) in spleen. (B-D) Percentage of lin- CD11chigh MHC II+ cDCs and PDCA-1+ B220+ pDCs in 
peripheral LN, mesenteric LN and small intestines. (E) FACS plots representing percentages of DC 
subsets in lymphoid organs and small intestines at different time point of HFD feeding.  
*p< 0.05, **p<0.01. 
 
 
Peripheral cDC subsets accumulate lipids during hypercholesterolemia  
As previously shown in vitro and in vivo, DCs have the capacity to take 
up lipoproteins.(13)  The finding that cDC depletion led to increased plasma 
cholesterol levels(14) led the authors to suggest that DCs are important for 
lipoprotein elimination from the periphery/ circulation. Here, we investigated 
lipid loading capacities of several peripheral DC subsets, isolated from 
lymphoid organs or small intestine, in response to a HFD shift. Splenic, 
peripheral lymph node, and mesenteric lymph node CD8- and CD8+ cDC 
subsets, and total cDCs in small intestine all exhibited a pronounced increase in 
cellular granularity already in the first week of HFD feeding. Granularity peaked 
after 1-3 weeks of HFD (Figure 3A-E). Of note, lymphoid organ resident CD8+ 
cDCs were more granular at baseline, under normolipidemic conditions, 
compared to CD8- cDCs, possibly reflecting their intracellular antigen-
processing machinery (Figure 3E). Cell granularity in pDCs from mesenteric 
lymph nodes and small intestines, increased as well with the onset of HFD 
feeding, and remained high (Figure 3C, D). Interestingly, splenic and peripheral 
lymph node pDCs presented a temporary, but striking increase in cellular 
granularity after 3 days of HFD feeding, normalizing to values of 
normolipidemic mice at 1 week (Figure 3A, B). In accordance with these data, 
cell granularity in peripheral cDC subsets, as depicted in Figure 4 for splenic 
and lymph node CD8- (Figure 4A, C) and CD8+ cDCs (Figure 4B, D), but not in 
pDCs (data not shown), correlated positively with increasing plasma 
cholesterol levels, suggesting that the aforementioned effects reflected lipid 
loading of these cells.  
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Figure 3. HFD feeding is associated with increased cellular granularity of various DC subsets. 
Depicted are the results of flow cytometry analysis on DC subsets isolated from diverse 
lymphoid organs and small intestines of Ldlr-/- mice fed a SFD (control; n=6) or HFD (3 days, 1 
week, 3 weeks or 5 weeks; n=6 per group). Percentage of granularity (measured as increase in 
granularity on side scatter (SSC)) in (A) spleen, (B) lymph nodes (LN), (C) mesenteric lymph 
nodes (mesenteric LN), and (D) small intestinal DC subsets (CD8- cDCs, CD8+ cDCs, PDCA-1+ B220+ 
DCs) is markedly increasing with the onset of HFD feeding. (E) FACS plots revealing splenic DC 
subset granularity after different time points of HFD feeding. *p< 0.05, **p<0.01. 
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Figure 4. Cellular granularity of splenic cDC subsets correlates with plasma cholesterol levels. 
To investigate whether DC granularity is increasing with increasing plasma cholesterol levels, a 
non-linear correlation analysis was performed comparing the granularity of cDC subsets with 
plasma cholesterol levels in Ldlr-/- mice on SFD (control; n=6) versus HFD (0.5 weeks, 1 week, 3 
weeks, 5 weeks; n=6 per group). Correlation analysis (non-linear correlation) of splenic (A) CD8- 
cDCs (R2=0.51), (B) CD8+ cDCs (R2=0.16) and lymph node (C) CD8-cDCs (R2=0.61), (D) CD8+ cDCs 
(R2=0.68). R2 = non-linear correlation coefficient.  
 
 
The straight correlation between plasma cholesterol levels and 
granularity change suggests that the latter is a measure of lipid loading of the 
cells. Therefore, we sorted CD8- cDCs, CD8+ cDCs and pDCs from spleen and 
peripheral lymph nodes from Ldlr-/- mice fed a standard or high fat diet, and 
performed Oil-Red-O staining. Indeed, splenic and lymph node CD8- and CD8+ 
cDCs from hypercholesterolemic mice were lipid-laden and had foam cell-like 
morphology (Figure 5A), whereas pDCs did not reveal any lipid deposits, 
concordant with their low cell granularity after 3 weeks of HFD feeding (Figure 
5A). Quantification of Oil-Red-O staining demonstrated a 13-fold increase in 
intracellular lipid content in splenic CD8- and to a lesser extent in CD8+ cDCs, 
from hypercholesterolemic mice, whereas pDCs stained negative (Figure 5B). 
The total number of lipid-laden cDCs (CD8- and CD8+ cDCs) was around 15%, 
suggesting that only a small fraction of peripheral cDCs had ingested 
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lipoproteins. These data were confirmed by flow cytometry analysis of Nile Red 
lipid staining, showing Nile Red signal in high granular splenic cDC subsets from 
hypercholesterolemic mice but not in low granular cDCs nor in pDCs (Figure 
5C). Again, high granular cDCs were sharply induced in hyperlipidemia, while 
hypercholesterolemic mouse pDCs retained a low granular cell phenotype 
(Figure 5C). Taken together, our data demonstrate that unlike pDCs, peripheral 
CD8- and less so CD8+ cDCs accumulate lipids, converting them into DC-derived 
foam cells already in the first week of HFD feeding. 
 
 
 
 
Figure 5. Peripheral cDC subsets from hypercholesterolemic Ldlr-/- mice engulf lipoproteins. DC 
subsets (PDCA-1+ B220+ pDCs, CD8- cDCs, CD8+ cDCs), sorted from lymphoid organs of 
hyperlipidemic (3 weeks of HFD; n=3) but not normolipidemic Ldlr-/- mice (SFD; n=3) show 
pronounced lipoprotein accumulation (A) Microscopic analysis of Oil-Red-O staining performed 
on cytospun splenic DC subsets. Red droplets represent intracellular accumulated lipoproteins. 
Cell nuclei are counterstained with haematoxylin. (B) Quantitative measurement of Oil-Red-O+ 
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cells. Slides were analyzed blindly using the Image J program. (C) Flow cytometry analysis of Nile 
Red lipid staining on low- and high-granular DC subsets (CD8- cDCs, CD8+ cDCs, pDCs) was 
performed to confirm intracellular lipoprotein storage. High-granular splenic cDC subsets show a 
clearly increased Nile Red signal, associating granularity with lipoprotein accumulation. 
*p<0.05, **p<0.01, ***p<0.001. 
 
OxLDL has been shown to induce apoptosis in resident monocytes and 
macrophages, an effect that was attributable to the pro-oxidant capacity of 
lipoprotein-entrapped agents, generating reactive oxygen species (ROS), such 
as superoxide anions.(30, 31) Therefore, we investigated whether lipoprotein 
uptake was accompanied by ROS accumulation in cDCs.(32) Flow cytometry of 
DCFDA-stained splenic cDC subsets, isolated from normo- and 
hypercholesterolemic Ldlr-/- mice, revealed markedly elevated intracellular ROS 
activity in CD8- cDCs from HFD compared to standard fed Ldlr-/- mice (Figure 
6A). Similarly, ROS activity in splenic CD8+ cDCs of HFD fed mice tended to be 
increased as well (Figure 6C). ROS signals were significantly augmented in high 
granular (lipid-laden) compared to low granular CD8- and CD8+ cDCs from HFD 
mice, suggesting a clear association between lipid ingestion and ROS 
accumulation (Figure 6B, D). 
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Figure 6. Lipoprotein accumulation in cDCs is associated with induced intracellular ROS 
activity. Depicted are the results of flow cytometry analysis on splenic cDC subsets isolated from 
Ldlr-/- mice fed a SFD (control; n=11) or HFD (3 weeks; n=11). (A, D) Percentage of ROS activity in 
cDC subsets from normo- and hyperlipidemic mice represents an increase in ROS activity in cDCs 
from HFD fed mice. (B-F) Percentage of ROS activity in low and high granular (B, C) CD8- and (E, 
F) CD8+ cDCs from HFD fed mice. High-granular cDCs show a marked 3-fold increase in ROS 
activity compared to low-granular cDCs. *p< 0.05, **p< 0.01, ***p< 0.001. 
 
Peripheral lipid-laden DC subsets display impaired maturation 
To determine whether lipid loading has affected DC phenotype and 
maturation, we analyzed surface expression of co-stimulatory molecules 
(CD40, CD86) and major histocompatibility complex (MHC) class II on splenic 
DC subsets from normo- and hypercholesterolemic Ldlr-/- mice. As has been 
shown before,(31) cDCs expressed intermediate levels of MHC II under 
normolipidemic conditions. MHC II surface expression was unaltered in high 
granular lipid-laden CD8- cDCs, and even tended to decrease in high granular 
CD8+ cDCs (Figure 7A, B). Strikingly, expression of CD40 and CD86 on high 
granular CD8- cDCs was significantly diminished (Figure 7A), and the same held 
for CD40 expression by high granular CD8+ cDCs from hypercholesterolemic 
mice (Figure 7B). pDCs displayed unaltered expression of MHC II, CD40 and 
CD86 upon HFD feeding (Figure 7C). To summarize, these data strongly 
support the idea that a hypercholesterolemic environment, not only results in 
the formation of lipoprotein-laden DCs, particularly of the CD8- subset, but also 
impairs DC maturation, a crucial step towards T cell priming. 
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Figure 7. Peripheral DC subsets display impaired maturation under hypercholesterolemic 
conditions. (A-C) Induction of maturation markers (CD40, CD86, MHC II) on high granularDC 
subsets (CD8- and CD8+ cDCs, PDCA-1+ B220+ pDCs) isolated from spleen from normolipidemic 
(SFD; n=3) and hyperlipidemic (HFD; n=3) Ldlr-/- mice. Expression levels are shown as mean 
fluorescence intensity (MFI). *p< 0.05. 
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Lipid-laden cDC subsets reveal a reduced ability to stimulate naïve T cells 
The unaltered or even diminished co-stimulatory molecule expression 
by lipid-laden DCs led us to investigate the T cell priming capacity of DCs under 
the hypercholesterolemic conditions generally associated with atherosclerosis. 
Splenic low and high granular (lipid-laden) CD8- and CD8+ cDCs from HFD and 
standard fed Ldlr-/- mice were co-cultured with naïve T cells (from standard diet 
fed mice). Importantly, splenic lipid-laden CD8- cDCs had a significantly 
reduced ability to induce naïve CD4+ (-40%) and CD8+ T cell proliferation (-
20%), compared to low granular cDCs from HFD mice or CD8- cDCs from SFD 
mice (Figure 8A, B, E). T-cell mitogenic capacity, expressed as number of cell 
divisions, was also quenched in the presence of lipid-laden vs lipid-free CD8- 
cDCs (Supplemental Figure 4A, B). Lipid-laden CD8+ cDCs from 
hypercholesterolemic mice were also less capable of priming naïve CD4+ (-34%) 
and CD8+ T cell proliferation (-25%) (Figure 8C, D, E; Supplemental Figure 4C, 
D). Conclusively, our data clearly demonstrate that lipid-laden CD8+ and CD8- 
cDCs are less functional, as judged by their attenuated ability to stimulate 
naïve T cells. 
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Figure 8. Lipid-laden cDC subsets reveal a reduced ability to stimulate naïve T cells.  
(A, B) Splenic (low and high granular) CD8- cDCs, or (C, D) splenic (low and high granular) CD8+ 
cDCs, isolated from SFD or HFD fed Ldlr-/- mice (n=3) were co-cultured in vitro with CFSE labeled 
naïve splenic CD4+ or CD8+ T cells (in triplo) from SFD fed Ldlr-/- mice. T cell proliferation was 
assessed by CFSE signal dilution, as a measure of T-cell divisions. (E) Flow cytometry plots 
illustrating CFSE signal dilution (T cell proliferative response; blue: 1st division; red: 2nd division; 
green: 3rd division; yellow: 4th division; grey: 5th division). *p<0.05, **p<0.01. 
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Discussion  
 
Recent work suggests a prominent role for DCs in atherosclerosis, as 
they are key players in triggering adaptive immune responses.(33) The 
decreased levels of circulating DC (precursors) in patients with coronary artery 
disease inversely correlated with their progressive accumulation in 
atherosclerotic plaque during lesion progression.(34) However, little is known 
about peripheral DC homeostasis and behaviour during conditions of 
hyperlipidemia, a key determinant in atherosclerosis. Here, we studied the 
early adaptive responses of DC (precursors) to high fat diet feeding, as well as 
the functionality of lipid-laden peripheral DC subsets. We have shown that in 
an immediate response to hypercholesterolemia, splenic and lymph node cDC 
subsets accumulated lipids and, possibly related, reactive oxygen species. 
Interestingly lipid-laden cDCs featured an immature phenotype and an 
impaired capacity to prime naïve T cells. 
High fat diet feeding was in our study shown to induce rapid bone 
marrow myeloid and dendritic cell precursor (MDP) expansion, in keeping with 
previous findings.(2) Splenic MDP numbers however, previously reported to 
increase during atherogenesis in ApoE-/- mice,(35) did not change in Ldlr-/- mice, 
potentially related to the more modest myelopoietic effects seen in the latter 
model.(10) Interestingly, while DC lymphoid organ distribution patterns were 
not profoundly affected, we did observe an initial decrease in small intestinal 
DC content (CD8- cDCs, pDCs) upon high fat diet feeding to normalize within 1 
week after diet change. Conceivably, this apparent drop could reflect prompt 
recruitment of DCs to mesenteric lymph nodes or thymus to present dietary 
epitopes to T cells.(36) Unaltered peripheral DC counts might be explained by 
MDP differentiation mainly into monocytes/ macrophages. FMS-like tyrosine 
kinase 3 ligand (Flt3L) and macrophage colony-stimulating factor (M-CSF) are 
the two main regulators of the development of DCs and macrophages, 
respectively.(37) A disbalance of these two signaling mediators under 
hyperlipidemic conditions potentially leads to monocytosis.(38-40) 
A second objective of this study was to address how peripheral DC 
subsets (lymphoid organ and small intestinal DC subsets) behave in response 
to chow- to high-fat diet change. Interestingly, recent findings of Lesnik and 
coworkers argued for a contributory role of cDCs to cholesterol homeostasis 
under hyperlipidemic conditions, possibly by taking up lipoproteins from 
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peripheral organs.(14) Our study indeed showed that granularity of lymphoid 
organ and small intestinal pDCs and CD11chigh cDC subsets is rapidly increased 
in response to high fat diet feeding to peak at 1-3 weeks. Notably, for splenic 
and peripheral lymph node pDCs augmented granularity only manifested 
immediately after onset of high fat diet feeding. Increased granularity of cDCs 
clearly reflected lipid accumulation as witnessed by the increased Nile Red lipid 
(flow cytometry) and Oil-Red-O staining (cytospin). However, only a small 
fraction of cDCs actually accumulated lipoproteins, potentially representing a 
(1) more long-lived cDC subset, (2) a population with highest capacity for or 
lowest mobilization/ apoptosis response to lipoprotein uptake, or (3) a DC 
population with a more activated intracellular antigen-uptake/ processing 
machinery. Of relevance in this regard is that resident intimal DCs were shown 
to account for lipoprotein accumulation and rapid formation of foam cells 
during very early stages of atherogenesis (5 days of high fat diet feeding).(20) 
A further intriguing finding was the increased reactive oxygen species 
(ROS) build-up in splenic cDC subsets in the immediate response to high fat 
diet feeding, particularly in the high granular (lipid-laden) cDCs. Accumulation 
of oxidized low density lipoproteins (oxLDLs) has been shown to promote 
apoptosis in macrophages, amongst others due to the generation of cytotoxic 
ROS, f.e. superoxide anions.(31) Interestingly,  DCs express high levels of 
antioxidant enzymes, such as Manganese superoxide dismutase (Mn-SOD) in 
response to oxLDL accumulation, which confers resistance to oxLDL induced 
apoptosis.(32) Whether or not the respiratory burst in high granular peripheral 
cDCs induces cell apoptosis, remains unclear. 
 Lipid-laden cDC subsets, as well as pDCs, from lymphoid organs from 
hypercholesterolemic mice featured an immature phenotype, with low or even 
abated surface expression of co-stimulatory molecules (CD40, CD86) and MHC 
class II. Additionally, hyperlipidemia led to impaired ability of splenic CD8- and 
CD8+ cDCs to stimulate naïve T cells, as indicated by the reduced T cell 
proliferative responses in vitro. As non lipid-laden cDC subsets retained their 
CD4+ and CD8+ priming ability, this effect obviously is resultant of lipid 
ingestion. Support for this notion may be derived from a study by Kopf and 
coworkers showing abrogated Toll-like receptor (TLR)-induced cytokine 
production, reduced co-stimulatory molecule expression by CD8- cDCs, and 
abated Th cell responses under hyperlipidemic conditions.(23) Herber et al.  
similarly evidenced that lipid-laden DCs in cancer were markedly impaired in 
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their capacity to process and present antigens to T cells, thus disturbing 
immune responses.(41) Otherwise, several studies have previously 
demonstrated that adaptive immune responses prevail in a cholesterol-rich 
environment in that DCs fully maintain their antigen-presenting and T cell 
priming ability, even when cholesterol-loaded.(13, 14, 42) It remains to be elusive 
which DC subsets are involved in cholesterol homeostasis and how excessive 
lipoprotein uptake quenches DC’s T cell priming capacity, potentially by 
impeding intracellular antigen processing and presentation machinery.(43-45)  
Altogether, these data indicate that high fat diet feeding acutely 
interferes with cDC activation, impairing their T cell stimulating capacity. This 
might compensate for the pro-atherogenic effect by priming T cells within the 
atherosclerotic plaque. Besides, it is conceivable that this reduced DC 
functionality will affect host’s immunity against pathogen-derived signals 
under dyslipidemic conditions, making the host more vulnerable/fragile to 
infectious diseases.  
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Supplemental Figures  
 
 
 
Supplemental Figure 1. Inflammatory plasma cytokine levels remain mainly unaltered under 
early conditions of hypercholesterolemia. Ldlr-/- mice were either placed for 3 days (n=6), 1 
week (n=6), 3 weeks (n=6) or 5 weeks (n=6) on HFD (0.25% cholesterol) or left on SFD (control; 
n=6). (A) Effects of HFD on plasma cytokine levels of IL-6, IL-12p70, IL-1β, IL-10, and CXCL1 
(mKC). *p< 0.05, **p<0.01. 
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Supplemental Figure 2. Hypercholesterolemia does not alter peripheral lymphocyte numbers. 
Depicted are the results of flow cytometry analysis on bone marrow, spleen and blood from Ldlr-
/- mice on SFD (control; n=6) versus HFD (3 days, 1 week, 3 weeks or 5 weeks; n=6 per group). (A, 
B) Percentage of CD45+ leukocytes, NKT cells (NK1.1low CD3low), total T cells (CD3+), CD4+ and 
CD8+ T cell subsets, and B cells (B220+) in bone marrow and spleen. (C) Absolute numbers of 
CD45+ leukocytes, total T cells (CD3+), CD4+ and CD8+ T cell subsets, and B cells (B220+) in blood. 
*p< 0.05. 
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Supplemental Figure 3. Immediate temporal response of cDC subset counts in peripheral 
lymphoid organs to high fat diet feeding. Depicted are the results of flow cytometry analysis on 
spleen, peripheral LN, and mesenteric LN from Ldlr-/- mice on SFD (control; n=6) versus HFD (3 
days, 1 week, 3 weeks or 5 weeks; n=6 per group). (A) Absolute numbers of splenic CD8- and 
CD8+ cDCs. (B, C) Percentage of CD8- or CD8+ CD11chigh cDCs in peripheral LN and mesenteric LN. 
*p< 0.05. 
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Supplemental Figure 4. Lipid-laden cDC subsets have reduced ability to stimulate naïve T cells. 
(A, B) Splenic (low and high granular) CD8- cDCs, or (C, D) splenic (low and high granular) CD8+ 
cDCs, both isolated from SFD or HFD fed Ldlr-/- mice were co-cultured in vitro with CFSE labeled 
naïve splenic CD4+ or CD8+ T cells isolated from SFD fed Ldlr-/- mice. T cell proliferation was 
assessed by CFSE signal dilution. This experiment was reproduced in triplicate and gave similar 
results.  
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 In the previous chapters we investigated a potential functional role for 
plasmacytoid dendritic cells (pDCs) in murine atherosclerosis, although they 
are almost absent within the mouse plaque. Besides, we examined phenotype 
and activation status/ functionality of murine and human (p)DCs in a 
hyperlipidemic environment. In the present study (Chapter 7) we finally 
addressed the question whether pDCs have an impact on its local immune cell 
context within the human atherosclerotic plaque.  
In the recent years pDCs have been described in inflammatory foci in the 
human atherosclerotic plaque, where they are thought to execute pro-
inflammatory actions through a type I interferon signature. Stimuli that 
potentially trigger pDC maturation and activation at lesion site are unknown. It 
is supposable that immunocomplexes, composed of self-DNA released from 
necrotic/ dying cells and joined with antimicrobial peptides or oxidized 
(lipo)proteins, formed in the advanced plaque, have the capacity to stimulate 
pDCs. Otherwise, pDCs may exert tolerogenic functions during processes of 
low-grade inflammation. To dissolve the question whether pDCs manipulate 
their cellular neighbourhood we employed Laser Capture Microdissection on 
pDC-enriched and pDC-deficient human plaque fractions, isolated RNA and 
performed whole genome arraying and bioinformatics analyses. This study 
allowed us to acquire pDC gene expression patterns within the human 
atherosclerotic lesion. 
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Abstract 
 
Background: Plasmacytoid dendritic cells (pDCs) are scarcely present in the inflamed 
human atherosclerotic plaque, where they are presumed to exert pro-inflammatory 
functions through release of type I interferons. However, the precise role of pDCs in 
human atherosclerosis yet remains to be established. Here, we investigated the impact 
of human plaque pDCs on its local context, applying state of the art genomics and 
bioinformatics.  
Methods and Results: pDC-enriched and pDC-deficient plaque fractions, isolated by 
laser capture microdissection from human carotid endarterectomy tissue samples, 
were used for genome-wide micro-array analysis. We determined gene expression 
pattern of pDC-enriched and pDC-deficient plaque fractions and employed network 
and module-trait correlation analyses to characterize clusters of tightly co-expressed 
gene modules for macrophages, T cells and microvessels, associating with the presence 
of pDCs. We uncovered five significantly overexpressed immune clusters in the T-cell 
module, highly enriched in genes involved in regulation of neutrophil chemotaxis and 
regulation of T cell differentiation/ proliferation. Moreover, we were able to identify 
two microRNAs, which target the pDC-T cell gene cluster.  
Conclusions: The present study reveals a direct cross-talk between pDCs and its 
immune cell context in the plaque, but also led to the unravelling of potential novel 
central modifiers in pDC-mediated immune responses in atherosclerosis.  
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Introduction 
 
Cardiovascular diseases (CVDs) are the number one killer in western 
countries, and projections say that by 2030 they will become the first cause of 
death and morbidity in Low-Middle-Income Countries (LMIC).(1) The 
pathogenesis of this complex disease is still subject of much debate, with 
models for plaque progression and destabilization/instability alternatively 
based on lipid and glucidic metabolism, tissue ageing, calcification, gut 
microbiota, and global and local immunity competing for our understanding 
and ability to influence the course of CVDs. Here, we are focusing on profiling 
local immunity to further our understanding of plaque physiology and to 
identify potential clinical targets. 
Among the leukocyte subsets that contribute to atherosclerosis (the 
main underlying lesion of CVDs), dendritic cells (DCs) are receiving growing 
attention.(2, 3) DCs are a family of antigen presenting cells displaying 
considerable diversity in trafficking modalities, anatomical location, 
phenotype, and functionality.(4, 5) While previous studies have focused mainly 
on conventional DCs (cDCs),(6-8) plasmacytoid DCs (pDCs) recently emerged as 
important players in the pathophysiology of atherosclerosis as well.(9-12) pDCs 
develop in bone marrow and migrate to lymphoid tissues.(13) They are highly 
specialized sensors of viral and bacterial infections, due to their selective 
expression of Toll-like receptor 7 (TLR7) and TLR9.(14, 15) Upon receptor 
activation, pDCs are capable to produce large amounts of type I interferons 
(IFNs), which amongst others can trigger T cell responses.(16, 17) Chronic pDC 
activation and type I IFN release in the absence of viral infection can result in 
the breakdown of tolerance, potentially leading to the development of 
autoimmune diseases.(18, 19) Vascular pDCs have been identified in human 
atherosclerosis.(9) Their presence in the plaque shoulder of advanced human 
lesions is supposed to drive inflammatory processes and plaque destabilization 
by the release of type I IFNs.(9, 10) However, a clear functional role for pDCs in 
human atherosclerosis has not been reported. Here, we investigated the 
impact of plaque pDCs on their local inflammatory context in human 
atherosclerosis. To this end, we employed laser capture microdissection (LCM) 
on human carotid endarterectomy tissue samples to isolate pDC-enriched and 
adjacent pDC-deficient plaque tissue fractions from the same plaque, and 
extracted RNA for genome-wide expression profiling. Differential gene 
A signature for pDCs in the human plaque | 7 
 
191 
expression analysis between pDC-enriched and pDC-deficient plaque fractions 
revealed gene sets implicated in pDCs’ role in atherosclerosis. Furthermore, co-
expression network reverse engineering and module-trait correlation analysis 
focused our attention on T-cell associated gene clusters, which are strongly 
linked to/imprinted by the presence of pDCs. To the best of our knowledge our 
analysis provides the first insights into the action/impact of pDCs on its local 
immune environment in the advanced atherosclerotic plaque, obtained in 
human tissue. 
 
 
Material and Methods 
 
Tissue samples  
Fresh atherosclerotic tissue samples (human carotid arteries) were 
obtained from endarterectomy (n=6). Collection, storage in the Maastricht 
Pathology Tissue Collection (MPTC) and use of tissue and patient data were 
performed in agreement with the "Code for Proper Secondary Use of Human 
Tissue in the Netherlands" (http://www.fmwv.nl). Detailed tissue and patient 
characteristics are added in Supplemental Table 1. Immediately after 
resection, tissue samples were snap-frozen in Tissue-Tek® OCT compound 
(Sakura Finetek Zoeterwoude, the Netherlands) and stored at -80°C. The stage 
of atherosclerosis was determined according to Virmani et al.(20) based on 
hematoxylin-eosin (HE) stained frozen tissue flanking sections. The samples 
were as all advanced plaques, stable (n=5; thin or thick fibrous cap atheroma) 
or unstable (n=1; complicated type VI lesions, with luminal thrombus and/or 
intraplaque hemorrhage (IPH)). The localization of pDCs was inferred from 
anti-BDCA-4 immunohistochemical staining of flanking frozen tissue sections. 
We evaluated RNA quality of the tissues before pDC isolation.  Total RNA of 
whole mount plaque tissue sections was isolated using RNeasy Micro kit 
(Qiagen, Hilden, Germany). RNA integrity was assessed using Agilent’s 2100 
Bioanalyzer System (Agilent Technologies, Palo Alto, CA, USA). From the same 
slice, inflammatory foci in the plaque shoulder area containing >5 BDCA-4+ 
pDCs/ μm2 (pDC-enriched) or 0 BDCA-4+ pDCs/ μm2 (pDC-deficient), were 
isolated by LCM. As quality control, the aforementioned procedure for RNA 
quality was repeated on RNA extracted from LCM fractions; patient samples 
were only included for microarray analysis if the RNA integrity value of both 
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pDC-enriched and pDC-deficient plaque fractions was higher than 4.5. All tools 
for LCM work were UV-sterilized before experiment to increase RNA quality. 
 
Tissue preparation and LCM 
For isolation of pDC-enriched and pDC-deficient plaque fractions, 4 μm 
thick OCT frozen sections were cut at -20°C in a cryostat (Leica CM 3050S) and 
placed on MembraneSlides (NF 1.0 PEN; Carl Zeiss Micro Imaging, Munich, 
Germany). Sections were fixed and dehydrated for 10 minutes in ice-cold 
sterile acetone before LCM (Palm Microlaser Technologies, Zeiss Microscope 
Palm Robo 4.3, Munich, Germany) to improve tissue catapulting. pDC-enriched 
and pDC-deficient plaque fractions from the very same plaque slices were 
isolated by LCM from 6-10 frozen tissue sections, respectively pooled and 
collected in nuclease and nucleid acid free tubes with an adhesive cap covered 
with tissue lysis buffer (RLT buffer) containing β-mercaptoethanol to improve 
RNA yield and minimize RNA degradation. pDC-enriched plaque fractions were 
harvested using BDCA-4 immuno-positivity on parallel sections as a navigator 
(pDC-enriched tissue fractions contained between 5 and 16 BDCA-4+ cells). 
pDC-deficient plaque fractions did not contain any BDCA-4+ cells. 
 
RNA isolation and amplification 
Total RNA was extracted form LCM drive pDC-enriched and pDC-
deficient plaque fractions immediately after dissection using the RNeasy Micro 
kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol for 
extraction of RNA from microdissected cryosections. DNA was removed by 
using 50U DNase I (Qiagen). RNA samples were speed vacuum centrifuged to 
increase RNA concentration. Total RNA (500-750pg) of pDC-enriched and pDC-
deficient plaque fractions was cDNA transcribed (double strand cDNA 
synthesis), purified (RNAClean beads) and amplified (Ribo-SPIA amplification 
process) using the Ovation Pico WTA System V2 (NuGEN Technologies, 
Bemmel, The Netherlands). 
 
 Array hybridization and analysis  
For array hybridization single primer isothermal amplified (SPIA) cDNA 
samples were enzymatically fragmented (input: 3 μg per sample) using the 
Ovation Pico WTA System V2. Size and quality of the amplified fragments were 
examined by gel shift assay and Agilent’s 2100 Bioanalyzer System. 
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Subsequently, cDNA samples were biotin-labeled to the 3-hydroxyl end of the 
fragmented cDNA using the Encore Biotin Module (NuGEN Technologies). 2.5 
μg of labeled cDNA of each sample was applied to Affymetrix GeneChip Human 
Gene 1.0 ST arrays (Affymetrix, Santa Clara, CA, USA). Images were acquired 
using the Affymetrix Gene Chip Scanner 7G and feature extraction was done by 
Gene Chip® Command Console 3.2 (AGCC) software.  
Raw data (available on Gene Expression Omnibus: GSE49670) were imported 
in R (R Core Team (2012), URL http://www.R-project.org) and pre-processed by 
GCRMA (Wu et al., Journal of the American Statistical Association 2004) for 
background correction, normalization and gene level summarization 
(Supplemental Figure 1). Data were annotated using the last updated 
annotation files available on the manufacturer’s website. Differential 
expression analysis of pDC-enriched versus pDC-deficient plaque fractions was 
performed by fitting each gene against a linear model with limma (Smyth et al., 
(2005). Limma: linear models for microarray data; Gentleman et al., Springer, 
New York). Empirical Bayes shrinkage of the standard errors has been used to 
moderate t-statistics, F-statistic, and log-odds of differential expression. To 
correct for repeated measurements False Discovery Rate (Benjamini, Yekutieli, 
Roy Statist Soc Ser B (Methodological) 1995) was used. An explorative gene 
ontology enrichment analysis of the 500 top differentially expressed genes was 
conducted using the Database for Annotation, Visualization and Integrated 
Discovery (DAVID).  
 
Reverse engineering of a co-expression network was performed by leveraging 
on the tools included in the R package WGCNA (Langfelder et al., BMC 
Bioinformatics 2008). The soft-threshold, used to reconstruct the network 
architecture, was optimized by inferential statistics to evaluate the scale-
freeness of the resulting network architecture for threshold values from 12-30 
(Supplemental Figure 2). Modules, clusters of densely interconnected genes, 
were identified using the default method of hierarchical clustering (Kaufman et 
al., John Wiley & Sons Inc, 1990) and the function cutree Dynamic (Langfelder 
et al., Bioinformatics 2008) to "prune" the branches of the tree. Module’s 
Eigengene were calculated and those too highly correlated were merged to 
optimize the following statistical analyses. We then reconstructed the 
consensus network between the pDC-enriched and pDC-deficient plaque 
fractions. We focused our attention on those modules which were unique to 
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the pDC-enriched samples, since we hypothesized that these gene clusters 
would be the most reflective of the biological changes induced by pDCs on 
their surrounding microenvironment. The relationship between quantitative 
phenotypic traits and gene clusters was estimated by canonical correlation of 
the Eigengenes and quantitative traits, and significance was estimated by 
Fisher's asymptotic p-value. Within each module, genes with high module 
membership in modules related to traits were selected for further 
investigation (Langfelder, Horvath, BMC Bioinformatics 2008). Module network 
data were uploaded into Cytoscape (Smoot et al., Bioinformatics 2011) for 
visualization and further analyses. The plugin ClueGene Ontology (GO) (Bindea 
et al., Bioinformatics 2009) was used to enrich the interesting modules for 
over-represented GO terms and pathways. 
 
Immunohistochemistry 
Human carotid endarterectomy tissue sections, obtained as above 
reported, were analyzed for expression of (1) pDCs (BDCA-4+; for LCM 
guidance), and (2) T cells (CD3+), macrophages (CD68+) and microvessels 
(CD31+) in pDC-enriched and pDC-deficient plaque fractions (analysis of 
immune cell expression patterns). Immunohistochemistry was performed on 
acetone-fixed frozen tissue sections (4μm thick) using the following primary 
antibodies: sheep anti-human BDCA-4 (1/40; R&D Systems, Minneapolis, MN, 
USA), rabbit anti-human CD3 (1/200; Dako, Glostrup, Denmark), mouse anti-
human CD68 (1/100; Dako) and mouse anti-human CD31 (1/50; Dako). Tissue 
sections were incubated with primary antibody for 60 minutes at room 
temperature. For CD31 staining, non-specific antigens were blocked for 30 
minutes in TBS containing 5% BSA prior to primary antibody incubation. For 
CD3 staining, endogenous peroxidases were blocked in methanol/H2O2. 
Secondary antibodies were added as follows: poly-horseradish peroxidase 
(HRP) conjugated goat anti-rabbit IgG (1/50, Immunologic, Duiven, the 
Netherlands) for CD3, biotin-labeled rabbit anti-sheep IgG (1/200, Zymed, 
Vienna, Austria) for BDCA-4, biotin-labeled sheep anti-mouse IgG (1/250, 
Amersham Pharmacia, Uppsala, Sweden) for CD68, or poly-alkaline 
phosphatase (AP) conjugated goat anti-mouse IgG (1/50, Immunologic) for 
CD31. Color development was assessed by use of Strep-ABC-alkaline (1/200, 
VectorLaboratories, Burlingame, CA, USA) and Vectastain Red 
(VectorLaboratories), or 3-amino-9-ethylcarbazole (AEC; Dako) according to 
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the manufacturer’s instructions. Cell nuclei were counterstained with 
hematoxylin. Slides were analyzed using the Leica DM3000 light microscope 
(Leica Microsystems, Wetzlar, Germany) coupled to a computerized 
morphometric system (Leica Qwin 3.5.1, Wetzlar, Germany). 
 
Statistical analysis of IHC  
Data were analyzed with the use of Graph Pad Prism 5 (Graph Pad 
Software Inc San Diego, CA, USA). All data are expressed as mean ± SEM. To 
compare individual groups, a Wilcoxon paired test was used. Values of p< 0.05 
were considered statistically significant. 
 
 
Results 
 
Presence of plasmacytoid dendritic cells in the human atherosclerotic plaque 
To identify pDC associated gene signatures in advanced human 
atherosclerotic plaques, we used the LCM technology to isolate similarly 
inflamed pDC-enriched and pDC-deficient plaque fractions in the same plaque 
of the same patient (Figure 1A, B). BDCA-4+ staining revealed the presence of 
pDCs in inflammatory regions in the plaque shoulder and at the plaque base 
close to plaque microvessels. Adjacent regions from the flanking section were 
subsequently captured by LCM. Quantitative measurement demonstrated that 
less than 2% of total cells in the pDC-enriched fractions were BDCA-4+ pDCs 
(Figure 1C) (number of BDCA-4+ pDCs in enriched tissue fractions diversified 
between 5 and 16 per fragment). pDC-deficient plaque fractions did not show 
any BDCA-4 positivity (Figure 1C). To exclude that expression patterns would 
be biased by differences in major cellular constituents in pDC-enriched vs. 
pDC-deficient plaque fractions, we assessed T cell and macrophage content, as 
well as the presence of microvessels in both groups by immunohistochemistry. 
Quantitative measurement did not reveal any differences in T cell (p=0.1875), 
macrophage (p=0.625) and microvessel (p=1.0) presence in pDC-enriched 
compared to pDC-deficient plaque fractions (Figure 2A, B, C). 
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Figure 1. Presence of pDCs in human atherosclerotic plaques, mainly in regions of 
inflammation and neovascularization. Microscopic analysis of human atherosclerotic plaque 
tissue specimens from carotid endarterectomy used for LCM. (A) Immunohistochemistry for 
BDCA-4+ pDCs in pDC-enriched plaque fractions. (B) Inflammatory region in the plaque shoulder 
of advanced lesions, negative for BDCA-4+ pDCs. (C) Percentage of BDCA-4+ pDCs per total cell 
number in pDC-enriched (n=6) and pDC-deficient fractions of advanced plaques (n=5). 
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Figure 2. Cellular composition and presence of vessels in pDC-enriched compared to pDC-
deficient plaque fractions. Microscopic analysis of human atherosclerotic plaque tissue 
specimen from carotid endarterectomy used for LCM. Immunohistochemistry and quantitative 
measurement of (A) CD68+ macrophages, (B) CD3+ T cells and (C) CD31+ vessels in pDC-enriched 
(n=6) versus pDC-deficient (n=5) plaque fractions of advanced plaques. 
 
 
Human atherosclerotic plaques, enriched in pDCs, reveal distinct patterns of 
immune pathways 
Differential expression analysis yielded ambiguous results. As shown in 
the volcanoplot of Figure 3A, several promising genes appeared in the results. 
However, after multiple testing adjustment, no gene had an adjusted p-value ≤ 
.05. A top list of 200 over- or underexpressed genes was extracted for 
exploratory purposes (Supplemental Table S2). Importantly, this tentative 
signature perfectly sets apart the pDC-enriched and pDC-deficient plaque 
fractions, as shown in the heatmap in Figure 3B. Subsequent pathway analysis 
resulted in a top 7 of networks overrepresented in the pDC-enriched plaque 
fractions, including amongst others T cell receptor and mitogen-activated 
protein kinase (MAPK) signaling pathways (Supplemental Table S3), suggesting 
that pDCs are present in an activated immune microenvironment.  
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Figure 3. Unsupervised analysis of differential gene expression in pDC-enriched versus pDC-
deficient plaque fractions. Gene array data were analyzed using the Affymetrix metadata 
software. (A) Volcano plot for pDC-enriched versus pDC-deficient plaque fractions, used to 
measure changes in the gene expression levels. The log 2-fold change is plotted on the x-axis (up 
or down), while the -log 10 p-value is plotted on the y-axis. The probesets shown in blue are the 
top-25 probesets ordered by log-ratio. The probesets highlighted in red are the top-25 ordered 
by p-value. (B) Hierarchical clustering of the top 200 genes that are over - or underexpressed 
(green and red, respectively) in pDC-enriched versus pDC-deficient plaque fractions results in 
four clusters, representing different expression patterns. Results are shown in heat map format. 
pDC-enriched plaques, samples 1-5, 11; pDC-deficient plaque samples 6-10. 
 
Inspired by these findings we sought to assess the impact of pDCs on 
its local immune context. Hereto, by co-expression networks analysis and 
subsequent module trait correlation, specific pDC-associated gene modules 
were identified and correlated with quantified phenotypes (T cells, 
macrophages and microvessels) using the methods first described by 
Langfelder and Horvath (BMC Bioinformatics, 2008). To differentiate strong 
and weak correlations and best approximate scale-free network topology, we 
conducted a scale-freeness estimation (Supplemental Figure S2). The module 
identification routine resulted in twenty-six distinct modules, whose individual 
Eigengenes were tested for correlation with T cells, macrophages and 
microvessels (Figure 4). The strongest association for T cells resulted in module 
MEbrown (p=0.02), consisting of 732 genes. The strongest associations for 
macrophages were with modules MElightcyan (p=0.03), consisting of 140 
genes, and MEturquoise (p=0.02; 846 genes). The strongest associations for 
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microvessels were with modules MEtan (p=0.01; 238 genes), MEblack 
(p=0.003; 431 genes), MEorange (p=3e-06; 38 genes), and MEcyan (p=0.01; 182 
genes). Because we selected modules which were unique to the pDC-enriched 
fractions (Supplemental Figure S3), the above mentioned correlation patterns 
for macrophages, T cells and microvessels are to be considered reflective of 
the interaction between pDCs and that particular trait. 
 
 
 
 
Figure 4. Network module association with macrophage, T cell and vessel traits in pDC-
enriched plaque fractions. For each trait and each module expression profile, a Spearman rank 
correlation was performed. Each row corresponds to a module (lettered from MEorange to 
MEdarkred) and each column to a particular trait (macrophages, T cells, microvessels). Each cell 
contains the probability that a correlation exists by chance and is colour-coded with red 
indicating a strong positive correlation and green a strong negative correlation. The modules 
most strongly associated with the macrophage trait are MElightcyan and MEturquoise, while the 
module most strongly associated with the T cell trait is MEbrown. The modules most strongly 
associated with the microvessel trait are modules MEtan, MEblack, MEorange and MEcyan (for 
all strong positive correlation). 
 
 
Gene significance and module membership in the ‘T cell module’ are 
connected 
As previous studies have alluded to an interaction between pDCs and 
CD4+ T cells in the human atherosclerotic plaque, driving Th1 polarization of 
CD4+ T cells,9 we further focused on the pDC-associated gene module that 
correlates with the presence of T cells (MEbrown, 732 genes), hereafter 
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referred to as the ‘T cell module’. In the ‘T cell module’ highly connected genes 
(referred to as intramodular hub genes) also had a high gene significance for T 
cells, meaning that these genes constitute the core of the module and are the 
most correlated with the T cell trait (cor.= 0.28; p= 1.2e-14; Figure 5). Genes 
that are most associated with the T cell trait are encircled in red 
(Supplemental Table 3).  
 
 
Figure 5. Connectivity and trait association within the T cell module. In the T cell module, there 
is a strong positive correlation between the intramodular connectivity and the gene significance 
for particular T cell genes, revealing that these genes are the most associated with the T cell trait 
(cor.= 0.28; p= 1.2e-14). Genes that are most associated with the T cell trait are encircled in red. 
  
We exported the T cell module data to Cytoscape to integrate our 
results (module structure and gene expression profiles) (Figure 6A). 
Furthermore, by importing gene functional annotations from the Gene 
Ontology (GO) and KEGG and BIOCarta pathways databases to the network in 
the T cell module, five immune clusters were significantly overrepresented: (1) 
regulation of leukocyte chemotaxis, (2) neutrophil chemotaxis, (3) regulation 
of neutrophil chemotaxis, (4) positive regulation of Th1/ Th17 cell 
differentiation, and (5) regulation of Th1/ Th17 cell differentiation (Table 1). 
We could also distinguish two major axes within the topology of the network 
that is representing the interactive genes, and the attributed pathways: 
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regulation of neutrophil chemotaxis and regulation of T cell activation/ 
proliferation (Figure 6B). Beyond, we could infer two microRNAs specifically 
overrepresented in the ‘T cell module’: microRNA-518A-5P and miRNA-382-5P. 
MicroRNA-382 has been implicated in CD4 T cell activation21, thus again 
pointing to the privileged immune microenvronment in pDC-enriched plaques. 
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Figure 6. Network and molecular pathway analysis in the T cell module. (A) Molecular 
interaction networks in the T cell module are visualized by Cytoscape. Nodes in blue represent 
genes whose association did not surpass multiple testing adjustment. Nodes in various shades of 
red represent genes associated to the phenotype. The darker the node the stronger is the 
association to the phenotype. Sizes of the nodes illustrate a continuous mapping of the 
importance of the gene in the architecture of the module. (B) Within the topology of the 
network, used to make strong correlations clear, two major axes are standing out: regulation of 
neutrophil chemotaxis and regulation of T cell proliferation. 
 
 
Table 1. Immune clusters in the ‘T cell module’ 
 
 
 
 
Discussion  
 
The presence of pDCs in the human advanced plaque, mainly in the 
inflamed plaque shoulder area and in regions with neovascularization, has 
been firmly documented.(9, 11, 12) Still, plaque pDCs’ association with plaque 
progression stage, as well as their precise role in disease progression, remain 
controversial. So far, pDCs are believed to induce Th1 polarization of naïve 
CD4+ T cells by release of type I IFNs, albeit some studies pointed to a 
tolerogenic role in low grade plaque inflammation in mouse models of 
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disease.(9-11) In this study we employed a whole genome expression analysis to 
investigate the impact of plaque pDCs on their local immune context within 
the human atherosclerotic plaque. Laser capture microscopy was used to 
isolate pDC-enriched and pDC-deficient plaque fractions for transcriptomics 
analysis, to investigate pDC-mediated context imprinting in human advanced 
atherosclerosis, ex vivo. We employed a co-expression network analysis from 
the same plaque to extract and characterize co-expressed gene modules from 
pDC-enriched plaque segments, strongly associated with T cells, macrophages, 
and/ or microvessels. Transcriptional profiling of pDC-enriched vs. pDC-
deficient plaque fractions did not identify a pDC-specific gene signature, 
probably due to the low number of our cohort, the interpatient heterogeneity 
and the subtle effects exerted by low pDC abundance. However, further 
exploration of the transcriptomics data highlighted a list of genes in pDC-
enriched plaque area and identified 7 overrepresented functions, amongst 
others T cell receptor signaling pathway and MAPK pathway. Given the similar 
T cell presence in both study groups this possibly reflects a more activated 
phenotype in the pDC-enriched advanced human plaque. p38 MAPK pathway 
activation in pDCs- enriched fractions might be associated with enhanced pDC 
recruitment to these areas. p38 MAPK pathway activation has furthermore 
been shown to be associated with IFN-α production, due to increased 
expression of the IFN regulatory factor (IRF) 7.(22) However, we were unable to 
identify the increased expression of genes encoding the IFN pathway (or IFN 
response genes) in pDC-enriched fractions, suggesting that other mediators 
rather than IFN-α are responsible for pDC-induced immunity in the human 
plaque. To investigate the impact of pDCs on the immune microenvironment 
of the atherosclerotic plaque in finer details, co-expression network reverse 
engineering and gene modules-traits correlation were performed. This analysis 
highlighted certain gene clusters for T cells, macrophages and microvessels 
that particularly emerged in the pDC-enriched plaque fractions and not in the 
pDC-deficient ones. Inspired by the above pathway analysis and the IFN/ tumor 
necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated interplay 
between pDCs and CD4+ T cells suggested by Weyand and coworkers,(9, 10) we 
focused on the T cell gene module, ascertaining gene pathways being involved 
in the possible pDC-T cell crosstalk in the human plaque. Of note, adoptive 
transfer of human plaque-sorted CD4+ T cells into mice engrafted with human 
atherosclerotic plaque resulted in TRAIL-dependent vascular smooth muscle 
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cell (vSMC) apoptosis.(23) These studies suggest a link between vascular pDCs 
and possible TRAIL-dependent T cell-induced fibrous cap thinning and plaque 
destabilization, a hypothesis worth further investigation also in light of our 
results. 
 Here, we identified five immune functions, over-expressed in the ‘T cell 
module’, including positive regulation of Th1/Th17 differentiation and 
regulation of leukocyte chemotaxis. These data support the idea of a key role 
for pDCs on its immune context in atherosclerosis. Likewise, previous studies 
demonstrated the involvement of pDCs in the initiation of autoimmune Th17- 
and Th1-cell responses in experimental autoimmune encephalomyelitis.(24) 
Similarly, in patients with psoriasis and systemic lupus erythematosus (SLE), 
pDC activation and type I IFN release were associated with disease severity, 
due to an activation of monocyte-derived DCs, T cells and B cells.(19, 25) Once 
again, in this study we were unable to link pDC presence in the advanced 
human plaque with a type I IFN signature. It needs to be further validated 
whether pDCs are bystanders or the actual driving force inducing Th1/Th17 
differentiation in pDC-enriched plaque regions. In fact, Th1 cells may release 
CXCL10, which might amplify the CXCL12-dependent pDC recruitment.(26) 
Further experiments are needed to support this notion. In any case, human 
inflammatory DCs are probably responsible for the induced immune 
response,(27, 28) and might be interesting targets for translational research. 
Furthermore, we identified two microRNAs, i.e. microRNA-382 and microRNA-
518a, targeting the pDC-T cell genes cluster. In literature, microRNA-382 was 
amongst others seen to be enriched in resting CD4+ T cells as compared to 
activated CD4+ T cells, to confer potent inhibition of human immunodeficiency 
virus type 1 (HIV-1) production.(21) In parallel, it is up-regulated by IFN-α and 
IFN-β in HIV-1 infected macrophages, inhibiting viral replication.(29) Further 
studies are awaited to address a functional role for these two microRNAs and 
their implication in pDC- T cell interplay in the context of atherosclerosis. 
 Conclusively, our study has uncovered a previously uncharacterized 
gene network associated with the presence of pDCs in the human 
atherosclerotic plaque, suggesting an extensive pDC/T cell cross-talk. We 
extracted five overrepresented functional immune pathways, including T cell 
polarization and leukocyte chemotaxis, in the T cell module, which are linked 
to the presence of pDCs. Moreover, two microRNAs were identified, targeting 
a subset of the pDC/T cell gene cluster. Thus, this study not only offers new 
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insights into pDCs imprinting on the immune microenvironment in advanced 
human atherosclerosis, but also exposes pDCs as potential therapeutic targets 
in human atherosclerosis. Further prospective validation experiments have to 
firmly establish the reported findings, thus consolidating how pDCs impact the 
immune context of human plaque. 
 
 
Supplemental Figures 
 
 
Supplemental Figure 1. Post-robust multi array average (GCRMA) normalization. Array data 
were pre-processed using the GCRMA algorithm to correct background and normalize signal 
intensities. (A) Correlation matrix of pDC-enriched and pDC-deficient plaque fractions based on 
all detectable genes. (B) Boxplots after GCRMA normalization, showing the distribution of the 
observed log2-intensities on the sample dataset. (C) Smoothed histograms for samples in the 
dataset post-robust multi array average normalization. 
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Supplemental Figure 2. Scale-free topology analysis within the pDC-enriched and pDC-
deficient plaque fractions. (A) The panel shows the scale free topology fit index R2 as a function 
of the soft-thresholding power. (B-D) The panels show the mean, median and max network 
connectivity. The networks become approximately scale-free when the soft-thresholding power 
becomes 12 (for pDC-deficient fractions), or >20 (for pDC-enriched fractions). 
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Supplemental Figure 3. Overlap of modules in the pDC-enriched and pDC-deficient plaque 
fractions. Each row corresponds to a module related to the pDC-enriched fractions, indicated by 
name and number of genes in the module. Conversely, each column corresponds to a module 
related to the pDC-deficient fractions, indicated by name and number of genes in the module. 
Numbers in the table represent the number of genes in the overlap. The table is coloured 
according to the log10 p-value, with a colour scale indicated on the right. Most modules related 
to the pDC-enriched plaque fractions do not or weakly overlap with modules related to the pDC-
deficient fractions. 
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Supplemental Tables 
 
Supplemental Table 1. Patient and tissue characteristics 
 
 
 
IPH =   intraplaque hemorrhage 
TkFCA =  thick fibrous cap atheroma 
TnFCA =  thin fibrous cap atheroma 
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Supplemental Table 2. Top of 179 genes over- or underexpressed in the pDC-
enriched plaque regions with p<0.01 as obtained by independent students t-
test (Ensembl Annotation, individual p-value and fold-change). 
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Supplemental Table 3. Overrepresentation of the top 7 networks in the pDC-
enriched plaque regions. 
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Supplemental Table 4. Genes that are the most associated with the T cell trait 
in the T cell modules (encircled in red in Figure 5) 
EntrezID p-value 
26777 7.25E+08 
2217 0.000188462086830394 
5224 0.000242516790962645 
6293 0.000382305933654084 
2796 0.000682946053090609 
5982 0.000833397240535827 
57122 0.000889817922496262 
92285 0.000990655535173302 
160851 0.0010064578366297 
128229 0.00115587755070108 
54482 0.00133679356133274 
9448 0.00134562535876311 
54148 0.0013933284697501 
340252 0.00139550575853281 
11198 0.00153569120797477 
3995 0.0015686216372194 
10572 0.00162908708427192 
84668 0.00169828161209434 
57609 0.00176971882666819 
23398 0.00219639462803895 
2752 0.00243357571599038 
7182 0.00244673075655807 
112939 0.0025555281157694 
9871 0.00316443304724345 
22978 0.00333071793788981 
133619 0.0043009249631973 
51313 0.00470120320472875 
407013 0.0047618176506613 
941 0.00480336618005059 
2054 0.00496711134782501 
441108 0.00519561491608452 
22848 0.00520292668870337 
145282 0.00531442710689766 
10111 0.00545681563161602 
2937 0.00547508622734234 
729080 0.00572589205802052 
1487 0.00599141238018546 
84876 0.00612337784993039 
5360 0.00615160076303719 
51187 0.00616594382472369 
63920 0.00620469988110582 
59277 0.00637388771760107 
51167 0.00672466089009627 
153396 0.00672525162841608 
55729 0.00721796042515293 
9167 0.00730424694809579 
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50862 0.00732351996668049
3136 0.00753626031690917 
2137 0.00754148255637059 
29945 0.00764029098391836 
149951 0.00789112636607362 
3096 0.00830898419516174 
84129 0.0084704368458084 
3384 0.00848487357230459 
1678 0.0084965463750001 
11333 0.00854783022445309 
153527 0.0086180635255337 
5533 0.00868551686692155 
84267 0.00878752305550031 
10897 0.00895092494954742 
79053 0.0091852222422393 
23654 0.00932697170353974 
9839 0.00951845960169084 
7328 0.00993222476780401 
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General Discussion 
 
The main goal of the studies presented here was to explore the impact 
of certain DC subsets within hyperlipidemia-associated atherosclerosis in 
experimental animal models and in human. One DC subtype that we studied in 
detail, are plasmacytoid dendritic cells (pDCs), which have previously been 
identified in the shoulder region of human atherosclerotic lesions.(1) Here, we 
demonstrated that specific pDC depletion in low-density lipoprotein receptor 
deficiënt (Ldlr-/-) mice significantly deteriorated lesion formation, suggestive of 
a protective role for pDCs in mouse atherosclerosis (Chapter 3). Furthermore, 
we examined the impact of pDCs in murine atherosclerosis by use of a second 
pDC depletion model, in which pDC ablation was based on the transgenic 
diphtheria toxin receptor (DTR) expression under the pDC-specific human 
BDCA-2 promoter (Chapter 4). 
 Based on previous findings(1, 2) and our findings in Chapter 3, we 
hypothezised that pDCs, despite their scarce presence in the human 
atherosclerotic plaque, probably act by impacting their local immune context. 
To address this notion, we used Laser Capture Microdissection (LCM), to 
isolate pDC-enriched and pDC-less plaque segments from human carotid 
endarterectomy tissue samples, and performed genome-wide microarraying 
(Chapter 7). Co-expression cluster analyses revealed gene module traits of T 
cells, macrophages and microvessels that were specifically associated with the 
presence of pDCs in the human plaque. 
In Chapter 5 we addressed the question, whether a hyperlipidemic 
environment interferes with pDC functionality. Therefore, we stimulated 
human pDCs with lipoproteins (LDL or oxLDL) and a Toll-like receptor 9 (TLR9) 
agonist. Interestingly, lipoprotein pretreatment inhibited the TLR9 agonist 
induced activation of pDCs, and their T cell priming ability in vitro, reflecting an 
impaired activation status of pDCs under hyperlipidemic conditions. In Chapter 
6 we additionally addressed the role of hyperlipidemia on murine DC 
(precursor) homeostasis, and their phenotype and maturation status in 
peripheral (lymphoid) organs. Splenic lipid-laden cDCs (CD8- and CD8+ cDCs) 
showed an impaired ability to prime naïve CD4+ and CD8+ T cells. 
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Plasmacytoid dendritic cells protect against atherosclerosis by tuning T cell 
proliferation and activity 
 
In 2006 the group of Weyand and coworkers characterized increasing 
numbers of pDCs in the advanced human atherosclerotic plaque by using an 
anti-CD123 antibody. Additionally, they associated interferon-α (IFN-α) 
secretion, most likely by pDCs, with plaque destabilization by promoting 
apoptosis of vascular smooth muscle cells (vSMC).(1) IFN-α was furthermore 
seen to trigger the surface expression of TLR4 on conventional DCs (cDCs), 
thereby potentially amplifying inflammatory processes within the plaque.(2) In 
keeping, Levy et al. confirmed IFN-α as a critical contributor to lesion 
formation in that repeated IFN-α injections into Ldlr-/- mice enhanced lesion 
formation.(3) Our group confirmed the presence of pDCs in the human plaque 
(Chapter 3), however pDCs were only marginally present, mainly in regions of 
inflammation, and pDC numbers did not differ between stable and vulnerable 
atherosclerotic lesions. Additionally, we failed to show co-localization of pDCs 
with IFN-α in the human plaque, thus challenging the concept that pDCs are 
the prime source of IFN-α. Other cells of the myeloid lineage, such as 
macrophages, might rather be the type I IFN producing cells within the 
atherosclerotic lesion.(4) 
Of note, we revealed an athero-protective function for pDCs in mouse 
atherosclerosis, despite their virtual absence within the mouse plaque 
(Chapter 3). Specific pDC depletion resulted in amplified peripheral T cell 
proliferation and activity, which led to increased T cell invasion into 
atherosclerotic lesions. In effect, pDC depletion significantly aggravated lesion 
formation. We showed that pDCs were able to suppress T cell proliferation in 
an indoleamine 2,3-dioxygenase (IDO)-dependent manner in the context of 
atherosclerosis. IDO expression in DCs has been shown to be a highly versatile 
modulator of T cell immunity.(5, 6) Due to the lack of pDCs in mouse 
atherosclerotic lesions, it is conceivable that they exert their protective 
functions in peripheral lymphoid organs, such as spleen or lymph nodes, by 
regulating T cell responses. Alternatively, pDCs might bear their effects in 
mucosa-associated lymphoid organs, the liver, or the thymus. Indeed, it has 
been demonstrated that pDCs are responsible for systemic tolerance by 
inducing T cell anergy in the liver, thus preventing oral sensitization to dietary 
antigens.(7) Likewise, peripheral pDCs were able to mediate central tolerance 
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by transporting self-antigens to the thymus for presentation to developing T 
cells.(8)  
 As against our results, two other groups demonstrated recently that 
pDC depletion in ApolipoproteinE deficient (ApoE-/-) mice significantly 
decreased plaque development, accompanied by a more stable plaque 
phenotype, and a reduced systemic inflammatory state, associating the 
presence of pDCs with aggravated lesion formation.(9, 10) Both groups were able 
to detect pDCs within the mouse atherosclerotic plaque. Interestingly, Doering 
et al. demonstrated elevated IFN-α levels in murine plaques and serum in high 
fat diet fed ApoE-/- mice, being reduced after pDC depletion, thus linking an 
immunogenic IFN-α signature to pDCs in mouse atherosclerosis.(9)  
pDCs show rapid release of large amounts of type I IFNs in response to viral or 
certain bacterial antigens, attributing pDCs a crucial role in anti-viral 
defense.(11, 12) Moreover, pDCs are considered to be involved in the 
pathomechanisms of autoimmune diseases, such as psoriasis or systemic lupus 
erythematosus (SLE), characterized by a type I IFN-signature and dsDNA-
targeted immune responses.(13) Nuclear antimicrobial peptides, f.e. LL-37 or 
antigens that are derived from necrotic cells, form immunocomplexes with 
self-DNA which have been shown to stimulate IFN-α production through 
activation of TLR9, expressed on pDCs.(14, 15) Hence, it is conceivable that these 
immunocomplexes, composed of self-DNA released from necrotic cells and 
assembled with antimicrobial peptides or oxidized proteins, form in the 
advanced plaque, and have the capacity to stimulate pDCs in a TLR9-
dependent manner. Indeed, Edfeldt et al. confirmed the presence of LL-37 in 
human atherosclerotic plaques.(16) In line, Zernecke and coworkers visualized 
lesional Cramp in murine plaques, and Cramp-DNA complexes stimulated IFN-α 
production by pDCs in vitro, albeit that induction capacity was rather poor and 
required high concentrations of Cramp-DNA.(9) In addition, Cramp-/-/Ldlr-/- mice 
displayed diminished lesion sizes, whereas ApoE-/- mice treated with Cramp 
revealed an increase in plaque formation.(9) The authors proposed that Cramp-
induced recognition of self-DNA may trigger pDC activation and IFN-α 
secretion, thus driving inflammatory processes in atherosclerosis.(9) 
The divergent findings in the different studies might be explained by 
the stage of lesion formation, and the use of different animal models. Indeed, 
our findings refer to conditions of low-grade inflammation, as we investigated 
the effect of pDC ablation in more progressed murine lesions, whereas Doering 
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et al. and MacRitchie et al. analyzed the impact of pDC depletion after 4 weeks 
of high fat diet feeding.(9, 10) It has to be noted that the injection regime of the 
pDC depletion antibody differed between the three studies. We injected our 
depletion antibody every two days over a period of four weeks, whereas 
Doering et al. only injected the depletion antibody on day 1 and 7 during 32 
days of high fat diet feeding. Mac Ritchie et al. injected the antibody every fifth 
day during high fat diet. Considering the antibody kinetics and the fast and 
entire repopulation of pDCs already after 24-48 hours,(17) it has to be 
mentioned that pDC depletion in both studies was performed only partially 
and not continuously throughout the experiment, thus carefully viewing the 
interpretation of their data. Moreover, both groups used the ApoE-/- mouse, a 
more aggressive atherosclerosis model than the Ldlr-/- mouse, to study effects 
of pDC depletion on plaque development. In more fulminant inflammatory 
stages during early lesion development pDCs potentially act immunogenic in 
response to triggers in their environment,(18) most likely immunocomplexes or 
even modified lipoproteins. In sharp contrast, chronic low-grade inflammatory 
processes have been shown to enhance the expression of tolerogenic markers, 
such as CTLA-4, CD200 or B7-1, by pDCs.(19, 20) We confirmed the increased 
expression of tolerogenic markers such as IDO and programmed death-ligand 1 
(PD-L1) by pDCs, isolated from atherosclerotic Ldlr-/- mice. Supportively, we 
were unable to detect differences in IFN-α expression in lymphoid pDCs either 
isolated from non-atherosclerotic or atherosclerotic mice. Similarly, we failed 
to reveal differences in IFN-α in circulating human pDCs in carotid 
endarterectomy patients compared to healthy controls, providing evidence 
that pDC activation during chronic inflammation is not very prominent. 
Regarding the complex pathophysiology of atherosclerosis and the 
considerable plasticity of pDCs, they could well elicit dual functions during 
different stages of atherosclerosis. This might be reflected by the rapid release 
of type I IFNs and other pro-inflammatory cytokines during inflammatory 
episodes, whereas in the context of chronic inflammation pDCs possibly act 
athero-protective by suppressing T cell mediated immune responses. The exact 
trigger(s) for pDC immunogenicity and/ or tolerance, and the actual underlying 
pathways that are activated in pDCs during different stages of atherosclerosis 
remain to be established. Certainly, local and peripheral environmental 
changes are critical in driving pDC phenotype and functionality in 
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atherosclerosis. Mechanisms, crucial for pDC activation in autoimmune 
diseases, might as well be substantial in atherosclerosis.(21)  
Further studies, using more advanced conditional pDC deficient animal 
models, are required to better understand pDC functionality in mouse 
atherosclerosis. The use of depletion antibodies (120G8, mPDCA-1 or 927) 
targeting bone marrow stromal antigen 2 (BST2), has been shown to eliminate 
pDCs quite efficiently. (18)  BST-2 is restricted to pDCs in the steady-state, but is 
induced on other cell subsets upon type I IFN stimulation. Thus, the use of anti-
BST2 antibodies potentially leads to the depletion of additional cell subsets 
during viral infections.(17) In the context of atherosclerosis we demonstrated 
the specific depletion of pDCs by use of the 120G8 mAb.(22) Nevertheless, to 
corroborate the results we obtained with antibody-mediated depletion, we 
made use of the inducible pDC ablation model based on the transgenic 
diphtheria toxin receptor (DTR) expression under the pDC specific human 
BDCA-2 promoter (Chapter 4).(23) To dissect potential pDC-CD4+ T cell crosstalk 
in atherosclerosis, we additionally depleted CD4+ T cells in a subset of mice. 
We were able to confirm previous results, showing that administration of 
diphtheria toxin (DT) to BDCA-2 DTR transgenic mice resulted in an almost 
complete depletion of pDCs.(24) Nevertheless, under hyperlipidemic, potentially 
pro-inflammatory conditions in Ldlr-/- mice, prolonged application of DT 
induced systemic toxicity possessed in gradual body weight loss, generalized 
infirmity complicated by sudden death, and acute pneumonia. The 
observations of our study led us to conclude that the BDCA-2 DTR model, while 
technically interesting in acute disease models (f.e. viral infections), is not 
applicable to study the impact of pDCs in a chronic disease as atherosclerosis, 
due to undesirable side effects (leaky expression) after repeated DT 
administration. The use of the diphtheria toxin A (DTA) subunit under the 
control of a pDC-specific promoter should be considered for conditional pDC 
depletion in chronic inflammatory disorders, such as atherosclerosis. 
Alternatively, mice expressing the Cre-recombinase under the control of a 
pDC-specific promoter could be crossed with mice expressing DTA under the 
control of a floxed neomycin resistance cassette from the ROSA26 locus to 
particularly deplete pDCs. This approach has been applied for CD11c–Cre mice, 
in which certain DC subsets (cDCs, pDCs and Langerhans cells) have been 
specifically depleted.(25) 
General Discussion | 8 
 
225 
To summarize, the above findings (Chapter 3) warrant further 
examination of (triggered) pDCs as potential therapeutic targets in the 
treatment of atherosclerosis. However, appreciating pDC behaviour in human 
atherosclerosis will be challenging, since humans are exposed to infections 
throughout their whole life, which may affect immune responses of pDCs. 
Additionally, immuno-aging might interfere with pDC phenotype and 
functionality in patients with CVDs, thus impairing the feasible therapeutic 
potential of pDCs.(26) 
 
An immune response network associated with the presence of plasmacytoid 
dendritic cells in the human atherosclerotic plaque 
 
By now it is well appreciated that pDCs are present in the human 
atherosclerotic plaque, although only scarcely, basically in regions of 
inflammation.(1, 22) However, whether pDCs are functionally active in the local 
human plaque context has not been solved yet. During acute events, such as 
intraplaque hemorrhage, it might well be that pDCs act immunogenic by the 
release of type I IFNs, due to changes in their local microenvironment. 
Otherwise, pDCs may exert tolerogenic activity during processes of low-grade 
inflammation. No information is available on gene expression profiles, 
underlying biological pathways and functions of in vivo atherosclerotic pDCs. In 
Chapter 7 we therefore addressed the question whether pDCs manipulate its 
cellular surroundings within the advanced human plaque. To dissolve this 
question we employed Laser Capture Microdissection (LCM) on pDC-enriched 
and pDC-deficient frozen human carotid endarterectomy tissue samples to 
isolate RNA, and subsequently perform genome-wide microarraying and 
bioinformatics analyses.  
LCM has been commonly used in other fields, f.e. in cancer research,(27) 
but has manifested to be a cutting edge approach in atherosclerosis, due to 
the difficulty to extract sufficient, high quality RNA/ DNA from atherosclerotic 
tissue samples. Plaque RNA/ DNA degradation is prominent in regions of 
necrosis and apoptosis and consequently leads to decreased quality of the 
material. Additionally, the marginal number of pDCs present within the human 
plaque renders it even more challenging to obtain enough high quality material 
for microarray hybridization. Thanks to improvements in the RNA/ DNA 
amplification technique we overwhelmed this issue. Furthermore, the LCM 
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technique afforded very precise excision of pDC-enriched and pDC-deficient 
control regions without prior modifications such as cell labeling or cell sorting, 
thereby avoiding inevitable changes in the gene expression.  
Here, we primarily performed transcriptional profiling of pDC-enriched 
and pDC-deficient regions and subsequent pathway analysis within the human 
plaque to characterize a plaque-specific gene signature for pDCs. 
Transcriptional profiling lacked statistical significance, probably due to the 
small number of patient samples included, but also due to the scarce presence 
of pDCs within an enriched region. Additionally, intrapatient heterogeneity, 
such as gender, age, CVD risk factors, and application of CVD-related 
medication, will influence the gene expression profile, thus introducing 
variability in the results. Nevertheless, seven overrepresented networks were 
identified in the pDC-enriched plaque regions, including activation of T cell 
receptor signaling pathway(s) and MAPK pathway(s) activation. This signature 
might reflect a more activated status of immune cells in the near presence of 
pDCs. Besides comparing gene expression patterns between pDC-enriched and 
pDC-deficient regions, we employed module trait correlation analysis to 
characterize clusters of gene modules, tightly co-expressed with macrophages, 
T cells and microvessels that are strongly associated with the presence of 
pDCs. Inspired by our own results (Chapter 3), but also by the findings of 
Weyand and coworkers,(1, 2) we particularly focused on T-cell co-expressed 
modules. Interestingly, in our study we characterized a number of significantly 
overexpressed immune clusters in the T cell module, including positive 
regulation of Th1/ Th17 differentiation and regulation of leukocyte 
chemotaxis. These data potentially corroborate the findings of Weyand and 
coworkers, stressing the idea that pDCs exert immunogenic functions within 
the unstable lesion. Nevertheless, other DC subsets, including inflammatory 
DCs, might well be responsible to trigger Th1/ Th17 responses in the 
atherosclerotic plaque.(28)  
Additionally, we tagged two microRNAs that target the pDC- T cell gene 
cluster, microRNA-382 and microRNA-518a. Although our study suggests that 
these microRNA’s are potentially being associated in T cell differentiation and/ 
or activation, a role in pDC- T cell crosstalk/interplay needs to be further 
demonstrated. The employment of fluorescent in situ hybridization (FISH) is 
one approach to confirm the co-localization of the two microRNAs with T cells 
in the close neighbourhood of pDCs in the atherosclerotic lesion, thus 
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excluding their feasible expression by other immune cell subsets. Future 
approaches, specifically aiming these microRNAs or pathways they are 
involved in, will assist to elucidate a potential functional role and to find their 
targets.  
To summarize, it will be of great importance to validate the 
aforementioned findings and identified candidates in pDC-related immune 
responses. Moreover, RNA/ DNA expression profiles are not always reflective 
of protein expression and cellular functionality.(29) Therefore, the performance 
of protein arrays and in vitro/ in vivo approaches will lead to a more 
comprehensive understanding in pDC biology in the human atherosclerotic 
plaque. Nevertheless, this study is the first to provide new insights and 
generates novel hypotheses on pDC actions on its local immune cell context in 
advanced human atherosclerosis, and led to the identification of potential 
central modifiers in pDC-mediated immune responses. 
 
Modified lipoproteins critically affect human pDC functions 
 
 pDCs are crucial in the host defense against viral and bacterial antigens 
through the rapid release of large amounts of type I IFNs.(30) TLR7 and TLR9-
mediated recognition of pathogenic antigens induces pDC maturation, and 
subsequent cytokine production.(30) Conditions that impact TLR signaling will 
have profound impact on pDC functionality in host defense. Hyperlipididemia 
has been shown to inhibit the activation of certain DC subsets, due to 
uncoupling of TLR-mediated signaling, thus compromising host resistance to 
microbial infections.(31) Oxidized low-density lipoprotein (oxLDL) appeared to 
be the key player. Thus, impaired maturation and functionality after 
lipoprotein exposure seems to be critically dependent on DC-subtype and its 
environment.  
Studies, which investigate the influence of hypercholesterolemia/ 
oxLDL on pDCs are lacking. Therefore, we have investigated in Chapter 5 
whether a hyperlipidemic environment impairs pDC functionality. We 
demonstrated that human pDCs are hypo-responsive after excessive 
lipoprotein exposure, despite the presence of the TLR9 agonist CpG-ODN, 
represented by the quenched ability to release type I IFNs, as well as other 
pro-inflammatory cytokines. In keeping, pDCs failed to induce T helper (Th) 
differentiation when pre-treated with oxLDL. As these experiments were 
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performed in vitro, it will be of importance to further ascertain whether a 
hyperlipidemic environment interferes with pDC responses to pathogen-
derived signals in vivo. Interestingly, in vitro oxLDL treatment of murine pDCs 
did not lead to the increased expression of the maturation markers and major 
histocompatibility complex II (MHC II).(9) OxLDL treatment resulted in elevated 
expression of the scavenger receptor CD36, one of the most important oxLDL 
uptake receptors.(32) Surprisingly, oxLDL-treated murine pDCs showed 
enhanced ability to trigger antigen-specific T cell proliferation in vivo.(9) 
Summing up, duration of lipoprotein incubation possibly is decisive in the 
impairment of pDC activity. Short-term lipoprotein exposure may conserve 
pDC capacity to process and present antigens to T cells,(9) whereas long-term 
pretreatment possibly interferes with pDC activation. Next to oxLDL, in vivo 
environmental factors may have triggered lipid-laden pDCs to stimulate T cell 
proliferation in the study of Doering et al. Thus, in vitro data have to be 
interpreted carefully, as they do not completely mimic the complex in vivo 
environment. Nevertheless, in vitro assays are a powerful tool to gain more 
insight into possible inter- and intracellular mechanisms in the context of 
hyperlipidemia that may occur in vivo. Notably, we performed our experiments 
in human pDCs, while Doering et al. used murine pDCs, rendering it more 
challenging to compare findings in these two studies.(9) Although mouse and 
human pDCs share similar markers, it will be of importance to validate, how 
representative murine (in vitro) models are for human disease.(33)  
Altogether, our data reveal that a hyperlipidemic environment abrogates TLR9 
agonist induced activation of human pDCs. It remains to be elusive how 
lipoproteins are engulfed, possibly by receptor-mediated endocytosis via 
specific surface receptors of the C-type lectin(34) or the siglec family.(35) 
Additionally, further studies are required to dissect which pathways and 
downstream lipid metabolites are responsible for the inhibitory effect of 
(ox)LDL, and the subsequent impact on disease/host defense. 
 
Effects of hypercholesterolemia on DC (precursor) homeostasis and 
peripheral DC subset functionality 
 
 It has recently been shown that certain DC subsets are able to 
incorporate lipoproteins both in vitro and in vivo, which may induce their 
maturation and activation.(36-39) A recent study observed the contribution of 
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vascular resident DCs to the onset of atherosclerosis by the rapid accumulation 
of lipoproteins, and ensuing foam cell formation during the first days of 
atherogenesis.(40) Interestingly, Gautier et al. revealed the cross-interaction 
between conventional DCs (cDCs) and cholesterol homeostasis under 
hyperlipidemic conditions, as specific cDC depletion led to increased plasma 
cholesterol levels. The authors suggest that DCs might favor lipoprotein uptake 
from the periphery. How/ whether (different stages of) hyperlipidemia impair 
DC homeostasis, including their development in the bone marrow, DC 
mobilization into the circulation, and migratory routes, remains to be 
addressed. Therefore, we investigated in Chapter 6 the effects of early and 
later time points of dietary-induced hypercholesterolemia on DC (precursor) 
homeostasis, as well as the phenotype of lipid-laden DC subsets, and their T 
cell priming capability. For this purpose, we fed Ldlr-/- mice either a normal 
standard fat diet, or a high fat diet for different time points, and analyzed cell 
composition, cell proliferation, and cell activation status in bone marrow and 
peripheral lymphoid organs. It is well appreciated that hypercholesterolemia 
induces monocytosis in ApoE-/- mice, which may be partly associated with a 
defect in ApoE-dependent suppression of hematopoietic stem and 
multipotential progenitor cell proliferation in the bone marrow.(41-43) Thus, 
hypercholesterolemia likely impairs DC development as well. In our study we 
observed that dietary-induced hypercholesterolemia resulted in significantly 
increased myeloid and dendritic cell precursor (MDPs) numbers in bone 
marrow. However, this increase is not reflected in lymphoid organ DC subset 
numbers. Several options could be responsible for this. MDPs are the most 
differentiated clonogenic precursors that can give rise to classical DCs (cDCs 
and pDCs) and monocytes.(44, 45) It might be that under dyslipidemic conditions 
MDPs preferentially differentiate into monocytes, as hyperlipidemia has been 
shown to be associated with monocytosis.(46) Alternatively, unaltered 
peripheral DC numbers could be explained by the direct migration of DC 
(precursors) to sites of inflammation (the inflamed artery), increased cell 
turnover or reduced release from bone marrow. We furthermore examined 
whether peripheral DC subsets, isolated from different lymphoid organs and 
small intestine, show features of lipoprotein accumulation, when exposed in 
vivo for different periods of time to a hyperlipidemic environment. We 
observed lipoprotein accumulation in a subset of splenic and lymph node cDCs 
in high fat diet fed Ldlr-/- mice. Notably, lipid-laden cDCs retained an immature 
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phenotype, shown by the unaltered or even lowered expression of co-
stimulatory molecules. Additionally, lipoprotein incorporation had functional 
consequences in that it impaired the ability of cDCs to stimulate naïve T cells. 
So far, whether and how cholesterol uptake and prolonged intracellular 
storage interferes with DC activation and their T cell priming capability remains 
subject to debate.(31, 36, 37) Interestingly, Gabrilovich and coworkers 
demonstrated that lipid-laden DCs, isolated from tumor-bearing mice and 
cancer patients, were unable to effectively present tumor-associated antigens 
and to stimulate T cells.(47) These data most likely suggest that a hyperlipidemic 
environment interdicts DC activation, which consequently impairs their T cell 
stimulatory capacity. These data corroborate our findings showing that certain 
lipid-laden DC subsets were impaired in their functionality. 
 
Conclusions and future perspectives 
 
In this thesis we have explored the impact of certain DC subsets in 
hyperlipidemia-associated atherosclerosis both in animal models and in 
human. The involvement of different DC subsets (vascular resident DCs, cDCs, 
pDCs) in the development and progression of atherosclerosis has been studied 
quite extensively in recent years. Nevertheless, their actions in atherosclerosis 
remain poorly understood. We were the first to establish a critical role of pDC-
dependent immune responses in murine atherosclerosis (Chapter 3). 
Furthermore, we addressed the question whether hyperlipidemia affects (p)DC 
functionality (in the periphery, but also within the local plaque context). We 
revealed that excessive lipoprotein exposure led to impaired functionality of 
human pDCs in vitro (Chapter 5). Such association between hyperlipidemia and 
pDC interferon response has profound implications for the host’s pathogen 
defense capacity in hyperlipidemic patients. In addition, we demonstrated that 
peripheral murine cDC subsets were affected in their T cell priming capability 
upon lipoprotein uptake (Chapter 6), strengthening the idea that a cholesterol-
rich environment potentially interferes with DC responses to host immunity. 
Future experiments will unravel how hyperlipidemia and lipoprotein exposure 
exactly quench (TLR-induced) activation of DCs. DC subset isolation (pDCs, 
cDCs, inflammatory DCs) from patients with familial hypercholesterolemia, and 
subsequent phenotypic characterization (cell sorting, genome-wide 
microarraying, functional assays) would certainly illuminate DC actions in a 
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cholesterol-rich environment. It should be critically addressed whether DC 
(subset) functions are affected systemically or just site-specific. In Chapter 7 
we revealed a direct cross-talk between pDCs and its local immune context 
within the advanced human atherosclerotic plaque, stressing the idea that 
pDCs, even though oxLDL-exposed, exert immunogenic functions. Conceivably, 
injury associated release of danger-associated molecular patterns (DAMPs) 
might trigger pDC activation and T cell priming ability at the inflamed locus, 
skewing the adaptive immune system towards Th1/17-like immune responses. 
These data emphasize that (p)DC activation/ functionality crucially depends on 
direct environmental signals, modifying DC phenotype. 
Altogether, despite the enormous progress that has been made in 
recent years to appreciate DC biology in the context of hyperlipidemia-
associated atherosclerosis, further studies are required to define molecular 
pathways that regulate DC differentiation, DC maturation, and their T cell 
priming ability in a disturbed lipoprotein environment- locally within the 
plaque and in the periphery.  
 
DCs-based immunotherapy in atherosclerosis and side effects 
 
 Despite the current incomplete understanding of DC functionality in 
hyperlipidemia-associated atherosclerosis (as discussed above), DC-based 
immunotherapy may become a therapeutic option for atherosclerosis. DC 
vaccination has already been successfully used in clinical trials for cancer 
research.(48, 49) Effective immuno-based vaccination strategies require the 
identification of tissue-specific epitopes, actual antigen presentation by 
specialized antigen-presenting cells (APCs), and T cell priming. DCs are 
specialized APCs, representing an ideal platform for vaccination, f.e. ex vivo 
pre-pulsing of DCs with individual tumor-bearing antigens induced specific 
CD8+ T cell responses in vivo.(50) This knowledge has encouraged several groups 
to ascertain the potential of DC-based vaccination in atherosclerosis. For 
instance, Hansson and coworkers illustrated recently that apolipoprotein B100 
and IL-10 pre-pulsed DCs trigger an immunosuppressive state, thus effectively 
attenuating atherosclerosis.(51) Beside, the use of immature pDCs, considered 
to be tolerogenic, hold promise as potential therapeutic tools in the treatment 
of atherosclerosis, as tolerized pDCs induced regulatory T cell development 
and prolonged vascularized cardiac graft survival in mice.(52) Important issues 
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regarding the immunological status of the patient, therapy timing, choice of 
the antigen, injection of fully matured versus immature/ pre-DCs and their 
trafficking routes, as well as possible side effects should be critically addressed. 
In murine models, DC-based vaccination proved to be successful during lesion 
development,(51, 53) though, it is questioned how favorable DC immunotherapy 
affects symptomatic/manifest atherosclerosis in human, and which time point 
would be the most ideal to start vaccination since atherosclerosis is a chronic 
inflammatory disease, mostly affecting people of advanced age. It is known 
that CVDs are linked to the age-associated deterioration of the immune 
system.(54-57) Therefore, it remains essential to explore whether immune cells, 
in particular DCs and T cells, are functionally impaired by aging in humans. Age-
associated alterations of signal transduction pathways in DCs may lead to 
defective triggering of adaptive immune responses, thus decreasing the 
therapeutic potential of DCs. Further analyses are required to better 
understand age-related effects on innate and acquired immunity, which will in 
turn improve the efficiency in immunotherapy,(57) specifically in elderly 
subjects. Moreover, the hyperlipidemic context might interfere with DC 
functionality, as has been discussed in Chapter 5 and 6 of this thesis.  
The activation status of certain DC subsets can additionally be modified 
in vivo by administration of CVD-related medication, such as statins.(58) Statins, 
primarily introduced to block cholesterol synthesis and to lower cholesterol 
serum levels, have been shown to have some beneficial side effects, f.e. anti-
inflammatory and anti-oxidant activities resulting in the reduction of 
cardiovascular risk, which might interfere DC-based vaccination efficiency. 
Finally, it is still of great importance to figure out the correct and/ or most 
efficient antigen for DC pulsing before transferring them in vivo.  
 
 
General Discussion | 8 
 
233 
References 
 
1. Niessner A, Sato K, Chaikof EL, Colmegna I, Goronzy JJ, Weyand CM. Pathogen-sensing 
plasmacytoid dendritic cells stimulate cytotoxic t-cell function in the atherosclerotic 
plaque through interferon-alpha. Circulation. 2006;114:2482-2489 
2. Niessner A, Shin MS, Pryshchep O, Goronzy JJ, Chaikof EL, Weyand CM. Synergistic 
proinflammatory effects of the antiviral cytokine interferon-alpha and toll-like 
receptor 4 ligands in the atherosclerotic plaque. Circulation. 2007;116:2043-2052 
3. Levy Z, Rachmani R, Trestman S, Dvir A, Shaish A, Ravid M, Harats D. Low-dose 
interferon-alpha accelerates atherosclerosis in an ldl receptor-deficient mouse model. 
Eur J Intern Med. 2003;14:479-483 
4. Goossens P, Gijbels MJ, Zernecke A, Eijgelaar W, Vergouwe MN, van der Made I, 
Vanderlocht J, Beckers L, Buurman WA, Daemen MJ, Kalinke U, Weber C, Lutgens E, de 
Winther MP. Myeloid type i interferon signaling promotes atherosclerosis by 
stimulating macrophage recruitment to lesions. Cell Metab. 2010;12:142-153 
5. Puccetti P, Grohmann U. Ido and regulatory t cells: A role for reverse signalling and 
non-canonical nf-kappab activation. Nat Rev Immunol. 2007;7:817-823 
6. Huang L, Baban B, Johnson BA, 3rd, Mellor AL. Dendritic cells, indoleamine 2,3 
dioxygenase and acquired immune privilege. Int Rev Immunol. 2010;29:133-155 
7. Goubier A, Dubois B, Gheit H, Joubert G, Villard-Truc F, Asselin-Paturel C, Trinchieri G, 
Kaiserlian D. Plasmacytoid dendritic cells mediate oral tolerance. Immunity. 
2008;29:464-475 
8. Hadeiba H, Lahl K, Edalati A, Oderup C, Habtezion A, Pachynski R, Nguyen L, Ghodsi A, 
Adler S, Butcher EC. Plasmacytoid dendritic cells transport peripheral antigens to the 
thymus to promote central tolerance. Immunity. 2012;36:438-450 
9. Doring Y, Manthey HD, Drechsler M, Lievens D, Megens RT, Soehnlein O, Busch M, 
Manca M, Koenen RR, Pelisek J, Daemen MJ, Lutgens E, Zenke M, Binder CJ, Weber C, 
Zernecke A. Auto-antigenic protein-DNA complexes stimulate plasmacytoid dendritic 
cells to promote atherosclerosis. Circulation. 2012;125:1673-1683 
10. Macritchie N, Grassia G, Sabir SR, Maddaluno M, Welsh P, Sattar N, Ialenti A, 
Kurowska-Stolarska M, McInnes IB, Brewer JM, Garside P, Maffia P. Plasmacytoid 
dendritic cells play a key role in promoting atherosclerosis in apolipoprotein e-
deficient mice. Arterioscler Thromb Vasc Biol. 2012;32:2569-2579 
11. Cella M, Jarrossay D, Facchetti F, Alebardi O, Nakajima H, Lanzavecchia A, Colonna M. 
Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts 
of type i interferon. Nat Med. 1999;5:919-923 
12. Ito T, Kanzler H, Duramad O, Cao W, Liu YJ. Specialization, kinetics, and repertoire of 
type 1 interferon responses by human plasmacytoid predendritic cells. Blood. 
2006;107:2423-2431 
13. Gilliet M, Cao W, Liu YJ. Plasmacytoid dendritic cells: Sensing nucleic acids in viral 
infection and autoimmune diseases. Nat Rev Immunol. 2008;8:594-606 
14. Lovgren T, Eloranta ML, Bave U, Alm GV, Ronnblom L. Induction of interferon-alpha 
production in plasmacytoid dendritic cells by immune complexes containing nucleic 
acid released by necrotic or late apoptotic cells and lupus igg. Arthritis Rheum. 
2004;50:1861-1872 
15. Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, Cao W, Wang YH, 
Su B, Nestle FO, Zal T, Mellman I, Schroder JM, Liu YJ, Gilliet M. Plasmacytoid dendritic 
cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007;449:564-569 
8 | General Discussion 
 
234 
16. Edfeldt K, Agerberth B, Rottenberg ME, Gudmundsson GH, Wang XB, Mandal K, Xu Q, 
Yan ZQ. Involvement of the antimicrobial peptide ll-37 in human atherosclerosis. 
Arterioscler Thromb Vasc Biol. 2006;26:1551-1557 
17. Blasius AL, Giurisato E, Cella M, Schreiber RD, Shaw AS, Colonna M. Bone marrow 
stromal cell antigen 2 is a specific marker of type i ifn-producing cells in the naive 
mouse, but a promiscuous cell surface antigen following ifn stimulation. Journal of 
immunology. 2006;177:3260-3265 
18. Swiecki M, Colonna M. Unraveling the functions of plasmacytoid dendritic cells during 
viral infections, autoimmunity, and tolerance. Immunological reviews. 2010;234:142-
162 
19. de Heer HJ, Hammad H, Soullie T, Hijdra D, Vos N, Willart MA, Hoogsteden HC, 
Lambrecht BN. Essential role of lung plasmacytoid dendritic cells in preventing 
asthmatic reactions to harmless inhaled antigen. J Exp Med. 2004;200:89-98 
20. Manicassamy S, Pulendran B. Dendritic cell control of tolerogenic responses. Immunol 
Rev. 2011;241:206-227 
21. Eloranta ML, Lovgren T, Finke D, Mathsson L, Ronnelid J, Kastner B, Alm GV, Ronnblom 
L. Regulation of the interferon-alpha production induced by rna-containing immune 
complexes in plasmacytoid dendritic cells. Arthritis Rheum. 2009;60:2418-2427 
22. Daissormont IT, Christ A, Temmerman L, Sampedro Millares S, Seijkens T, Manca M, 
Rousch M, Poggi M, Boon L, van der Loos C, Daemen M, Lutgens E, Halvorsen B, 
Aukrust P, Janssen E, Biessen EA. Plasmacytoid dendritic cells protect against 
atherosclerosis by tuning t-cell proliferation and activity. Circ Res. 2011;109:1387-1395 
23. Dzionek A, Sohma Y, Nagafune J, Cella M, Colonna M, Facchetti F, Gunther G, Johnston 
I, Lanzavecchia A, Nagasaka T, Okada T, Vermi W, Winkels G, Yamamoto T, Zysk M, 
Yamaguchi Y, Schmitz J. Bdca-2, a novel plasmacytoid dendritic cell-specific type ii c-
type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta 
induction. J Exp Med. 2001;194:1823-1834 
24. Swiecki M, Gilfillan S, Vermi W, Wang Y, Colonna M. Plasmacytoid dendritic cell 
ablation impacts early interferon responses and antiviral nk and cd8(+) t cell accrual. 
Immunity. 2010;33:955-966 
25. Ohnmacht C, Pullner A, King SB, Drexler I, Meier S, Brocker T, Voehringer D. 
Constitutive ablation of dendritic cells breaks self-tolerance of cd4 t cells and results in 
spontaneous fatal autoimmunity. The Journal of experimental medicine. 2009;206:549-
559 
26. Solana R, Tarazona R, Gayoso I, Lesur O, Dupuis G, Fulop T. Innate immunosenescence: 
Effect of aging on cells and receptors of the innate immune system in humans. Semin 
Immunol. 2012;24:331-341 
27. Espina V, Heiby M, Pierobon M, Liotta LA. Laser capture microdissection technology. 
Expert Rev Mol Diagn. 2007;7:647-657 
28. Segura E, Touzot M, Bohineust A, Cappuccio A, Chiocchia G, Hosmalin A, Dalod M, 
Soumelis V, Amigorena S. Human inflammatory dendritic cells induce th17 cell 
differentiation. Immunity. 2013 
29. Miller DT, Ridker PM, Libby P, Kwiatkowski DJ. Atherosclerosis: The path from 
genomics to therapeutics. J Am Coll Cardiol. 2007;49:1589-1599 
30. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, Antonenko S, 
Liu YJ. The nature of the principal type 1 interferon-producing cells in human blood. 
Science. 1999;284:1835-1837 
31. Shamshiev AT, Ampenberger F, Ernst B, Rohrer L, Marsland BJ, Kopf M. Dyslipidemia 
inhibits toll-like receptor-induced activation of cd8alpha-negative dendritic cells and 
protective th1 type immunity. J Exp Med. 2007;204:441-452 
General Discussion | 8 
 
235 
32. Moore KJ, Freeman MW. Scavenger receptors in atherosclerosis: Beyond lipid uptake. 
Arterioscler Thromb Vasc Biol. 2006;26:1702-1711 
33. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, 
McDonald-Smith GP, Gao H, Hennessy L, Finnerty CC, Lopez CM, Honari S, Moore EE, 
Minei JP, Cuschieri J, Bankey PE, Johnson JL, Sperry J, Nathens AB, Billiar TR, West MA, 
Jeschke MG, Klein MB, Gamelli RL, Gibran NS, Brownstein BH, Miller-Graziano C, 
Calvano SE, Mason PH, Cobb JP, Rahme LG, Lowry SF, Maier RV, Moldawer LL, Herndon 
DN, Davis RW, Xiao W, Tompkins RG, the I, Host Response to Injury LSCRP. Genomic 
responses in mouse models poorly mimic human inflammatory diseases. Proc Natl 
Acad Sci U S A. 2013 
34. Kanazawa N. Dendritic cell immunoreceptors: C-type lectin receptors for pattern-
recognition and signaling on antigen-presenting cells. J Dermatol Sci. 2007;45:77-86 
35. Pillai S, Netravali IA, Cariappa A, Mattoo H. Siglecs and immune regulation. Annu Rev 
Immunol. 2012;30:357-392 
36. Gautier EL, Huby T, Saint-Charles F, Ouzilleau B, Pirault J, Deswaerte V, Ginhoux F, 
Miller ER, Witztum JL, Chapman MJ, Lesnik P. Conventional dendritic cells at the 
crossroads between immunity and cholesterol homeostasis in atherosclerosis. 
Circulation. 2009;119:2367-2375 
37. Packard RR, Maganto-Garcia E, Gotsman I, Tabas I, Libby P, Lichtman AH. Cd11c(+) 
dendritic cells maintain antigen processing, presentation capabilities, and cd4(+) t-cell 
priming efficacy under hypercholesterolemic conditions associated with 
atherosclerosis. Circ Res. 2008;103:965-973 
38. Alderman CJ, Bunyard PR, Chain BM, Foreman JC, Leake DS, Katz DR. Effects of 
oxidised low density lipoprotein on dendritic cells: A possible immunoregulatory 
component of the atherogenic micro-environment? Cardiovasc Res. 2002;55:806-819 
39. Perrin-Cocon L, Coutant F, Agaugue S, Deforges S, Andre P, Lotteau V. Oxidized low-
density lipoprotein promotes mature dendritic cell transition from differentiating 
monocyte. J Immunol. 2001;167:3785-3791 
40. Paulson KE, Zhu SN, Chen M, Nurmohamed S, Jongstra-Bilen J, Cybulsky MI. Resident 
intimal dendritic cells accumulate lipid and contribute to the initiation of 
atherosclerosis. Circ Res. 2010;106:383-390 
41. Yvan-Charvet L, Pagler T, Gautier EL, Avagyan S, Siry RL, Han S, Welch CL, Wang N, 
Randolph GJ, Snoeck HW, Tall AR. Atp-binding cassette transporters and hdl suppress 
hematopoietic stem cell proliferation. Science. 2010;328:1689-1693 
42. Drechsler M, Megens RT, van Zandvoort M, Weber C, Soehnlein O. Hyperlipidemia-
triggered neutrophilia promotes early atherosclerosis. Circulation. 2010;122:1837-
1845 
43. Murphy AJ, Akhtari M, Tolani S, Pagler T, Bijl N, Kuo CL, Wang M, Sanson M, 
Abramowicz S, Welch C, Bochem AE, Kuivenhoven JA, Yvan-Charvet L, Tall AR. Apoe 
regulates hematopoietic stem cell proliferation, monocytosis, and monocyte 
accumulation in atherosclerotic lesions in mice. J Clin Invest. 2011;121:4138-4149 
44. Auffray C, Fogg DK, Narni-Mancinelli E, Senechal B, Trouillet C, Saederup N, Leemput J, 
Bigot K, Campisi L, Abitbol M, Molina T, Charo I, Hume DA, Cumano A, Lauvau G, 
Geissmann F. Cx3cr1+ cd115+ cd135+ common macrophage/dc precursors and the 
role of cx3cr1 in their response to inflammation. J Exp Med. 2009;206:595-606 
45. Satpathy AT, Wu X, Albring JC, Murphy KM. Re(de)fining the dendritic cell lineage. Nat 
Immunol. 2012;13:1145-1154 
46. Swirski FK, Libby P, Aikawa E, Alcaide P, Luscinskas FW, Weissleder R, Pittet MJ. Ly-6chi 
monocytes dominate hypercholesterolemia-associated monocytosis and give rise to 
macrophages in atheromata. J Clin Invest. 2007;117:195-205 
8 | General Discussion 
 
236 
47. Herber DL, Cao W, Nefedova Y, Novitskiy SV, Nagaraj S, Tyurin VA, Corzo A, Cho HI, 
Celis E, Lennox B, Knight SC, Padhya T, McCaffrey TV, McCaffrey JC, Antonia S, Fishman 
M, Ferris RL, Kagan VE, Gabrilovich DI. Lipid accumulation and dendritic cell 
dysfunction in cancer. Nat Med. 2010;16:880-886 
48. Pecher G, Haring A, Kaiser L, Thiel E. Mucin gene (muc1) transfected dendritic cells as 
vaccine: Results of a phase i/ii clinical trial. Cancer Immunol Immunother. 2002;51:669-
673 
49. Arnason J, Avigan D. Evolution of cellular immunotherapy: From allogeneic transplant 
to dendritic cell vaccination as treatment for multiple myeloma. Immunotherapy. 
2012;4:1043-1051 
50. Tacken PJ, de Vries IJ, Torensma R, Figdor CG. Dendritic-cell immunotherapy: From ex 
vivo loading to in vivo targeting. Nat Rev Immunol. 2007;7:790-802 
51. Hermansson A, Johansson DK, Ketelhuth DF, Andersson J, Zhou X, Hansson GK. 
Immunotherapy with tolerogenic apolipoprotein b-100-loaded dendritic cells 
attenuates atherosclerosis in hypercholesterolemic mice. Circulation. 2011;123:1083-
1091 
52. Ochando JC, Homma C, Yang Y, Hidalgo A, Garin A, Tacke F, Angeli V, Li Y, Boros P, Ding 
Y, Jessberger R, Trinchieri G, Lira SA, Randolph GJ, Bromberg JS. Alloantigen-presenting 
plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol. 
2006;7:652-662 
53. Habets KL, van Puijvelde GH, van Duivenvoorde LM, van Wanrooij EJ, de Vos P, 
Tervaert JW, van Berkel TJ, Toes RE, Kuiper J. Vaccination using oxidized low-density 
lipoprotein-pulsed dendritic cells reduces atherosclerosis in ldl receptor-deficient 
mice. Cardiovasc Res. 2010;85:622-630 
54. Shaw AC, Joshi S, Greenwood H, Panda A, Lord JM. Aging of the innate immune 
system. Curr Opin Immunol. 2010;22:507-513 
55. Panda A, Arjona A, Sapey E, Bai F, Fikrig E, Montgomery RR, Lord JM, Shaw AC. Human 
innate immunosenescence: Causes and consequences for immunity in old age. Trends 
Immunol. 2009;30:325-333 
56. Fulop T, Larbi A, Witkowski JM, McElhaney J, Loeb M, Mitnitski A, Pawelec G. Aging, 
frailty and age-related diseases. Biogerontology. 2010;11:547-563 
57. Grubeck-Loebenstein B, Della Bella S, Iorio AM, Michel JP, Pawelec G, Solana R. 
Immunosenescence and vaccine failure in the elderly. Aging Clin Exp Res. 2009;21:201-
209 
58. Montecucco F, Mach F. Update on statin-mediated anti-inflammatory activities in 
atherosclerosis. Semin Immunopathol. 2009;31:127-142 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
General Discussion | 8 
 
237 
 
 
 238 
        
 
 
Summary 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
239 
Summary 
 
Atherosclerosis,  the  underlying  pathological  process  of  most 
cardiovascular  diseases  (CVDs),  is  a  chronic  inflammatory  disease,  which 
critically  implies  specialized  immune  cells  such  as monocytes/ macrophages, 
granulocytes,  B  and  T  cells  in  its  pathomechanism.  Activated  immune  cells 
elaborate a range of inflammatory processes, which tremendously account for 
disease  onset  and  progression.  In  recent  years  another  immune  cell  subset, 
dendritic  cells  (DCs),  has  been  identified  in  the  healthy  and  diseased 
vasculature. DCs,  specialized  antigen‐presenting  cells  (APCs),  are  essential  in 
linking  innate and adaptive  immune responses against pathogen‐derived, but 
also modified  self‐antigens  present  at  sites  of  injury,  thus  triggering  T  cell‐
mediated  immunity. DC numbers were described  to be elevated  in advanced 
human atherosclerotic plaques, mainly present in inflammatory foci within the 
plaque  shoulder.  In  this  regard,  a  possible  role  for  DCs  as  contributors  to 
inflammatory  processes  in  atherosclerosis  is  attaining  more  and  more 
attention. Particular plaque‐derived epitopes that might induce DC maturation 
and  activation  within  their  local  context  have  not  been  identified  yet. 
Additionally,  the  maintenance  of  antigen‐presentation  and  T  cell  priming 
ability  by  DCs  under  hyperlipidemic  conditions,  even  after  excessive  lipid‐
loading  remains  poorly  understood,  and  studies  addressing  these  issues  are 
diverging. Consequently, this thesis focuses on elucidating the contribution of 
certain  DC  subsets  in  hyperlipidemia‐associated  atherosclerosis.  Besides,  it 
addresses  the  question  whether  a  hypercholesterolemic  environment 
interferes with DC activation and its ability to prime T cell immune responses.  
Studying  dendritic  cell  (DC)  biology  in  a  majority  of  cardiovascular 
diseases  (CVDs) has gained  intensive attention  in  the  last years, due  to  their 
prominence  to  trigger  adaptive  immune  responses.  Nevertheless,  the  full 
scope of DC‐driven effects  in CVDs  is still unclear. In Chapter 2 we present an 
in‐depth overview of  the current knowledge on  the  impact of DC  subsets on 
several CVDs  in order to reveal underlying patterns, and to demonstrate gaps 
and  shortcomings  in  the  knowledge  of  DC  function  in  CVDs.  Besides,  we 
highlight the therapeutic potential of DCs in cardiac transplantation which may 
provide an example for a future atherosclerosis vaccination strategy. 
  pDCs are  thought  to contribute  to atherosclerotic  lesion  formation  in 
human by a  type  I  interferon  (IFN)  signature.  In Chapter 3 we demonstrated 
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the  scarcely  presence  of  pDCs within  the  human  plaque, whereas  they  are 
almost completely absent  in murine atherosclerotic  lesions. Surprisingly, pDC 
ablation  by  systemic  administration  of  the  120G monoclonal  antibody  was 
seen  to  aggravate  lesion  formation  in  low‐density  lipoprotein  receptor 
deficiënt  (Ldlr‐/‐)  mice,  thus  attributing  pDCs  an  athero‐protective  role.  In 
keeping, peripheral lymphoid organ pDCs from atherosclerotic mice dampened 
T  cell  activation  and proliferation  in  an  indoleamine  2,3‐ dioxygenase  (IDO)‐
dependent manner. Altogether, our  research  identifies a  tolerogenic  role  for 
pDCs  in atherosclerosis,  rendering  them an  interesting new  target  for  future 
therapeutic approaches.  
In  Chapter  4 we made  additional  use  of  the  inducible  pDC  ablation 
model  based  on  the  transgenic  diphtheria  toxin  receptor  (DTR)  expression 
under  the  pDC‐specific  human  blood  dendritic  cell  antigen  2  (BDCA‐2) 
promoter. Administration of diphtheria  toxin  (DT)  to BDCA‐2 DTR  transgenic 
Ldlr‐/‐  mice  resulted  in  an  almost  complete  pDC  ablation.  To  explore  pDC‐
induced CD4+ T  cell  immunity  in atherosclerosis a  subset of mice obtained a 
CD4+  T  cell  depletion  antibody.  Next  to  pDC  depletion,  prolonged  DT 
administration  induced  unexpected  systemic  toxicity  and  immune  cell 
modulations,  shown by a dramatic  increase  in  circulating granulocyte  counts 
accompanied  by  tremendous  immune  cell  infiltration  in  the  lungs. We  thus 
conclude  that  the  BDCA‐2 DTR model, while  technically  interesting  in  acute 
disease models, is not appropriate to study pDC immunity in a chronic disease 
as atherosclerosis, due to unrequested ectopic side‐effects caused by repeated 
DT application. 
pDCs  are  crucial  in  anti‐viral  defense mechanisms  through  the  rapid 
release of huge amounts of type  I  IFNs. Factors  in their environment, such as 
lipoproteins, might interfere with signaling pathways crucial for pDC‐mediated 
immune  responses.  In  Chapter  5  we  addressed  the  question  whether  a 
hyperlipidemic  environment  leads  to  impaired  functionality  of  human  pDCs. 
Indeed, we  have  demonstrated  that  exposure  to  excessive  amounts  of  pro‐
atherogenic lipoproteins (LDL and oxLDL) completely ablated Toll‐like receptor 
9  (TLR9)  agonist  induced  pDC  activation  in  vitro,  shown  by  the  quenched 
production  of  pro‐inflammatory  cytokines,  as  well  as  the  up‐regulation  of 
maturation markers. In keeping, oxLDL‐induced abrogation of pDC stimulation 
profoundly  impaired their ability to trigger CD4+ T helper (Th) cells. It remains 
to be  elusive whether  such  an  association between hyperlipidemia  and pDC 
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IFN‐response  compromises  the  host’s  pathogen  defense  capacity  in 
hyperlipidemic patients. 
  In  Chapter  6 we  additionally  addressed  temporal  effects  of  dietary‐
induced  hypercholesterolemia  on  DC  (precursor)  homeostasis,  and 
consequences of lipid accumulation on phenotype and T cell priming capability 
of lymphoid organ DC subsets in Ldlr‐/‐ mice. Congruent to results described in 
Chapter  5,  lipid  loading  by  peripheral  conventional  DC  (cDC)  subsets  was 
accompanied by a sharply reduced capacity to stimulate naïve T cells, a finding 
that may have consequences  for host defense mechanisms against  infectious 
diseases. 
In Chapter 7 we addressed the question whether pDCs, rarely present 
in the human advanced plaque, impact their local context. Hereto, we applied 
genome‐wide microarraying and bioinformatics analyses on pDC‐enriched and 
pDC‐deficient plaque fragments, isolated by laser capture microdissection from 
human  carotid  endarterectomy  tissue  samples.  Network  analysis  and 
subsequent module‐trait  correlation  analysis were performed  to  identify  co‐
expressed  gene module  clusters  for macrophages,  T  cells  and microvessels, 
tightly  linked  to  pDC  presence  within  the  plaque.  Amongst  others,  we 
characterized immune clusters in the T cell module being involved in Th1/ Th17 
differentiation,  stressing  the  idea  that  pDCs  exert  immunogenic  functions, 
even  though  exposed  to  modified  lipoproteins.  Conclusively,  this  study 
promotes  the  concept  that  pDCs  interfere  their  immune  cell  context  in  the 
human plaque. 
Finally,  Chapter  8  discusses  the most  relevant  findings  of  this  thesis 
and provides future perspectives. Altogether, this thesis affords novel  insights 
into  DC  biology  in  hyperlipidemia‐associated  atherosclerosis  both  in  animal 
models and in human, emphasizing an athero‐protective role for murine pDCs.  
Otherwise, pDCs  in  the human advanced atherosclerotic plaque  likely  induce 
Th1/  Th17  responses within  their  local  immune  cell  context. Moreover, we 
demonstrated that a cholesterol‐rich environment impairs the functionality of 
peripheral  lymphoid  organ  DC  subsets,  thus  potentially  interfering with  the 
host’s immunity against pathogen‐derived signals. 
 
 
 
 
 242 
 
 
 
Samenvatting 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
243 
Samenvatting 
 
Atherosclerose, het pathologische proces wat ten grondslag ligt aan de 
meeste  cardiovasculaire  ziekten  (CVZ),  is  een  chronisch  inflammatoire 
aandoening.  Hierbij  spelen  gespecialiseerde  immuun  cellen  zoals 
monocyten/macrofagen,  granulocyten,  B  en  T  cellen  een  grote  rol. 
Geactiveerde  immuun  cellen  zijn  verantwoordelijk  voor  een  aantal 
ontstekingsreacties,  die  bijdragen  aan  het  ontstaan  en  de  progressie  van 
atherosclerose.  Recent  werd  een  ander  immuun  celtype  gedetecteerd  in 
normale  en  atherosclerotische  slagaders,  namelijk  de  dendritische  cel  (DC). 
DCs, gespecialiseerde antigeen presenterende cellen,  zijn essentieel voor het 
koppelen van het aangeboren en het verworven  immuun systeem. Ze kunnen 
een  T  cel  immuun  respons  opwekken  tegen  exogene,  maar  ook 
gemodificeerde auto‐antigenen aanwezig bij schade. Een verhoogd aantal DCs 
werd  in  gevorderde  atherosclerotische  plaques  gevonden,  voornamelijk  in 
schouder regio’s met veel inflammatoire loci. Er wordt dan ook meer en meer 
aandacht  besteed  aan  de  mogelijke  bijdrage  van  DCs  aan  de 
ontstekingsprocessen  in  atherosclerose.  Plaque‐specifieke  epitopen,  die  DC 
ontwikkeling  en  activering  lokaal  kunnen  induceren,  zijn  tot  nog  toe  niet 
geïdentificeerd. Verder  is over het behoud van antigeen presentatie en T cel 
activering door DCs  in hyperlipidemie, zelfs na overmatige vetophoping  in de 
DC, nog maar weinig bekend en resultaten van reeds uitgevoerde studies zijn 
niet eenduidig. Dit proefschrift focust dan ook op de bijdrage van DC subtypes 
in  hyperlipidemie‐geassocieerde  atherosclerose  –  lokaal  in  de  plaque, maar 
ook in perifere lymfoïde organen. Daarnaast wordt de vraagstelling behandeld 
of hypercholesterolemie de activering van DC en de resulterende T cel immuun 
respons, beïnvloedt. 
In de afgelopen jaren werd veel aandacht besteed aan het bestuderen 
van DC biologie  in de meeste CVZ, omdat DC een adaptieve  immuun respons 
opwekken. Toch is het volledige spectrum van DC‐gemedieerde effecten in CVZ 
nog steeds niet bekend. In Hoofdstuk 2 geven we een diepgaand overzicht van 
de huidige kennis over de rol van DC subtypes  in CVZ. Hier proberen we ook 
onderliggende patronen te ontrafelen en tekortkomingen in de kennis over DC 
functie  in CVZ  in  kaart  te brengen. Daarnaast benadrukken we  het mogelijk 
therapeutische  potentieel  van  DCs  voor  harttransplantaties  en  als mogelijk 
vaccin tegen atherosclerose.  
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  Plasmacytoide  DCs  (pDC)  kunnen  bijdragen  aan  het  ontstaan  van 
atherosclerotische plaques via een type I interferon (IFN) respons. We tonen in 
Hoofdstuk  3  dat  pDCs  nauwelijks  voorkomen  in  humane  plaques,  en 
bovendien  bijna  helemaal  afwezig  zijn  in  atherosclerotische  plaques  van 
muizen. In tegenstelling tot verwacht, verergerde de antilichaam‐gemedieerde 
depletie  van  pDCs  de  ontwikkeling  van  plaques  in  low‐density  lipoproteïne 
receptor deficiënte  (Ldlr‐/‐) muizen. Dit  suggereert dat  in de  Ldlr‐/‐ muis pDCs 
een anti‐atherogeen effect hebben. Bovendien veroorzaken pDCs uit perifere 
lymfoïde  organen  van  atherosclerotische  muizen  een  remming  van  T  cel 
activering  en  proliferatie.  Dit  tolerogene  effect  werd  gemedieerd  via 
indoleamine  2,3‐  dioxygenase.  De  T‐cel  remming  door  pDCs  verklaart 
waarschijnlijk het anti‐atherogene effect van pDCs. Concluderend, onze studie 
identificeert  een  tolerogene  rol  voor  pDCs  in  atherosclerose  en  maakt  ze 
daarom een interessant doel voor toekomstige therapeutische strategieën. 
In  hoofdstuk  4  gebruiken wij  een  induceerbaar  pDC  depletie model, 
waarin  transgene  expressie  van  de  difterie  toxine  receptor  (DTR)  onder  de 
controle staat van de pDC‐specifieke humane dendritische cel antigen 2 (BDCA‐
2) promotor. Toediening  van difterie  toxine  (DT)  aan BDCA‐2 DTR  transgene 
Ldlr‐/‐ muizen  resulteerde  in  een  bijna  complete  pDC  depletie. Om  de  pDC‐
geïnduceerde CD4+ T cel immuniteit in atherosclerose te bestuderen, werd een 
CD4+  T  cel  depleterend  antilichaam  aan  een  subgroep  van muizen  gegeven. 
Herhaalde DT  toediening  resulteerde echter niet alleen  in pDC ablatie, maar 
induceerde  ook  onverwachte  systemische  toxiciteit  en moduleerde  immuun 
cellen.  Deze  bijwerkingen  werden  duidelijk  door  de  waarneming  van 
verhoogde aantallen circulerende granulocyten met gelijktijdige  infiltratie van 
de long door immuun cellen. Wij kunnen dus concluderen, dat het BDCA‐2 DTR 
model  niet  geschikt  is  om  pDC  immuniteit  in  de  chronische  ziekte 
atherosclerose  te  bestuderen,  omdat  de  DT  toediening  ectopische 
bijwerkingen veroorzaakt. Aan de andere kant, zou het systeem wél technisch 
interessant zijn als model voor acute ziekten.  
pDCs  zijn  belangrijk  voor  antivirale  afweermechanismen  door  hun 
snelle en grote productie van type  I  IFNs. Factoren  in de omgeving van pDCs, 
zoals  lipoproteïnen,  zouden  de  immuun  signalering  van  pDCs  kunnen 
beïnvloeden.  In  hoofdstuk  5  hebben  wij  bestudeerd  wat  de  effecten  van 
hyperlipidemie  zijn op de  functie  van  humane pDCs.  Inderdaad  zagen wij  in 
vitro,  dat  de  activatie  van  pDCs,  geïnduceerd  door  een  Toll‐like  receptor  9 
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(TLR9)  agonist,  geremd  wordt  door  een  overmaat  van  de  pro‐atherogene 
lipoproteïnen LDL en oxLDL. Deze  remming van pDC activatie werd zichtbaar 
door  een  verlaagde pro‐inflammatoire  cytokine productie  en  een  verhoogde 
expressie  van  maturatie  markers.  In  overeenstemming  daarmee  was  de 
stimulatie van CD4+ T helper cellen door pDCs verlaagd in de aanwezigheid van 
oxLDL. Desondanks moet nog bevestigd worden of het  remmende effect van 
hyperlipidemie  op  de  IFN  productie  door  pDCs,  werkelijk  het 
afweermechanisme  van  hyperlipidemische  patiënten  tegen  pathogenen  kan 
verminderen.  
In  hoofdstuk  6  onderzochten  wij  het  temporele  effect  van  dieet‐
geïnduceerde  hypercholesterolemie  op  de  ontwikkeling  en  rijping  van muis 
DCs. Verder bestudeerden wij de  gevolgen  van  vetopname door muis pDCs, 
geïsoleerd uit perifere  lymfoïde organen, op DC fenotype en DC‐gemedieerde 
cel  stimulatie.  In overeenstemming met de pDC  resultaten  van hoofdstuk 5, 
veroorzaakt  vetopname door perifere  conventionele DC  (cDC) ook  een  sterk 
verminderde stimulatie van naïve T cellen. Dit resultaat heeft mogelijk nadelige 
gevolgen voor de afweermechanismen tegen infectie ziekten.  
In hoofdstuk 7 bestudeerden wij of pDCs hun lokale omgeving kunnen 
beïnvloeden, ondanks het lage aantal pDCs in vergevorderde humane plaques. 
In  operatief  verwijderde  humane  arteria  carotis  plaques werden  segmenten 
geïdentificeerd met  hoge  concentratie  pDCs  en  afwezige  pDCs. Na  extractie 
van de segmenten met laser capture microdissectie, werd RNA geïsoleerd voor 
een  gen  expressie  analyse  van  het  hele  genoom.  Bio  informatica  analyses 
werden gebruikt om gen clusters te identificeren specifiek voor macrofagen, T 
cellen en microvaten, die een sterk verband vertoonden met de aanwezigheid 
van pDCS. Met deze  techniek werd een T‐cel gen cluster geïdentificeerd, wat 
de  aanwezigheid  van  pDCs  relateerde  aan  Th1/Th17  differentiatie.  Dit 
suggereert  dat pDCs  toch  in  staat  zijn  een  immuun  respons  te  veroorzaken, 
ondanks blootstelling aan lipoproteïnen in de plaque. Deze studie ondersteunt 
het  concept  dat  pDCs  de  immuun  cellen  in  humane  plaques  kunnen 
beïnvloeden. 
Tenslotte werden  in hoofdstuk 8 de meest opmerkelijke bevindingen 
van  deze  thesis  bediscussieerd  en  toekomstverwachtingen  aangegeven. 
Samenvattend,  geven de  resultaten  in deze  thesis nieuwe  inzichten over DC 
biologie in hyperlipidemie‐geassocieerde atherosclerose in dier modellen en in 
de  humane  situatie.  In  het  bijzonder,  ondersteunen  de  resultaten  een  anti‐
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atherogene rol voor pDCs  in de muis.  In tegenstelling daarmee,  lijken pDCs  in 
gevorderde  humane  plaques  juist  in  staat  om  een  Th1/Th17,  dus  pro‐
inflammatoire  reactie  in  hun  lokale  immuun  cel  omgeving  te  stimuleren. 
Bovendien  hebben  wij  aangetoond,  dat  een  cholesterol‐rijke  omgeving  de 
functie van perifere pDCs en cDCs kan remmen. Cholesterol zou dus mogelijk 
ook het afweermechanisme tegen exogene pathogenen kunnen remmen. 
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Arteriosklerose,  der  zugrunde  liegende  pathologische  Prozess  der 
meisten  kardiovaskulären  Erkrankungen,  ist  eine  chronisch  entzündliche 
Gefäβerkrankung, in deren Pathomechanismus spezifische Immunzellen, unter 
anderem Monozyten/ Makrophagen, Granulozyten, B‐ und T‐Zellen,  impliziert 
sind. Aktivierte  Immunzellen  führen  eine Anzahl  an  entzündlichen Prozessen 
durch,  welche  entscheidend  zum  Beginn  und  dem  Voranschreiten  der 
Krankheit  beitragen.  In  den  letzten  Jahren  wurde  ein  weiterer  Immunzell‐
Subtyp  in  gesunden  und  erkrankten  Blutgefäβen  identifiziert  –  dendritische 
Zellen.  Dendritische  Zellen  sind  spezialisierte  Antigen‐präsentierende  Zellen, 
welche  eine  zentrale  Rolle  in  der  angeborenen  und  erworbenen 
Immunantwort  spielen,  indem  sie  Antigene  von  Krankheitserregern  oder 
modifizierte körpereigene Antigene naiven T‐Zellen präsentieren und somit die 
T‐Zell  vermittelte  Immunität  stimulieren.  Mehrere  Studien  haben  eine 
Zunahme  von  dendritischen  Zellen  in  humanen  vorangeschrittenen 
arteriosklerotischen  Plaques  beschrieben,  hauptsächlich  in  entzündlichen 
Herden  in  der  Schulterregion  der  Plaques.  Diese  Ergebnisse  haben  dazu 
beigetragen, dendritischen Zellen eine Rolle in entzündlichen Prozessen in der 
Arterioskleroseentstehung  zuzuschreiben.  Spezifische,  in  den  Plaques 
vorkommende Epitope, welche die Reifung und Aktivierung der dendritischen 
Zellen  induzieren könnten, wurden bisher nicht  identifiziert. Zudem  ist es bis 
jetzt unklar, ob dendritische Zellen  in einer hyperlipidämischen Umgebung – 
nach übermäβiger intrazellulärer Lipidanreicherung ‐ ihre Funktion als Antigen‐
präsentierende Zellen beibehalten und T‐Zellen  in gleichem Maβe stimulieren 
können.  Folglich  fokussiert  sich  diese  Doktorarbeit  darauf,  die  Funktion 
verschiedener  dendritischer  Zell‐Subtypen  in  der  hyperlipidämischen‐
assoziierten  Arteriosklerose  aufzuklären.  Zudem,  wird  in  dieser  Thesis 
untersucht,  ob  eine  hypercholesterolämische  Umgebung  die  Aktivierung 
dendritischer Zellen und deren Fähigkeit T‐Zell  Immunantworten  zu  schärfen 
beeinträchtigt. 
Da dendritischer Zellen die erworbene Immunantwort triggern, hat die 
Untersuchung  ihrer  Immunobiologie  in  einer Mehrzahl  von  kardiovaskulären 
Erkrankungen  in  den  letzten  Jahren  intensive  Aufmerksamkeit  erlangt. 
Nichtsdestotrotz  ist  der  volle  Umfang  der  Auswirkungen,  welche  durch 
dendritische  Zellen  angetrieben  werden,  bisher  unklar.  In  Kapitel  2 
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präsentieren wir  eine  fundamentale Übersicht  über  das momentane Wissen 
des Einflusses dendritischer  Zell‐Subtypen  in  verschiedenen  kardiovaskulären 
Erkrankungen,  um  grundlegende  Muster  zu  zeigen,  und  Lücken  und 
Unzulänglichkeiten  über  die  Funktion  von  dendritischen  Zellen  aufzudecken. 
Des Weiteren heben wir das  therapeutische Potential dendritischer Zellen  in 
der  Herztransplantation  hervor,  welches  als  Beispiel  für  zukünftige 
Impfungsstrategien  in  der  Arterioskleroseforschung  herangezogen  werden 
könnte. 
Es wird  vermutet,  dass  plasmazytoide  dendritische  Zellen  durch  das 
Freisetzen  von  Typ  I  Interferonen  zur  Ausbildung  von  arteriosklerotischen 
Plaques beitragen.  In Kapitel 3 demonstrieren wir die  spärliche Anwesenheit 
plasmazytoider  dendritischer  Zellen  in  humanen  Plaques, wohingegen  sie  in 
murinen arteriosklerotischen Läsionen nicht vorzufinden sind. Die Entfernung 
plasmazytoider dendritischer Zellen durch die systemische Verabreichung des 
monoklonalen  Antikörpers  120G8  in  low‐density  Lipoprotein‐Rezeptor 
defizienten  Mäusen  hat  unerwarteterweise  eine  Verschärfung  der 
arteriosklerotischen Plaques hervorgerufen, welches auf eine protektive Rolle 
plasmazytoider  dendritischer  Zellen  in  der  Arteriosklerose  hindeutet.  Im 
Einklang  mit  diesem  Resultat  konnten  wir  zeigen,  dass  plasmazytoide 
dendritische  Zellen,  welche  aus  den  peripheren  lymphoiden  Organen 
arteriosklerotischer  Mäuse  isoliert  wurden,  die  T‐Zellaktivierung  und  deren 
Proliferation  in  einer  indoleamine  2,3‐  dioxygenase  (IDO)‐abhängigen  Art 
gedämpft haben. Zusammengefasst zeigen unsere Daten, dass plasmazytoide 
dendritische  Zellen  eine  tolerogene  Funktion  in  der  Arteriosklerose 
übernehmen,  welches  sie  zu  einem  interessanten  Zielobjekt  für  zukünftige 
therapeutische Ansätze macht. 
In  Kapitel  4  haben wir Gebrauch  von  einem weiteren  induzierbaren 
plasmazytoiden dendritischen Zell Ablationsmodell gemacht, basierend auf der 
Expression  des  transgenen  Diphtheria  Toxin  Rezeptors  unter  dem 
plasmazytoiden  dendritischen  Zell‐spezifischen  Promoter  BDCA‐2  (blood 
dendritic  cell  antigen  2). Die Verabreichung  von Diphtheria  Toxin  zu BDCA‐2 
transgenen low‐density Lipoprotein‐Rezeptor defizienten Mäusen resultierte in 
der  fast  vollständigen Depletion plasmazytoider dendritischer  Zellen. Um die 
plasmazytoide  dendritische  Zell‐induzierte  CD4+  T‐Zell  Immunität  in  der 
Arteriosklerose  zu  untersuchen, wurde  einem  Teil  der Mäuse  zusätzlich  ein 
CD4+  T‐Zell  Depletionsantikörper  eingespritzt.  Neben  der  Entfernung 
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plasmazytoider  dendritischer  Zellen  hat  die  anhaltende  Verabreichung  von 
Diphtheria  Toxin  jedoch  unerwartete  Nebeneffekte  hervorgerufen.  Unter 
anderem  haben wir  eine  systemische  Toxizität  und  Immunzellmodulationen 
festgestellt,  verdeutlicht  durch  die  dramatische  Zunahme  zirkulierender 
Granulozyten, und begleitet durch die enorme Einwanderung von Immunzellen 
in die Lunge. Hierdurch schlussfolgern wir, dass das BDCA‐2 Diphtheria Toxin 
Rezeptor  Modell,  welches  in  der  Untersuchung  akuter  Krankheitsmodelle 
technisch  interessant  ist,  aufgrund  der  unerwünschten  Nebeneffekte  nicht 
anwendbar  ist, um die Immunobiologie plasmazytoider dendritischer Zellen in 
chronischen Erkrankungen wie der Arteriosklerose zu untersuchen. 
Plasmazytoide dendritische Zellen sind durch die schnelle Freisetzung 
groβer  Mengen  von  Typ  I  Interferonen  unentbehrlich  in  der  antiviralen 
Abwehr. Faktoren in ihrer direkten Umgebung, wie zum Beispiel Lipoproteine, 
könnten  Signalwege,  welche  wichtig  für  plasmazytoide  dendritische  Zell‐
vermittelte  Immunantworten  sind,  behindern.  In  Kapitel  5  haben  wir 
untersucht,  ob  eine  hyperlipidämische  Umgebung  zu  einer  verminderten 
Funktionalität humaner plasmazytoider dendritischer Zellen führt. Wir konnten 
in der Tat zeigen, dass die Toll‐like Rezeptor 9 Agonist  induzierte Aktivierung 
plasmazytoider dendritischer Zellen nach Aussetzen  in eine hyperlipidämische 
Umgebung in vitro komplett gehemmt wurde. Dies wurde durch die signifikant 
verminderte  Freisetzung  pro‐entzündlicher  Zytokine,  sowie  die  gedämpfte 
Expression  von  Maturierungsmarkern  bewiesen.  In  Übereinstimmung  mit 
diesen  Resultaten  konnten  wir  zeigen,  dass  die  Fähigkeit  plasmazytoider 
dendritischer Zellen CD4+ T‐Helfer Zellen zu aktivieren,  in der Gegenwart von 
oxLDL  schwer  beeinträchtigt  wurde.  Es  bleibt  zu  untersuchen,  ob  die 
Assoziierung  zwischen Hyperlipidämie  und plasmazytoider dendritischer  Zell‐
vermittelter  Interferon‐Antwort die Abwehrkapazität gegen Krankheitserreger 
in hyperlipidämischen Patienten gefährdet. 
In  Kapitel  6  haben  wir  die  zeitlichen  Effekte  einer  Diät‐induzierten 
Hypercholesterolämie in low‐density Lipoprotein‐Rezeptor defizienten Mäusen 
auf die Homeostase dendritischer (Vorläufer‐) Zellen untersucht. Zudem haben 
wir erforscht, ob die Lipidanreicherung  in dendritischen Zell‐Subtypen,  isoliert 
aus  lymphoiden  Organen,  deren  Phänotyp  verändert  und  ihre  Fähigkeit  T‐
Zellen  zu  stimulieren,  beeinträchtigt.  Übereinstimmend  mit  unseren 
Resultaten  in  Kapitel  5  konnten  wir  hier  zeigen,  dass  die  intrazelluläre 
Lipidanreicherung  in peripheren  konventionellen dendritischen  Zell‐Subtypen 
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zu einer Verminderung  ihrer Kapazität, naïve T‐Zellen  zu  stimulieren,  führte; 
eine Erkenntnis, welche Konsequenzen für die Immunabwehr gegen infektiöse 
Erreger haben könnte. 
  In Kapitel 7 haben wir erforscht, ob plasmazytoide dendritische Zellen, 
welche  spärlich  in  vorangeschrittenen  humanen  Plaques  vorzufinden  sind, 
einen  Einfluss  auf  ihr  lokales  Umfeld  ausüben.  Hierzu  haben  wir  Plaque 
Regionen  aus  humanen  Karotis‐Gewebeproben  mit  Hilfe  der  Laser  Capture 
Mikroskopie isoliert, welche plasmazytoide dendritische Zellen enthielten oder 
negativ  für  diese  Zellen  waren.  Anschlieβend  wurde  ein  Genom‐weites 
Microarraying  mit  bioinformatischer  Analyse  auf  diese  Proben  appliziert. 
Network  und  nachfolgende  module‐trait  Korrelationsanalysen  wurden 
durchgeführt,  um  Ko‐expressions  Cluster‐Module  für Makrophagen,  T‐Zellen 
und  Mikrogefäβe  zu  identifizieren,  welche  mit  der  Anwesenheit 
plasmazytoider  dendritischer  Zellen  in  den  humanen  arteriosklerotischen 
Plaques verknüpft werden können. Wir konnten unter anderem Immun‐Cluster 
im  T‐Zellmodul  charakterisieren,  welche  in  die  T‐Helfer  1/  T‐Helfer  17 
Differenzierung  involviert  sind.  Diese  Resultate  unterstützen  die  Hypothese, 
dass plasmazytoide dendritische Zellen  immunogene Funktionen  in humanen 
Plaques  ausüben,  obwohl  sie  einer  Lipid‐reichen Umgebung  ausgesetzt  sind. 
Zusammenfassend  avanciert  diese  Studie  das  Konzept,  dass  plasmazytoide 
dendritische  Zellen  in  humanen  arteriosklerotischen  Läsionen  einen  Einfluss 
auf ihren Immunzell‐Kontext ausüben. 
Letzlich  diskutiert  Kapitel  8  die  wichtigsten  Erkenntnisse  dieser 
Doktorarbeit  und  bietet  Zukunftsperspektiven.  Zusammenfassend  gibt  diese 
These  einen  neuen  Einblick  in  die  Biologie  dendritischer  Zellen  in  der 
hyperlipidämischen‐assoziierten Arteriosklerose. Wir  konnten eine protektive 
Rolle für plasmazytoide dendritische Zellen in der Maus‐Arteriosklerose zeigen. 
Andererseits  sind  plasmazytoide  dendritische  Zellen  wahrscheinlich  in  die 
Induktion  von  inflammatorischen  T‐Helferzellen  in  humanen 
arteriosklerotischen Plaques  involviert. Des Weiteren haben wir demonstriert, 
dass  eine  Cholesterol‐reiche  Umgebung  die  Funktionalität  peripherer 
dendritischer Zell‐Subtypen beeinträchtigt, welches enorme Konsequenzen für 
die Immunabwehr gegen infektiöse Erreger haben könnte. 
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ACI‐S  asymptomatic cerebral infarction stenosis 
AEC  3‐amino‐9‐ethylcarbazole 
AHS  acute haemorrhagic stroke 
AIS  acute ischemic stroke 
AMI  Acute myocardial infarction 
Ang   angiotensin 
APC  Antigen‐presenting cell 
APC  Allophycocyanin 
ApoE‐/‐  Apolipoprotein deficient 
ASMA  Α‐smooth muscle actin 
Batf3  basic leucine zipper transcription factor, ATF‐like 3 
BCA  bicinchoninic acid 
BDCA  Blood dendritic cell antigen 
BSA  Bovine serum albumine 
BST‐2  Bone marrow stromal antigen‐2 
CAD  Coronary artery disease 
CBA  Cytometric bead array 
cDC  Conventional dendritic cell 
CDP  Common dendritic cell precursor 
CEA  Carotid endarterectomy 
CLI  critical limb ischemia 
CLP  Common lymphoid progenitor 
CLP  Common lymphoid precursor 
CLR  C‐type lectin receptor 
CMP  Common myeloid progenitor 
CTL  Cytotoxic T cell 
CTLA‐4  Cytotoxic T‐lymphocyte antigen 4 
Ctr  Control 
CVD  Cardiovascular disease 
DAMP  Danger‐associated molecular pattern 
DC  Dendritic cell 
DCF  2’, 7’ –dichlorofluorescin 
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DCFDA  2′,7′‐dichlorofluorescein diacetate 
DCIR  Dendritic cell immuno receptor 
DiI  1,1‘‐dioctadecyl‐3,3,3‘,3‘‐ tetramethylindocarbocyanine perchlorate 
DMSO  Dimethyl sulfoxide 
DT (A)  Diphtheria toxin (A) 
DTM  Diphtheria toxin mutant 
DTR  Diphtheria toxin receptor 
E4BP4  E4 promoter‐binding protein 4 
EC  Endothelial cell 
EDTA  ethylenediaminetetraacetic acid 
EGFP  Enhanced green fluorescent protein 
FACS  Fluorescence activated cell sorter 
FGF  Fibroblast growth factor 
FITC  Fluoresceinisothiocyanat 
Flt3L  FMS‐like tyrosine kinase 3 ligand 
GM‐CSF(R)  granulocyte– macrophage colony‐stimulating factor (receptor) 
GO  Gene ontology 
GTC  Guanidine thiocyanate 
GvHD  Graft versus host disease 
HE  Hematoxylin and eosin 
HF  Heart failure 
HFD  High fat diet 
hGH  Human growth hormone 
HIV  Human immunodeficiency virus 
HLA  Human leukocyte antigen 
HMGB‐1  High‐mobility group box 1 
HSC  Hematopoietic stem cell 
HSP  Heat shock protein 
HT  Heart transplantation 
i.p.  Intraperitoneal 
i.v.  intravenous 
IC  intermittent claudication 
ICAM  Intracellular adhesion molecule 
ICOS‐L  Inducible costimulator ligand 
ID2  inhibitor of DNA binding 2 
IDO  indoleamine‐2,3‐dioxygenase 
IFN  Interferon 
IL  Interleukin 
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ILT7  Immunoglobulin‐like receptor 7 
IPH  Intraplaque hemorrhage 
IRAK‐4  Interleukin‐1 associated kinase‐4 
IRF  IFN regulatory factor 
IRI  Ischemia and reperfusion injury 
L. major  Leishmania major 
LAL  Limulus amebocyte lysate 
LCM  Laser capture microdissection 
LDL  Low density lipoprotein 
Ldlr‐/‐  Low‐density lipoprotein receptor deficient 
LMPP  lymphoid‐primed multipotent progenitor 
LN  Lymph node 
mAB  Monoclonal antibody 
M‐CSF(R)  macrophage colony‐stimulating factor (receptor) 
MDA‐Ldl  malondialdehyde modified LDL 
MDP  Myeloid dendritic cell progenitor 
MFI  Mean fluorescence intensity 
MHC  Major histocompatibility complex 
MLN  Mesenteric lymph node 
MLR  Mixed leukocyte reaction 
MMP  Matrix metaloproteinase 
MPD  Monocyte and dendritic cell precursor 
MPO  Myeloperoxidase 
NET  Neutrophil extracellular traps 
NK  Natural killer 
NKT cell  Natural killer T cell 
NYHA  New York Heart Association 
ORO  Oil‐Red O staining 
oxLDL  Oxidized low density lipoprotein 
oxPL  Oxidized phospholipids 
PAD  Peripheral arterial disease 
PAMP  Pathogen‐associated molecular pattern 
PBMC  Peripheral blood mononuclear cell 
PBS  Phosphate buffered saline 
PD‐1  Programmed death‐1 
pDC  Plasmacytoid dendritic cell 
PDGF  Platelet‐derived growth factor 
PD‐L1  Programmed death ligand 1 
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PE  Phycoerythrin 
PFA  Paraformaldehyde 
PRR  Pattern recognition receptor 
RMA  Robust multiarray average 
ROS  Reactive oxygen species 
SAP  Stable angina pectoris 
SEB  Staphylococcus Enterotoxin B 
SFD  Standard fat diet 
SLE  Systemic lupus erythematosus 
SSC  Side scatter 
T2D  Type II diabetes 
T‐bet  T‐box transcription factor TBX21 
TBS  Tris buffered saline 
TCR  T cell receptor 
TGF‐β  Tumor growth factor‐β 
Th  T helper 
TIA  transient ischemic attack 
TkFCA  Thick fibrous cap atheroma 
TLR  Toll‐like receptor 
TnFCA  Thin fibrous cap atheroma 
TNF‐α  Tumor necrosis factor‐α 
TRAIL  Tumor necrosis factor‐related apoptosis‐inducing ligand 
Treg  Regulatory T cell 
UAP  Unstable angina pectoris 
VCAM  Vascular cell adhesion molecule 
vSMC  Vascular smooth muscle cell 
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und  viele  hilfreiche  Ideen  und  Tipps  im  Zusammenhang  mit  unseren 
Forschungsprojekten.  Liebe  Frau  Mayer,  ich  möchte  mich  auch  bei  Ihnen 
nochmal für all Ihre Hilfe bedanken. 
 
Furthermore, I would like to thank Prof. Golenbock and my colleagues 
that I met during my short‐term stay at UMass: Carolina, Wayra, Parisa, Jenny, 
Donghai, Bruno, Ari, Kristen, Lukas and Nelsy. I felt immediately comfortable in 
the  lab! Thanks  for a great and helpful working atmosphere, and  some nice 
moments outside  the  lab.  Parisa,  a big  thank‐you  for  your  support with  the 
confocal microscopy.  This  definitely  contributed  to  a  progress  in my  human 
pDC‐project. Jenny, thanks a lot for teaching me the FlowSight. 
 
Lisa  und  Dorith,  ich  danke  euch  für  unsere  witzigen  Abende  und 
Gespräche ausserhalb der Pathologie. Es gab immer wieder interessante News 
 Lisa, vielen vielen Dank für das tolle Coverbild! Lieber Janis, liebe Silja, Stella, 
Claudi, Bine und Katha. Danke, dass ich immer wieder auf ein offenes Ohr von 
eurer Seite zählen konnte! Mes belles amis d’ ERASMUS (Lara, Anna, Eva, Laura 
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et Ainara).  Je  suis  super  contente qu’ on  se  rencontrait! Vous êtes vraiment 
des  amies  superbe!  Meine  liebe  Nancy:  dir,  Robert  und  Mika  möchte  ich 
natürlich  auch  danke  sagen  für  all  die  vielen  schönen Momente,  Ausflüge, 
etc…. Ich schätze das sehr, dass ihr immer für mich da seid! Ich bedanke mich 
natürlich auch bei meinen Mädels von der Mosel: vor allem Carmen, Anna und 
Rebecca,  Eva,  Tina, und Nadine!  Ich war  zwar  eher  selten dabei,  aber dafür 
war’s  dann  immer  sehr  lustig!  Und  vor  allem  ein  perfekter  Ausgleich  zum 
stressigen  Alltag  im  Labor.  Ich  hoffe,  dass wir  auch  in  Zukunft  noch  oft  so 
witzige Abende zusammen verbringen werden. 
 
Lieber Papa,  liebe Simone,  liebe Jutta, Raimund und Oma Mia, Birgitt, 
Hannelore  und  Nadine, Micha  und  Lissy,  Angela  und  Rüdiger:  zum  Schluss 
bedanke  ich  mich  natürlich  bei  euch  für  das  groβe  Verständnis  und  die 
tatkräftige  Unterstützung  während  der  letzten  vier  Jahre.  Danke,  dass  ihr 
oftmals  geduldig  versucht  habt  zu  verstehen  worum  es  geht  und  mich  zu 
ermutigen, und dass ihr vor allem immer an mich geglaubt habt!  
Liebe Simone,  lieber Papa, danke, dass  ihr mir  in so vielen Momenten 
den Rücken  freigehalten  habt.  Ich weiβ das wirklich  sehr  zu  schätzen. Ohne 
euch hätte ich das so nicht geschafft! 
